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HIV-1 Nef expression in microglia causes mania-like
behaviors with altered dopaminergic function
ShaonaAcharjee1,William Branton1, Pornpun Vivithanaporn1,
FerdinandMaingat1, Amber Paul1, Peter Dickie2, Glen Baker3,
Christopher Power1
(presenting author: chris.power@ualberta.ca)
1Department of Medicine, University of Alberta;
2Department of Medical Microbiology and Immunology,
University of Alberta
3Department of Psychiatry, University of Alberta
Background: Neuropsychiatric disorders in HIV/AIDS are
common although the contribution of HIV-1 infection of the
brain, and in particular individual HIV-1 genes, to the occur-
rence of these brain disorders is unknown. Herein, an in vivo
transgenic model was generated in which the HIV-1 Nef
gene was expressed in myeloid cells and the ensuing neu-
robehavioral phenotype and associated molecular changes
were investigated.
Methods: Transgenic (Tg) mice were generated that expressed
full length HIV-1 nef under the control of the c-fms promoter.
Neurobehavioral performance was assessed by locomotory,
forced swim (FST), elevated plus maze (EPM) and T-maze
tests. Host gene and transgene expression was assessed in brain
and myeloid cells by sqRT-PCR, immunoblotting, enzymatic
activity and immunohistochemistry. Biogenic amines were
measured by HPLC.
Results: Tg animals exhibited Nef expression in brainmicroglia
and cultured macrophages. Tg animals displayed hyperactive
behaviors including augmented locomotor activity, decreased
immobility in forced swim test and increased open-arm EPM
exploration compared to wildtype (Wt) littermates (p<0.05).
Total dopamine levels, MAO activity and dopamine transporter
(DAT) expression were reduced in the striatum of Tg animals
(p<0.05). Tg animals displayed increased CCL2 expression
with concurrent IFN-alpha suppression in striatum compared
with wildtype littermates (p<0.05).
Conclusions: Nef expression in microglia disrupted striatal
dopaminergic pathways in conjunction with increased CCL2
expression, resulting in a mania-like behavioral phenotype.
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Atypical neurologic complications of varicella zoster virus
Shruti Agnihotri1, Nagagopal Venna2
(presenting author: sagnihot@bidmc.harvard.edu)
1Massachusetts General Hospital, Harvard Medical School,
Boston,MA. Current affiliation: Beth Israel DeaconessMedical
Center, Boston
2Massachusetts General Hospital, Harvard Medical School,
Boston, MA
Background: Varicella Zoster Virus (VZV) reactivation is well
known to cause herpes zoster. However, it is also associated
with various other neurologic complications that can occur
with or without a rash. Here, we describe such cases seen at
our institution, which can present a diagnostic challenge.
Case 1: A 59 year old healthy male presented with hemi-
neglect due to a parietal hemorrhage. Over next several
months, he developed multi-territory ischemic infarcts and
then seizures. Vascular imaging and Cerebrospinal fluid
(CSF) examination were normal. Eight months since initial
presentation, he developedmeningoencephalitis, herpes zoster
and CSF was positive for VZV PCR.
Case 2: A 56 year old male with AIDS, recent chemotherapy
for Burkitt’s lymphoma presented with progressive
monoparesis followed by paraparesis and urinary retention.
MRI showed patchy T2 hyperintense and gadolinium enhanc-
ing lesions in the lower spinal cord and conus. A zoster rash
emerged about 10 days into his illness and CSF PCR for VZV
was positive.
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Case 3: A 32 year old HIV positive male, not on treatment
developed fever, dysphagia and somnolence.MRI demonstrated
hydrocephalus, confluent T2 hyperintensities along the basal
cisterns, slyvian fissures along with diffuse leptomeningeal
enhancement. Initial LP showed 9 WBCs which increased
to 75, three days later. He later developed a zoster rash,
seizures and CSF VZV PCR was positive.
Case 4: A 30 year old female with AIDS developed hemiparesis
and difficulty with speech. MRI of the brain identified multiple
acute infarcts and CTA showed irregularities is multiple large
and medium sized vessels. CSF showed 0 WBCs, normal
protein and was positive for VZV PCR.
Conclusion: VZV reactivation can be complicated by
vasculopathy, meningoencephalitis, cranial nerve palsies, my-
elopathy or myeloradiculitis. These can also occur in seem-
ingly immunocompetent patients, preceded by or even in
absence of rash. CSF may or may not show pleocytosis.
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Characterizing HIV-Infected Monocytes that
Transmigrate Across an In-Vitro Blood-Brain-Barrier as
a Tool to Study HAND Pathogenesis
Melissa Agsalda-Garcia1, Dionna W. Williams2, Joan W.
Berman2, Cecilia Shikuma1, Lishomwa C. Ndhlovu1, Bruce
Shiramizu1
(presenting author: bshirami@hawaii.edu)
1Hawaii Center for AIDS, John A. Burns School of Medicine,
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2Albert Einstein College of Medicine, New York, NY
Background: CD14+ monocytes (MO) are an increasingly
recognized reservoir for HIV that are implicated in the path-
ogenesis of HIV-associated neurocognitive disorders (HAND)
despite effective combination antiretroviral therapy (cART).
The transmigrating characteristics of monocytes that traffic to
the central nervous system by MO subset and HIV DNA
content may be important in understanding mechanisms lead-
ing to HAND. We sought to adapt an established in-vitro
blood-brain-barrier (BBB) model for use in a translational
approach. Using blood from patients drawn in real time, we
set up PBMC co-cultures to establish MO subset transmigra-
tion through this BBB model and quantitated HIV DNA from
subsets.
Materials: Fresh peripheral blood mononuclear cells (PBMC)
were obtained from 2 cART-suppressed HIV-seropositive pa-
tients. Four distinct MO subsets based on variations in CD14
and CD16 expression were isolated from PMBC by cell
sorting and integrated HIV DNA quantified from each MO
subset by PCR (pre-BBB). Another aliquot of PBMC was
placed in a transwell culture in an in-vitro BBB model
established from human vascular endothelial cells and astro-
cytes and targeted for migration using the MCP-1 chemokine.
After 24 hours, the transmigrated cells were re-phenotyped to
assess MO subsets representation and cell sorted to re-analyze
for HIV DNA copy number (post-BBB).
Results: The MO subsets from PBMC that transmigrated
across the BBB were characterized by flow cytometry. There
was an approximately 1 log higher copy number of HIV DNA
in the post-BBB transmigrated MO cells.
Conclusion: Translational use of this in-vitro BBBmodel may
be helpful in clinical research examining the role of MO in
HAND. Incorporating a combination of in-vitro BBB trans-
migration studies and quantifying HIV DNA to characterize
MO subsets in intervention studies may contribute to our
understanding of the pathogenesis of HAND. [AI081450,
NS053345, MD007584 (MA, CS, LN, BS); MH075679
(JWB, DWW), Merck Graduate Science Dissertation Fellow-
ship (DWW)]
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Differential HIV-1 X4 and R5 genetic signatures
within the LTR, Tat and Vpr
Benjamas Aiamkitsumrit1, Michael Nonnemacher1, Wen
Zhong1, Tatyana Russo1, Vanessa Pirrone1, Brian Frantz1,
Matthew Rimbey1, Shendra Passic1, Brandon Blakey1,
Nirzari Parikh1, Julio Martin-Garcia1, Jeffrey Jacobson2,
Brian Moldover3, William Dampier1, Brian Wigdahl1
(presenting author: ba52@drexelmed.edu)
1Department of Microbiology and Immunology, Center for
Molecular Virology and Translational Neuroscience, Institute
for Molecular Medicine and Infectious Disease, Drexel
University College of Medicine;
2Division of Infectious Diseases and HIV Medicine, Depart-
ment of Medicine, Drexel University College of Medicine;
3B-Tech Consulting, Ltd
Human immunodeficiency virus type 1 (HIV-1) infection
results in the production of an extensive number of genetic
variants based on the infidelity of viral reverse transcriptase
and selective pressures encountered during the course of dis-
ease. Viral adaptation involves genetic alterations across the
genome with genetic signatures preferentially associated with
viral phenotypes which can be categorized based on the co-
receptor usage that are CCR5-utilizing (R5), CXCR4-utilizing
(X4) and the dual tropic (X4R5) viruses. The envelope-V3
(Env-V3) sequence is currently a major co-receptor usage
determinant, which can be predicted by different in silico
methodologies. Utilizing the position-specific scoring matrix
(PSSM) algorithm, Env-V3 sequences derived from the Los
Alamos National Laboratory (LANL) database and
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DrexelMed HIV/AIDS Genetic Analysis cohort, can be clas-
sified into X4 and R5 genotypes, with associated specific
co-linear long terminal repeat (LTR), Tat, and Vpr, geno-
typic patterns. Differential amino acid (DAA) signatures in
both Tat and Vpr, as well as differential nucleotide (DN)
signatures in the LTR were identified between the R5 and
X4 virus. Utilizing maximum likelihood tree building
strategy, genetic relatedness of Env-V3 between X4 and
R5 was readily characterized, whereas, those of Tat, Vpr
and LTR were not. On the other hand, genetic diversities
of all genes/region of interest determined by the mean
genetic distance (MGD) were evaluated between the group
of X4 and R5, indicating the differential evolution of viral
genetics. It has been theorized that these differential signatures
can also be used to define different genotypes and phenotypes
of X4 and R5 viruses more accurately in order to develop the
next generation of diagnostic and prognostic tools to examine
HIV-1 disease and to develop new therapeutics and vaccines
to prevent and treat HIV/AIDS and associated neurological
complications. This work is supported by NIH/NINDS R01
NS32092, NIDA R01 DA19807, NIMH P30MH092177, and
NIMH T32 MH079785.
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The NCOR2-Nurr1-CoREST Transrepression Axis
Impairs HIV Reactivation in Latently Infected Microglial
Cells
David Alvarez, Biswajit Das, Jonathan Karn
(presenting author: dxa150@case.edu)
Case Western Reserve University
Whereas the incidence of HIV-associated dementia (HAD)
has declined due to successful anti-retrovirals treatment, prev-
alence of milder forms of HAD, which include asymptomatic
neurocognitive impairment (ANI) and minor neurocognitive
disorder (MND) has increased. Both ANI and MND are part
of what is known as HIV-associated neurocognitive disorders
(HAND). However, the molecular mechanisms explaining
regulation of HIV activation in the brain remain ill-defined.
The Nurr1/CoREST transrepression pathway has been recent-
ly described as a regulator of glial cells response to brain
inflammation by limiting over-reactivation of NF-kappaB-
dependent pro-inflammatory genes. We report here that, un-
like in latently-infected T-cells, in latently-infected microglial
cells (CHME-5/HIV), HIV is induced by pharmacological
inhibitors of the CoREST complex chromatin-modifying en-
zymes LSD1 and G9a/GLP; these inhibitors also sensitized
CHME-5/HIV cells for LPS-mediated HIV reactivation.
shRNA-mediated knockdown of Nurr1, LSD1, or CoREST
yielded similar results. Chromatin immunoprecipitation
analysis followed by high throughput next generation se-
quencing revealed that upon microglia treatment with
TNFalpha, the nuclear receptor co-repressor 2 (NCOR2/
SMRT), which strongly interacts with Nurr1 to facilitate
transrepression, is present at the HIV promoter before activa-
tion, then recruited at the earliest time points, and then its
presence fluctuates over time. Likewise, Nurr1, CoREST,
LSD1, and G9a are recruited to the HIV promoter, changing
the epigenetic signature (lower H3K4Me/higher H3K9Me2).
The repressor role of these proteins in regulating HIV emer-
gence from latency has been confirmed by unbiased shRNA
screens for factors involved in maintaining HIV silenced in
latently-infected microglial cells. Our data indicate that the
NCOR2-Nurr1-CoREST axis plays a role in preventing HIV
over-reactivation in microglial cells, and studying this mech-
anism in detail may provide therapeutic targets for the treat-
ment of HAND.
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Distinct Patterns of TLR-Mediated HIV Reactivation
in Latently-Infected Microglial Cells and Monocytes
David Alvarez, Yoelvis Garcia-Mesa, Biswajit Das, Stephanie
Milne, Rojas Roxana, Jonathan Karn
(presenting author: dxa150@case.edu)
Case Western Reserve University
Toll-like receptors (TLRs) recognize molecules derived from
microbes and play a key role in mediating innate immune
responses. Multiple TLRs are typically expressed in cells of
the monocytic lineage, including microglia. Microglial cells
constitute the major reservoir for HIV infections in the brain,
where inflammatory conditions in the central nervous system
(CNS) are believed to induce HIV-associated neurocognitive
disorders (HAND). Using HIV-latently infected microglial cell
lines, we investigated whether TLR stimulation can induce
HIV transcription. Treatment with a panel of TLR ligands,
including Mycobacterium tuberculosis (Mtb)-derived mole-
cules, we found that, unlike in monocytic cells, reactivation
of HIV by TLR ligands was significantly restricted in microg-
lia. Flagellin (TLR5 agonist) and, to a lesser extent, lipopoly-
saccharide (LPS; TLR4 agonist) were able to reactivate HIV in
hTERT-immortalized glial (hT_Hmicroglia/HIV) and in SV40-
immortalized (CHME-5/HIV) human fetal microglial cells. By
contrast, agonists for TLR1, 2, 4, 5, 6, or 8 (but not for TLR3, 7,
or 9), potently reactivated HIV in THP-1/HIV cells and, to a
lesser extent, in U937/HIV and SC/HIV monocytic cells in an
NF-kappaB-dependent manner. Mtb-derived molecules PIM6
and LprG, which are potent TLR2 agonists, reactivated HIV in
THP-1/HIV, but not in U937/HIV or SC/HIV cells which,
unlike THP-1/HIV, showed no significant expression of
12th ISNV, Washington, DC, USA S3
TLR2. We conclude that TLR signaling probably plays
only a minor role in activating HIV replication in the
CNS, but can potentially drive replication in peripheral
monocytic cells.
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HIV+ Brains With Neurocognitive Disorders (HAND)
Without Encephalitis Have Higher RNA Expression
of Heme Oxygenase-1 (HO-1) than HIV- Brains
Surendra Ambegaokar1, Alexander Gill1, Colleen Kovacsics1,
Stephanie Cross1, Patricia Vance1, Lorraine Kolson1,
Benjamin Gelman2, Dennis Kolson1
(presenting author: asuren@mail.med.upenn.edu)
1Department of Neurology, Perelman School of Medicine,
University of Pennsylvania;
2Department of Pathology,University of TexasMedical Branch
In primary human monocyte-derived macrophages (MDM)
infected with HIV, expression of the inducible antioxidant
response protein heme oxygenase-1 (HO-1) is specifically
and strongly reduced late in infection at a time that correlates
with increased neurotoxin release from infected MDM. We
examined RNA derived from frontal cortex of 157 autopsied
individuals from the Texas NeuroAIDS Research Center brain
bank. Of this cohort, 67 were HIV- and 90 were HIV+; of the
90 HIV+ cases, 37 were confirmed to have HAND with no
encephalitis, and 14 were confirmed with encephalitis
(HIVE). RNA levels were measured by qPCR with ABI
Taqman primers. Target genes were normalized to GAPDH;
values are reported as deltaCt. In contrast to HO-1 protein
reduction, there was a significant and specific increase in HO-
1 mRNA in HIV+ patients. When grouped separately, this
difference was significant in HIVE patients but not in non-
encephalitic brains. Additionally, HAND patients without en-
cephalitis also showed increased HO-1 mRNA levels. We
observed an positive correlation of HO-1 mRNA to interferon
induced changes in the proteasome apparatus, which may lead
to increased HO-1 degradation despite the increased RNA.
There is a small but significant decrease of HO-1 RNA inn
HIV infected MDM, but there are similar decreases in Nqo1
and Nrf2 RNA, and thus cannot account for the strong and
specific reduction of HO-1 protein. We infer that the source of
the increased HO-1 RNA in HIV+ brains is not from infected
MDM, and posit that astrocytes, in which HO-1 is highly
inducible, are the major source of HO-1 RNA. We conclude
that HO-1 RNA expression is induced as a potential anti-
inflammatory response in the brain, but that HIV infection
leads to specific HO-1 protein loss, possibly through enhanced
proteasomal degradation. Restoring this HO-1 loss could be a
feasible therapeutic target for neuroprotection against HAND.
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Mechanism of dengue infection and CNS dysfunction
in the human central nervous system
Carlo Amorin Daep, Eliseo Eugenin
(presenting author: carlo.daep@rutgers.edu)
Rutgers University - Public Health Research Institute
Dengue virus (DENV) annually affects 100 million individ-
uals worldwide, with approximately 20% of cases developing
into dengue hemorrhagic fever. With no known treatments or
available vaccines currently on the market and increasing
global dispersal of DENV and its mosquito vectors, this
emerging pathogen demands further attention. Patients suffer-
ing from severe DENVinfection often exhibit encephalopathy
and encephalitis. This suggests that the virus successfully
infiltrates the blood-brain barrier (BBB) and infects local cell
populations, thus negatively impacting normal central nervous
system (CNS) function. However, the exact mechanism of
DENV neuropathogenesis is unknown. Currently, our data
shows that DENV infection of human primary PBMC’s
leads to 2- and 3-fold increases (T = 24 and 48 hrs P.I.)
in absolute monocyte populations as compared with the
uninfected control. We also detected significant eleva-
tion of several adhesion molecules (i.e. CD99, JAM-A
and PECAM-1) on the surface of monocytes that are
required for monocyte transmigration across the BBB as
determined by qRT-PCR, western blot, and confocal
microscopy. Furthermore, our results showed that de-
spite infecting only ~4% of human primary astrocytes,
a ~1.4- to 1.7-fold increase in CCL2 was observed in
culture supernatants collected from DENV-infected hu-
man primary astrocytes. Similarly, our laboratory previ-
ously showed, that CCL2 elevation during HIV infection
is essential for enhance monocyte transmigration into
the CNS. Together, these data suggest that DENV infection
increases monocyte populations and, akin to HIV, increase
adhesion molecule expression and chemokine production
among BBB cells such as astrocytes. We propose that eleva-
tion of CCL2 in astrocytes and the increased expression of
surface adhesion molecules are key components of DENV
neuropathogenesis.
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Accumulation of neurofilament heavy chain in neurons
and CSF of HIV patients on antiretroviral drugs
with normal neurocognitive function
Caroline Anderson1, Gloria von Geldern1, Tory Johnson1,
Ned Sacktor2, Justin McArthur2, Avindra Nath1
(presenting author: caroline.anderson2@nih.gov)
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Background: While it is clear that neurocognitive dysfunction
may occur despite adequate antiretroviral therapy, it is unknown
if there may be ongoing neuronal injury in neurocognitively
normal individuals.
Methods: We immunostained autopsy brain tissue from seven
HIV-infected virologically well-controlled individuals and
five HIV-negative age and gender matched controls with
antibody to neurofilament heavy chain (NfH). We developed
an ELISA for measurement of NfH (sensitivity of 19.2 pg/ml).
CSF from a cohort of HIV infected patients was analyzed and
compared to patients with remitting relapsing multiple sclerosis
(MS) (n=29) and other non-inflammatory neurological diseases
(OND) (n=15). All values are presented as mean+SEM.
Results: Immunostaining of the parietal lobes showed that NfH
was found in the cytoplasm of neurons of HIV-infected individ-
uals more frequently than the HIV negative controls (P=0.02).
CSF analysis at baseline showed that HIV patients had signifi-
cantly (P<0.0001) elevated NfH (range: 42-207 pg/ml) vs MS
(11-88 pg/ml) andOND (10-45 pg/ml). Individuals withNormal
neurocognitive function (n=9) had (109+13.5 pg/ml) which was
not significantly different from asymptomatic (n=18; 107+6.2
pg/ml), mild neurocognitive dysfunction (n=10; 87.5+9.2 pg/
ml) or dementia (n=24; 95.2+6.2). All patients had undetectable
CSF and plasma viral load. In this group, patients >50 yrs of age
had higher NfH levels (120.7+5.0 versus 107+3.3; P<0.02). No
correlation with nadir CD4 cell counts or CNS penetration
efficacy score of ARTwas noted. At 12 month follow up older
patients had greater increase NfH levels.
Conclusions: There is clear evidence of ongoing neuronal
injury in neurocognitively normal individuals with HIV infec-
tion. The degree of injury is comparable to neurocognitively
impaired individuals but is influenced by age.
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HTLV-1 epigenetic modification of the FoxP3 TSDR
in HAM/TSP decreases the functional proliferative
suppression of Tregs
Monique Anderson1, Yoshimi Enose-Akahata2, Raya
Massoud2, Nyater Ngouth2, Yuetsu Tanaka3, Unsong Oh4,
Steven Jacobson2
(presenting author: andersonmr2@mail.nih.gov)
1Neuroimmunology Branch, NINDS, NIH, UVA;
2Neuroimmunology Branch, NINDS, NIH;
3Department of Immunology, Graduate School of Medicine,
University of the Ryukus;
4Department of Neurology, Virginia Commonwealth University
HTLV-1 is a human retrovirus that is associated with adult T-
cell leukemia/ lymphoma (ATLL) as well as the
neuroinflammatory disorder HTLV-1 associated myelopathy/
tropical spastic paraparesis (HAM/TSP). In these patients,
HTLV-1 is primarily found in the CD4+CD25+ T cell subset
(Regulatory T cells or Tregs), the cells that are responsible for
peripheral immune tolerance and which are known to be dys-
functional in HAM/TSP. However, due to the inherent inflam-
matory component of HAM/TSP, markers normally used to
characterize T regs, such as CD25, FoxP3, and CTLA4 are
problematic in differentiating Tregs. Recent evidence has
shown that FoxP3 expression and function is determined epi-
genetically, specifically through DNA methylation in the Treg-
specific methylation region (TSDR). To more precisely charac-
terize Treg cells, we analyzed the methylation status of specific
CpGs in the TSDR in PBMCs, CD4+ T cells, and CD4+
CD25+ T cells from normal healthy donors (NDs) and HAM/
TSP patients. We demonstrated that there is decreased deme-
thylation in PBMCs and CD4+CD25+ T cells from HAM/TSP
patients as compared to NDs, despite the increased CD4+
CD25+ frequency in HAM/TSP. Further, decreased TSDR
demethylation correlates with decreased functional suppres-
sion in Treg cells of HAM/TSP patients. Additionally,
increased HTLV-1 tax expression in PBMC culture corre-
lates with this decrease in FoxP3 TSDR demethylation.
Overall, we suggest that HTLV-1 infection decreases Treg
functional suppressive capacity in HAM/TSP through epi-
genetic modification within the FoxP3 locus and that this
dysregulation of Treg function may contribute to HAM/TSP
disease pathogenesis.
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Multiple HIV-1 LTR single nucleotide polymorphisms
(SNPs) that occur in peripheral blood and correlate
with disease severity are also present in infected brain
samples
Gregory Antell1, Michael Nonnemacher2, Vanessa Pirrone2,
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Sonia Shah2, Shendra Passic2, Brandon Blakey2, Wen Zhong2,
BrianMoldover3, Rui Feng4, Jeffrey Jacobson5, BrianWigdahl1
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Systems, Drexel University, Department of Microbiology and
Immunology, Center for Molecular Virology and Translational
Neuroscience, Institute for Molecular Medicine and Infectious
Disease, Drexel Unive;
2Department of Microbiology and Immunology, Center for
Molecular Virology and Translational Neuroscience, Institute
for Molecular Medicine and Infectious Disease, Drexel
University College of Medicine,
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The identification of HIV-1 long terminal repeat (LTR) single
nucleotide polymorphisms (SNPs) from peripheral blood
(PB)-derived integrated proviral DNA that correlate with clin-
ical parameters of disease severity can be used to inform the
role of viral genetics in HIV-1 pathogenesis. HIV-1 LTR
sequences from subtype B patients enrolled in the DrexelMed
HIV/AIDS Genetic Analysis Cohort in Philadelphia were
analyzed with respect to CD4+ T-cell count and viral load
over multiple visits. The HIV-1 LTR serves as the viral pro-
moter and is responsible for regulating the transcriptional
activity of the integrated provirus. Current studies focus on
the identification of LTR signatures derived from PB virus that
can be used as molecular markers of increased risk for devel-
opingmore severe HIV disease or neurological complications.
To date, eight SNPs have been identified that associate with
CD4+ T-cell count or viral load. To complement and compare
data collected from the integrated provirus of cells in the PB
compartment, brain samples obtained from the National
NeuroAIDS Tissue Consortium (NNTC) were also analyzed.
The LTR sequences derived from provirus extracted from
multiple brain regions demonstrated the presence of all eight
SNPs, which independently associated with neurocognitive
status at the time of death. These results suggest that evolution
of the HIV-1 genomic swarm throughout disease may result in
viral phenotypes that are indicative or predictive of severe
HIV disease. Given that these SNPs were also present in the
CNS at end stage disease, these polymorphisms may also be
associated with HIV-associated neurocognitive disorders
(HAND). This work is supported by NIH/NINDS R01
NS32092, NIDA R01 DA19807, NIMH P30 MH092177,
and NIMH T32 MH079785.
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Characterization of Monocytes and Microglia of SIV
Infected Pigtailed Macaques
Claudia Avalos, Suzanne Queen, Brandon Bullock, Ming Li,
Erin Shirk, Lucio Gama, Janice Clements
(presenting author: cavalos2@jhmi.edu)
Molecular and Comparative Pathobiology, Johns Hopkins
School of Medicine
The main barrier to HIVeradication continues to be the presence
of viral reservoirs in infected patients despite treatment with
antiretroviral drugs. Furthermore, as patients are living longer
under treatment, the prevalence of HIV-associated
neurocognitive disorders (HAND) has increased. Postmortem
analyses of CNS tissues suggest that HAND is dependent on
the migration of monocytes to the brain. Monocytes have been
shown to traffic through the blood brain barrier and populate the
perivascular sites where they differentiate into macrophages and
contribute to viral persistence and latency. In addition, infected
monocytes have been found in the blood of HIVinfected patients
treated with HAART. Our laboratory has developed and charac-
terized an accelerated, consistent SIV infected pigtailed macaque
model for HIVAIDS and neurologic disease. Using SIV infected
pigtailed macaques we have characterized by flow cytometry the
activation state of monocytes and microglia during infection. In
addition, we have recently developed an assay to quantitate the
number of infected blood monocytes and tissue macrophages
similar to the quantitative outgrowth assay used on HIVand SIV
CD4+ Tcells. Our assay has allowed us to further investigate the
number of SIV infected cells in peripheral blood and tissues of
SIV infected pigtailed macaques that could potentially contribute
to SIV persistence in the brain.
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Morphine reduces gp120-mediated cell death
in vitro by altering the processing of proBDNF
Alessia Bachis, Lee Campbell, Allyssia Boelk, Italo
Mocchetti
(presenting author: bachisa@georgetown.edu)
Department of Neuroscience, Georgetown University
Medical School
Opioids have been shown to potentiate glia responses to HIV
viral protein Tat and gp120 and to exacerbate gp120 and Tat
toxicity. However, morphine protects cortical cultures against
the toxic effect of M-tropic gp120 BaL. Using rat primary
neurons we have observed that repeated exposure to morphine
for 5 days attenuates gp120 IIIB-mediated neurotoxicity. Thus,
further research is required to determine whether opioids ex-
hibit neuroprotective or neurotoxic activity in the presence of
HIV and HIV viral proteins. HIV and the envelope protein
gp120 have been shown to reduce the levels of the trophic
factor BDNF by altering the enzymatic processing of its pre-
cursor proBDNF. Interestingly, chronic morphine has been
shown to increase the levels of tissue plasminogen activator
(tPA), the activator of plasmin, that converts proBDNF into
BDNF. Thus, opioidsmay reduce the neurotoxic effect of HIV/
gp120 by augmenting the downstream enzymatic processing
of proBDNF. Using rat cortical neurons, we observed that
morphine increases the levels and release of BDNF while at
the same time decreases proBDNF. Interestingly, a similar
S6 12th ISNV, Washington, DC, USA
imbalance in the ratio proBDNF/mature BDNFwas confirmed
in rats chronically (5 days) injected with morphine. The effect
of morphine on proBDNF is due to an increase in the levels
and activity of tPA. These data suggest that morphine’s
ability to alter proBDNF processing might be crucial to its
neuroprotective effect against gp120. Our studies identify a
new mechanism of interaction between morphine and HIV
proteins.
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Manganese EnhancedMRI as a Diagnostic Tool for HIV-1
Associated Neurocognitive Disorders in Murine
NeuroAIDS
Aditya Bade1, Santhi Gorantla1, Prasanta Dash1, Edward
Makarov1, Jaclyn Knibbe1, Larisa Poluektova1, Howard
Gendelman1, Michael Boska2, Yutong Liu2
(presenting author: yutongliu@unmc.edu)
1Department of Pharmacology and Experimental Neuroscience,
University of Nebraska Medical Center;
2Department of Pharmacology and Experimental Neuroscience,
Department of Radiology, University of Nebraska Medical
Center
Despite the wide-spread use of antiretroviral therapy (ART), up
to 52% of infected patients suffer some form of cognitive
impairment termed HIV-1 associated neurocognitive disorders
(HAND). HAND, however, remains a diagnosis of exclusion of
a range of opportunistic infections and cancers. Thus, tests that
can distinguish HAND from such disorders are sorely needed
in monitoring disease progressions and for therapeutic inter-
vention. To this end, we developed manganese enhanced mag-
netic resonance imaging (MEMRI) to differentiate the specific
consequence of HIV-1 infection to the brain in a mouse model
of human neuroAIDS. MEMRI signal intensity, in the hippo-
campus and amygdala, of virus-infected animals showed pro-
found changes in Mn2+ accumulation. Such region-specific
affects highlight neuronal aberrations linked to cognitive func-
tion in infected animals.We posit thatMEMRI could be used as
imaging biosignature to investigate neuropathologic aberrations
associated with advanced viral infection.
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Activation of TRPML1 clears intraneuronal Abeta
in pre-clinical models of HIV infection
Mihyun Bae1, Veera Venkata Ratnam Bandaru1, Myounghwa
Lee2, Avindra Nath2, Xuesong Chen3, Jonathan D. Geiger3,
Myriam M. Gorospe4, Mark P. Mattson5, Norman Haughey1
(presenting author: mbae002@gmail.com)
1The Johns Hopkins University School of Medicine, Depart-
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The widespread use of cART in developed countries has
dramatically increased the expected lifespan of HIV-
infected patients. This extended lifespan is frequently
accompanied by premature brain aging, and accelerated
deposition of amyloid beta (Abeta) peptides primarily
located to lysosomal and autophagic compartments. The
molecular mechanism that regulates the intraneuronal
deposition pattern of Abeta is not understood. In this
study we identified a series of cellular events evoked by
neurotoxic HIV-gp120 that promotes the formation and
intraneuronal deposition of Abeta. In triple transgenic
gp120/APP/PS1 mice, Abeta1-42 containing plaques
were deposited at a younger age with an intraneuronal
deposition pattern. This Abeta deposition was accompa-
nied by increased levels of sphingomyelin and ceramide.
Ultrastructural analysis of brain tissues showed enlarged
lysosomes with numerous electron dense and lipid in-
clusions in gp120/APP/PS1 mice. In neuronal cultures,
gp120 accelerated the formation and perturbed the clear-
ance of Abeta through mechanisms that involved an
atypical activation of the chemokine receptor CXCR4,
with signaling through protein kinase A, and cJun N-
terminal kinase (JNK). This mitogen activated protein
kinase pathway diverged at the level of JNK to increase
transcriptional expression of beta-secretase (BACE1)
through inhibition of peroxisome proliferator-activated
receptor gamma, and increased amyloid precursor pro-
tein (APP) expression through a post-transcriptional
mechanism involving enhanced binding of the heteroge-
neous nuclear ribonucleoprotein C (hnRNPC) to APP
mRNA. APP and BACE1 were co-sequestered into
membrane microdomains where BACE1 activity was
enhanced, and Abeta production increased. This in-
creased Abeta was not effectively cleared, and accumu-
lated in lysosomes in conjunction with sphingomyelin
and calcium. Stimulating calcium efflux from lysosomes
with an agonist of TRPML1 channels facilitated the
clearance of sphingomyelin and Abeta. These data sug-
gest that strategies to preserve or restore lysosomal
function in neurodegenerative settings may provide neu-
ronal protection by increasing the cellular clearance of
sphingolipids and Abeta peptides.
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Varicella zoster virus (VZV), an exclusively human neuro-
tropic alphaherpesvirus, causes varicella (chickenpox). After
primary infection, VZV becomes latent in ganglionic neurons
along the entire neuraxis. VZV reactivation usually results in
zoster (shingles), often complicated by postherpetic neuralgia,
and less frequently by VZV meningitis, vasculopathy, mye-
lopathy and ocular disease. Attempts to study VZV infection
of neurons in vitro has been difficult, primarily because "con-
taminating" non-neuronal cells become lytically infected
leading to destruction of the culture. During lytic VZV
infection, VZV DNA replicates, viral genes are transcribed
and translated, and high titers of infectious particles are
produced leading to cell death in a week or less. Herein,
we show that VZV-infected differentiated neurons (>95%
beta III-tubulin positive) do not develop a cytopathic effect
and lack markers of an activated apoptotic pathways (cleaved
caspase-3 and -9). In neuronal cultures, a steady state level of
VZV DNA is maintained; virus gene transcription is delayed
~7 days and reduced 3- to 6-fold compared to lytically
infected fibroblasts. VZV glycoprotein C, an important struc-
tural protein involved in virion assembly, is reduced. Electron
microscopic analysis revealed high numbers of aberrant viral
particles, frequently lacking DNA cores, suggesting that non-
lytic infection of neurons in vitro results from defective virus
assembly, in part due to reduced glycoprotein C production.
Our successful development of a model of non-lytic VZV
infection of neurons will allow studies that elucidate molecu-
lar mechanisms involved in virus reactivation.
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Despite effective viral control through combinational
antiretroviral therapies, approximately half of HIV-
infected patients will develop some form of cognitive
impairment. While we do not fully understand why
some individuals infected with HIV will develop cogni-
tive impairments while others do not, persistent low-
level inflammation is thought to contribute to cognitive
decline. Eicosanoids are a family of signaling molecules
produced through the oxidation of 20-carbon fatty acids
that regulate inflammation and immunity. Although the
eicosanoids are comprised of a large number of prod-
ucts, those derived from the omega-3 fatty acids
docosahexaenoic acid (DHA), or eicosapentaenoic acid
(EPA) tend to be protective, while those obtained
through omega-6 fatty acids arachidonic acid (AA), or
linoleic acid (LA) are more often pro-inflammatory. In
the present study, we measured eicosanoids in plasma
from 98 HIV+ patients, and 25 healthy control subjects.
We found 8 eicosanoid metabol i tes that were
undetectable in control subjects and elevated in HIV+
patients. These included a mixture of EPA derived me-
tabolites (15-HEPE, 18-HEPE, 8(9)-EpETE), DHA de-
rived metabolite (13-HDoHE), and AA metabolites
(LXA4, 8(9)-DiHETrE, HxB3, 5(12)-DiHETE). At baseline,
cognitively impaired HIV+ patients who had better cognitive
performance at the following visit had higher levels of 26
eicosanoid metabolites compared to HIV+ patients who were
either cognitively normal, or cognitively impaired at both
visits, or to cognitively normal control subjects. These includ-
ed 3 EPA metabolites, DHA and 9 DHA metabolites, LA and
4 LA metabolites, AA and 8 AA metabolites. A number of
these metabolites have been associated with vascular and
cardiac dysfunction, and altered platelet aggregation. As these
HIV+ patients cognitive status improved, levels of these
metabolites decreased. These preliminary results suggest
that alterations in eicosanoid production in HIV-infected
patients may contribute to cognitive impairment through
mechanisms that involve alterations in vascular and platelet
function. Supported by P30-Pilot Award, JHUNIMH Center
to Bandaru
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HIV encephalitis (HIVE) is the neuropathological corre-
late of the most severe form of HIV-associated
neurocognitive disorders (HAND), which affect most
HIV infected individuals. Previously, we reported expan-
sion of a monocyte subset (CD14+/CD163+/CD16+) in
HIV infected individuals with detectable plasma viremia
that is phenotypically similar to macrophages that accu-
mulate in the central nervous system (CNS) in HIVE.
We hypothesize that macrophage colony stimulating fac-
tor (M-CSF), which is elevated in cerebral spinal fluid
in HIVE, drives expansion of this monocyte subset. In
peripheral blood mononuclear cells (PBMC), M-CSF
increases the frequency of FLT3+ monocytes. Hence,
we examined CNS tissue from SIV infected rhesus
macaques and patients with HIV for possible alterations
in FLT3 expression. Independent of the presence or
absence of infection, neuronal expression of FLT3 is
observed in all CNS tissues examined but is increased
in SIV/HIV, with even greater expression in SIVE/
HIVE. A relationship between FLT3 expression and
neuronal injury is implied by the corresponding de-
crease in MAP2 positivity with increased FLT3. FLT3
ligand (FL) reveals a similar pattern of increased neu-
ronal expression in SIVE. In contrast to neuronal FLT3
and FL, macrophage/microglial expression is only ob-
served in SIV/HIV infection, with greater expression
seen in encephalitis. In vitro studies demonstrate altered
FLT3 expression in differentiated SK-N-SH cells in
response to various concentrations of FL, interleukin-
34 (IL-34) and M-CSF and over different time intervals,
suggesting multiple factors may contribute to altered
FLT3 expression in the CNS. The functional role of
FLT3/FL expression in SIV/HIV is unclear; however,
interaction of FLT3 with its ligand is associated with
neuronal survival in the developing CNS. As such,
FLT3 and FL expression in CNS disease may be neu-
roprotective through promotion of neuronal survival.
FLT3 expression by macrophage/microglia, however,
may contribute to CNS pathogenesis in HIV/SIV by
promoting survival of activated infected and non-
infected macrophages/microglia.
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Recent outbreaks of encephalomyelitis caused by arthropod-
borne alphaviruses reveal their importance as an emerging
cause of human disease and disability. Patients that recover
from the acute disease, especially infants and children, are
often left with life-long debilitating neurological defects, such
as cognitive deficits, impaired motor control, and emotional
and behavioral disturbances. Sindbis virus (SINV), the proto-
typic alphavirus, produces rash and arthritis in humans but is
neurotropic in mice, providing an excellent model for study-
ing alphavirus-induced encephalomyelitis. Previous studies
have shown that infectious virus is cleared within 7-8 days,
but viral RNA is clearedmore slowly and persists at low levels
for the life of the animal. Neuronal damage seen with
alphavirus infection is thought to be due to both the immune
response and glutamate excitotoxicity. Five-week-old C57BL/
6 mice were intranasally inoculated with SINV or PBS. A
battery of behavioral tests was used to assess motor and
neurocognitive function at different phases of infection.
Following behavioral tests, brains and spinal cords were
collected, and infectious virus titers, SINV RNA levels,
and viral antigen presence were assessed. At the height of
active virus infection, characterized by peak infectious
virus titers and detectable viral antigen in the brain,
SINV-infected mice demonstrated increased activity in
open field-testing and markedly impaired hippocampal-
dependent memory in contextual and cued fear condition-
ing. Following recovery from clinical disease, SINV-
infected mice continued to show memory deficits in con-
textual fear conditioning when only viral RNA was present
in the brain. Treatment with a glutamine inhibitor that
affects both inflammation and glutamate excitotoxicity, 6-
diazo-5-oxo-L-norleucine, partially inhibited clinical dis-
ease and neurological deficits as measured by contextual
fear conditioning. These findings show that SINV induces
long-term neurological sequelae in mice that persist be-
yond active virus infection, and inhibition of both inflam-
mation and glutamate excitotoxicity can partially mitigate
development of these deficits.
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Multiple sclerosis (MS) is a debilitating chronic inflammatory
disease of the nervous system which affects approximately
one million individuals worldwide with higher occurrences in
females. Consomic mouse lines, also known as chromosome
(Chr) substitution strains, are unique in that they allow for
accelerated detection (compared to traditional backcross or F2
intercross mapping) of binary/quantitative trait loci by direct
genome-wide physical mapping from genetically distinct pa-
rental strains. We have employed myelin oligodendrocyte
glycoprotein-induced experimental allergic encephalomyelitis
(MOG-EAE), a mouse model of MS, to evaluate the sex
differences in consomic B6-Chr#PWD/PhJ mice (Mus
musculus domesticus). We utilized a panel of 26 B6-
Chr#PWD/PhJ consomic and sub-consomic strains of mice
covering 17 autosomes from the wild derived PWD strain
(Mus musculus musculus) to position genes controlling
MOG-EAE in this strain combination, fifteen of which exhib-
ited evidence of such loci. Of the twenty linkages found, seven
were male-specific, four female-specific, and nine were non-
sex specific, suggesting a greater genetic load in males than in
females.We then identified common evolutionarily conserved
pathways underlying the sexual dimorphisms in EAE and
multiple sclerosis (MS) susceptibility. We find that there is a
greater overlap of pathways common to MS and male EAE
compared to female EAE (33 vs. 7) that are the basis for these
sexual dimorphisms. Importantly, our results provide a
scheme by which consomic mouse strains can provide a better
understanding of polygenic human diseases.
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Immune pressure exerted by MHC class I-mediated cytotoxic
T-lymphocytes (CTLs) drives HIV escape mutations; none-
theless, the relationship between viral escape and HIV CNS
disease remains poorly understood. MHC-I allele Mane-
A1*084:01:01 confers resistance to SIV-induced CNS disease
in pigtailed macaques, and prototypic escape (K165R) de-
velops in the immunodominant SIV Gag KP9 epitope. We
hypothesize that 1) escaped virus has reduced fitness in vivo
and in vitro, and 2) CTL-mediated immune pressure switches
from the immunodominant Gag epitope to a subdominant
epitope in animals inoculated with SIV K165R. We used
site-directed mutagenesis to insert the K165R Gag escape
mutation into the backbone of the neurovirulent molecular
clone SIV/17E-Fr, producing the clone SIV/17E-Fr
K165R. Replication of SIV/17E-Fr K165R versus SIV/
17E-Fr was compared in CEMx174 cells and primary
macaque microglia, macrophages, and lymphocytes. Al-
though K165R was replication competent in all cell types,
viral replication was reduced compared to SIV/17E-Fr. To
extend in vitro findings, Mane-A1*084:01:01 expressing
macaques were inoculated: three with SIV/17E-Fr K165R,
and three with wildtype, parental SIV/17E-Fr. There were
no differences in plasma viral loads and slightly lower
CSF viral loads in animals inoculated with K165R versus
those inoculated with wildtype. In the absence of the
immunodominant epitope Gag KP9, CTL-mediated im-
mune pressure redirected to the sub-dominant Mane-
A*084:01:01-restricted SIV Tat epitope KVA10 with no
viral escape evident. Most surprisingly, in animals inocu-
lated with K165R, the escape mutation K165R was geno-
typically stable in the plasma, but rapidly reverted to WT
Gag KP9 in both CSF and in microglia. These data
clearly demonstrate that viral fitness in the CNS is differ-
ent from the periphery. As therapeutic vaccination strate-
gies to enhance CTL responses against HIV gag could
promote HIV escape, it is vital that we understand the
consequences of viral escape on CNS disease.
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The gene ApoE is mapped to chromosome 19, and the E*4
allele is found in approximately 14%of the population. Several
recent studies have examined ApoE among individuals with
HIV disease, and to date, the data suggest that any links are
weak, at best. We describe here the relationships among ApoE
genotypes, subject characteristics, incident neuropsychological
impairment, and time to death among men enrolled in the
Multicenter AIDS Cohort Study (MACS). Genomic DNA
was isolated from lysates of either buffy-coat or B-cell immor-
talized cell lines from 2846 men (median age: 34, range: 17-
69) in the MACS. Genomic DNA concentration and quality
was assessed using UV and/or by fluorometric quantitation.
End-point genotyping of ApoE variants rs429358 [C/T] and
rs7412 [C/T] was performed using TaqMan and OpenArray
technologies. 1689 of the men were HIV-infected and 1157
were uninfected. 23.2% of the men who identified themselves
as white had at least one copy of the E*4 allele, whereas 31.2%
of other races had at least one E*4 allele (Odd’s Ratio = 0.65
(0.54 - 0.79)). In separate models by race (White/Minority), we
found no significant associations between the presence of an
E*4 allele and age, HIV status, death, or neuropsychological
outcome. We used Cox Proportional Hazard Models to inves-
tigate time to death and found a significant association between
HIV infection and time to death (all cause), as well as older
age, race, and education. ApoE status was not significantly
associated with time to death. There were significant associa-
tions between time to neuropsychological impairment, age,
education, and HIV serostatus, but no association with
ApoE*4. There were no interactions between ApoE*4, HIV
infection, age and the outcomes of interest. These results
confirm and extend previous findings that that the ApoE*4
allele is not associated with death or neuropsychological im-
pairment among men in this age group.
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The Multicenter AIDS Cohort Study follows the natural and
treated history of HIV, and a key component is the biannual
assessment of cognitive functions. We describe here an anal-
ysis of cohort and survivorship factors. 5470 men (78.5%) in
the MACS cohort completed at least one neuropsychological
test battery; 3687 enrolled in Cohort 1 (1984/1985), 474 in
Cohort 2 (1987/90) and 1309 in Cohort 3 (2001/03. C1 was
predominantly white, whereas C2 and C3were predominantly
African-American. Also, C1 had more education than C2,
which had more education than C3. The men in C3 were older
than those in C1 or C2. The men in C3 endorsed more
depressive symptoms than did C1 or C2. Estimated IQ dif-
fered as a function of cohort (i.e., C1>C2>C3) and on mea-
sures of psychomotor speed, verbal and non-verbal memory
and fine motor coordination. As of December 2012, the men
were classified as active, inactive, or dead; 32% of C1 and C2
were still active, compared with 66% of the men in C3.
Among the uninfected men, there was no difference in the
rate of cognitive abnormality between C1/C2 (combined) and
C3, whereas, for the infected men, the rate of abnormality was
significantly lower in C3 than in C1/C2. The seronegative men
who remained alive and active in the study showed a small, but
consistent increase in the rate of abnormal cognition between
the first and last visits (6.8 vs. 9.2%). Severe cognitive abnor-
mality rose to 12.5% among the inactive men and 16.4%
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among the individuals who died during follow-up. Differences
in volunteer recruitment are reflected in the cohort character-
istics at the baseline visit, and they tended to persist among the
active participants in 2012. Loss of data due to death or drop-
out may affect the estimates of prevalence of neuropsycholog-
ical abnormalities among the study participants.
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Progressive multifocal leukoencephalopathy (PML) onset,
caused by Polyomavirus JC (JCPyV) in patients affected by
multiple sclerosis (MS) during natalizumab treatment, raised
concerns about the safety profile of this agent. Therefore, the
aims of this study were the JCPyV reactivation monitoring
and the noncoding control region (NCCR) and viral protein 1
(VP1) analysis in patients affected by MS and treated with
natalizumab. We performed JCPyV-specific quantitative PCR
of biological samples collected at moment of recruitment (t0)
and every 4 months (t1, t2, t3) for 1 year. Subsequently,
analysis of NCCR and VP1 rearrangements was carried out.
Moreover a 2-step virus-like particle-based enzyme-linked
immunosorbed assay was performed at t0 and t3, to detect
specific anti-JC virus antibodies in serum of the enrolled
subjects. Data were analyzed using chi-square test. Results
showed a significant association between JC viruria and
JCPyVantibodies after 1 year of natalizumab (p=0.04). More-
over, sequences isolated from peripheral blood mononuclear
cells (PBMCs) of 2 patients with JCPyVantibody at t0 and t3,
showed a NCCR Type IIR with a duplication of a 98bp unit
and a 66bp insert, resulting in a boxB deletion and 37 T to G
transversion into the Spi-B binding site. In all patients, a
prevalence of genotypes 1A and 1B, the predominant JCPyV
genotypes in Europe, was observed. In conclusion, it could be
important to understand whether the specific inflammatory
scenario of multiple sclerosis could affect JCPyV reactivation
from latency, in particular from kidneys. Moreover, for a more
accurate PML risk stratification, testing JC viruria seems to be
useful to identify patients who harbor JCPyV but with an
undetectable JCPyV-specific humoral immune response. In
these patients, it may also be important to study the JCPyV
NCCR rearrangement: in particular, Spi-B expression in
PBMCs could play a crucial role in JCPyV replication and
NCCR rearrangement.
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HAND patients exhibit changes in the key brain regions
responsible for motivational drive (mesocorticolimbic sys-
tem). The HIV-1 transgenic rat is chronically exposed to low
levels of HIV-1 proteins in the brain, which may occur in
humans with cART. The present study used adult female,
ovariectomized, HIV-1 transgenic rats (N=29). Initially, a five
bottle preference test, using 0%, 1%, 3%, 10%, and 30% (w/v)
sucrose solutions, following 22 h of water restriction, was
used to evaluate response to novelty as well as potential
sensory differences between HIV-1 and control rats. Although
there was no difference in overall volume consumed on the
initial test day, HIV-1 rats consumed significantly more of the
10% sucrose solution, suggesting a heightened novelty re-
sponse. Across the following 5 days of testing, HIV-1 and
control rats did not significantly differ in their pattern of
consumption of sucrose, suggesting that overall taste prefer-
ence for sucrose was not altered. Subsequently, rats learned to
respond for 5% sucrose (w/v) reinforcement in operant con-
ditioning chambers. Animals were briefly water restricted
during autoshaping; all animals eventually progressed onto
non-restricted training, according to an increasing fixed-ratio
requirement (FR1, FR2, FR3). There was a significant retar-
dation in the rate at which the HIV-1 rats progressed to higher
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FR schedules compared to controls, suggesting a change in
the basal internal motivational state. Most critically, the pres-
ent results suggest alterations in the internal motivational state
of HIV-1 animals, as displayed by their inability to meet
criterion and progress through the fixed ratio schedules, which
were not readily attributable to any alterations in novelty or
taste preference. These results suggest that the HIV-1 trans-
genic rat may have underlying internal motivational deficits
for obtaining natural rewards such as sucrose, not unlike their
alterations in responding for drugs of abuse.
Grant numbers: DA013137, HD043680, GM081740
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Objective: In endemic areas, malaria and HIV frequently
infect the same host but their combined effects on the brain
are poorly understood. We hypothesized that the combination
of malaria and HIV would amplify monocyte/macrophage
activation and contribute to worsening of neurologic HIV
disease.
Methods: 269 subjects, 174 HIV+ and 95 HIV-, were evalu-
ated using a comprehensive neuropsychological test battery.
Global and domain-specific deficit scores (GDS and DDS)
were generated and used for determining impairment. All
subjects lacked symptoms of acute malaria and AM was
diagnosed based on peripheral smear findings. Hemoglobin,
hematocrit, CD4+ T-cell counts, HIV RNA levels, soluble
CD163, and soluble CD14 were measured.
Results: AM was not statistically significantly more common
in HIV+ than in HIV- subjects (36% vs. 29%, odds ratio (OR)
1.36, p > 0.10). Overall, AM was not associated with NCI
(p > 0.10). Among AM subjects, HIV+ were more likely to
have motor impairment than HIV- (35% vs. 42%, p=0.03).
AM trended toward an association with executive functioning
impairment after accounting for HIV status (p<0.10). An
interaction between CD4+ counts and AM was present: AM
was associated with NCI among people with CD4+ counts
below 200 (35% vs. 22%, OR 1.90) but the opposite was true
for subjects who had higher CD4+ counts (21% vs. 30%, OR
0.61). sCD14 levels were significantly higher in the M+/H+
group compared to the M-/H+ group (p=0.015). Higher
sCD14 levels were associated with higher odds of impairment
(OR=9.4, 95% CI=1.1,88; p=0.046) but the interaction with
malaria was not significant.
Conclusion: AM is common among HIV+ individuals in
Nigeria. Malaria may lead to worse NC functioning, specifi-
cally in motor and executive functioning. Individuals with
greater immunosuppression are more likely to experience
impairment when co-infected with malaria. Malaria also re-
sults in higher levels of biomarkers of monocyte/macrophage
activation.
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Human beta-defensins (hBDs) are broad-spectrum antimicro-
bial peptides, secreted by epithelial cells and astrocytes, which
we and others have shown to inhibit HIV-1 in primary CD4+
T cells. In T cells, the intracellular inhibitory activity is medi-
ated by CCR6, a receptor that binds both the chemokine MIP-
3alpha and hBDs. Although loss of T cells contributes to
mucosal immune dysfunction, macrophages, by virtue of their
roles in both innate and adaptive immunity, are a major source
of persistence, spread of HIV, and development of complica-
tions, especially in the brain. Interestingly, hBDs are
expressed in the CNS but very little is known about their role
in the brain. We hypothesized that, besides T cells, hBDs
protect microglial cells and perivascular macrophages from
productive HIV infection. Our data on primary monocyte-
derived macrophages (MDM), which we use as an in vitro
model for microglial cells, show that hBD2 and -3 inhibit HIV
replication in a dose-dependent manner. We investigated the
mechanism(s) involved. We determined that hBD2 neither
alters surface expression of HIV receptors nor induces
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expression of anti-HIV cytokines or beta-chemokines in
MDM. Studies using a G-protein signaling antagonist in a
single-cycle reporter virus system showed that hBD2 sup-
presses HIV at an early post-entry stage via GPCR-mediated
signaling. Our data also illustrate that hBD2 blocks HIV by
enhancing expression of APOBEC3A and 3G. MDM express
the shared chemokine-hBD receptors CCR2 and CCR6,
albeit at variable levels among donors. However, neither
of these receptors is necessary for hBD2-mediated HIV
inhibition, suggesting that hBD2 can signal via addition-
al receptor(s). Preliminary data also show that hBD2 is
internalized in early endosomes in MDM. These find-
ings suggest that hBD2 inhibits HIV in MDM via more
than one mechanism, and may aid the development of
new approaches to treat HIV infection systemically and
in the CNS.
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Background: Previous studies suggested a possible role for
HHV-6B in mesial temporal lobe epilepsy (MTLE). HHV-6B
is the etiologic agent of roseola, while HHV-6A is associated
with central nervous system (CNS) disorders and may be
more neurotropic than HHV-6B.
Methods: Using digital droplet PCR (ddPCR) to examine
HHV-6A and HHV-6B viral DNA, we studied a new cohort
of 10 MTLE patients and six with focal cortical dysplasia
(FCD). DdPCR is a highly sensitive and precise novel PCR
technology that enables absolute quantification of target DNA
molecules.
Results: Viral DNA was detected in 60% of MTLE patients.
This positivity frequency is consistent with our previous find-
ings. In addition, we detected HHV-6A as well as HHV-6B.
Moreover, HHV-6A and HHV-6B DNA also were detected in
a subset of FCD patients. The detected viral copy numbers
varied across a wide range between patients and even within a
given patient, depending on regional sampling.
Conclusions: Our new data suggest viral presence in patients
with FCD and extend our findings in patients with MTLE,
with detection of HHV-6A not previously reported.
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Multiple sclerosis (MS) is a demyelinating disorder of the
central nervous system (CNS), believed to be autoimmune
in nature. Characteristic presence of oligoclonal bands
(OCBS) in CSF of almost 95% of MS patients supports the
long standing hypothesis of viral etiology. OCBs are found in
infectious CNS disorders where their antigenic target repre-
sents the causative agent, but a definite target of OCBs in MS
patients remains obscure. Mouse hepatitis virus (MHV) in-
duced neuroinflammation in mice is an experimental model
used to study mechanisms of demyelination. Neurotropic
MHV strains induce meningitis, encephalitis, and myelitis
during their acute phase and progressive demyelination in
the chronic phase of infection when viral particle is cleared
and acute inflammation is resolved. Affymetrix microarray
analysis of the mRNA expression from demyelinating MHV
strain infected spinal cord tissue revealed that during acute
infection there is a robust upregulation of various innate
immune genes which are mainly involved in antiviral immune
responses, phagolysosome maturation and MHC Class-II ex-
pression. During chronic infection, there is a 10-fold upregu-
lation of several Ig mRNAs (Ighg3, IGJ, Igk-V28 andIgkv4-
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68), with a shift of Th1 and Th2 immune responses in acute
and chronic inflammation stages. It has been known for a long
time that viral infection can induce Ig molecules, but the
mechanism of induction was not clear. Demyelinating MHV
infection induced innate immune signalling and the innate
immune effector molecules induce B cell activation and ex-
pression of several oligoclonal genes which could play a
major role in antibody mediated progressive demyelination.
This cause effect relationship of viral infection and induction
of oligoclonal Ig mRNAs paves a way to understanding B cell
activation in demyelination. Findings may help advance our
understanding of viral induced and antibody mediated
demyelination in MS.
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Symptomatic abnormalities of the peripheral nervous system
(PNS) are among the most common complications of HIV-1
infection. Although anti-retrovirals have been successful in
ameliorating the constitutional manifestations of AIDS and
reducing the severity of many neurological complications
caused by HIV infection, there has been no significant impact
on the incidence or severity of HIV sensory neuropathy (HIV-
SN). Here, we used 12 SIV-infected CD8 depleted rhesus
macaques as a model of HIV-SN and 5 uninfected controls.
10 of the 12 SIV-infected animals (83%) developed moderate-
to-severe dorsal root ganglia (DRG) pathology. DRG tissues
had extensive activation of satellite cells, as measured by
CD68 and CD163 immunoreactivity, some of which were
productively SIV-infected via immunohistochemistry
(0.1-8.2%). BrdU pulse studies showed an increase in mono-
cyte traffic from bone marrow to the DRGs, which correlated
with the severity of pathology; uninfected 0.8%, mild 1.7%,
moderate 2.6% and severe 6.7%. Intraepidermal nerve fiber
(IENF) densities were determined from biopsies of the central
food pad. There was a significant decline in IENF densities in
7 of the 8 animals by 21 days post infection with an average of
a 48.7% loss in fibers at necropsy. A positive correlation
between the percentage of CD163+ macrophages surrounding
the sacral DRG neurons and the percent loss of IENF densities
was seen at necropsy (r= 0.94, P= 0.006). We conclude that
both resident macrophage activation and monocyte infiltration
play significant primary roles in DRG damage during HIV-
SN. Our data also suggest a link between macrophage activa-
tion in the DRGs, DRG pathology, and IENF loss in the
periphery in a rhesus macaque model of AIDS-induced pe-
ripheral neuropathy. Thus, future adjunctive therapies that
diminish macrophage activation and monocyte infiltration
may serve to ameliorate the HIV-SN severity previously
observed.
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HIV invasion of the CNS is coincident with acute HIV infec-
tion, and persists due to the chronic infection of long-lived
microglial cells, astrocytes and perivascular macrophages.
Cerebrospinal fluid (CSF) is becoming one of the most fre-
quently used biofluids for physiological studies of neurolog-
ical disorders since it is an ultra-filtrate of plasma and is the
collection point for drainage of the brain parenchyma. In this
proteomics study we used a relative quantitation method to
study pooled CSF samples from 10HIV-infected patients with
cognitive impairment, 10 HIV-infected patients with normal
cognition, and 10 healthy individuals, with the goal to identify
potential biomarkers for cognitive impairment. We used ad-
vanced two dimensional separation strategies and bioinfor-
matics to identify a total of identification of overall 673
proteins. Using statistical interpretation of the isobaric tags
for relative and absolute quantitation (iTRAQ) reporter
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intensities, 193 proteins with 95% confidence interval and p-
value ≤ 0.05 were selected based on permutation test that were
interpretable for quantitation. Using a cut off of 1.5 fold for
upregulation and 0.6 fold for downregulation, 16 proteins
were differentially expressed in HIV-infected individuals with
cognitive impairment (reporter p-value ≤ 0.05). Seven of these
proteins have been previously described as HIV-interacting
proteins including: endoplasmin, mitochondrial damage
mediator-BH3-interacting domanin death agonist (BID),
orosomucoid, apolipoprotein E, metalloproteinase inhibitor
2, peroxiredoxin-2 and the nuclear protein, ruvB-like 2. Sev-
eral proteins with possible neurological implications were also
identified including: forming-binding protein 1, C-reactive
protein, leukocyte-associated immunoglobulin receptor
1, renin receptor, mediator of RNA polymerase II transcription
subunit 14, multimerin-2, alpha-N-acetylglucosaminidase,
caldesmon, cadherin EGF LAGG-type receptor. This suggests
that not only a few but possibly a combination of biomarkers
that are highly correlated can predict neurocognitive status in
HIV-infected patients and might be involved in monocyte or
macrophage activation.
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Background: JCV causes progressive mult ifocal
leukoencephalopathy (PML) in immunocompromised pa-
tients. While there is no effective anti-viral therapy against
JCV, the cellular immune response is crucial in containment
of viral replication and is associated with PML survival. There-
fore, a preventative and therapeutic vaccine against JCV, which
can elicit this cellular immune response is urgently needed.
Methods: Replication incompetent adenovirus vaccine vector
serotype 5 (rAd5) was generated by insertion of the JCV VP1
gene. Naive C57BL/6 wildtype mice were immunized with a
single injection of either the rAd5-JCV or DNA rAd5-JCV.
Days 14 to 21 after immunization, mice were sacrificed and
splenocytes were isolated, stimulated with overlapping JCV
VP1 peptide pools and assayed by intracellular cytokines
staining (ICS) for IFN-gamma. Control mice were injected
with PBS and JC Mad-4 virions.
Results: Mice remained asymptomatic up to 21 days after
injections of JC virions, rAd5-JCV, DNA rAd5-JCVor PBS.
While JC virions elicited minimal cellular immune responses,
rAd5-JCV and DNA rAd5-JCV significantly increased the
percentages of JCV-specific CD4+ T-cells compared with
those elicited by JC virions (p<0.05). In addition, rAd5-JCV
significantly increased JCV-specific CD8+ T-cells compared
to DNA rAd5-JCV (p=0.05), and to JC virions (p<0.05).
Furthermore, DNA rAd5-JCV significantly increased JCV-
specific CD8+ T-cells compared to JC virions (p<0.05).
Conclusions: Both recombinant Adenovector and DNA plas-
mids expressing JCV VP1 proteins elicit strong JCV-specific
cellular immune responses in mice. Further development of
these vaccines may lead to clinical applications for prevention
and treatment of JCV-associated brain diseases.
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HIV-associated neurocognitive disorders (HAND) are preva-
lent in patients given highly active anti-retroviral therapy
(HAART). Neurotransmitter systems including inhibitory
GABAergic elements often are neurochemically abnormal in
HAND patients given HAART. We surveyed GABAergic
inhibitory neurotransmission in 449 brain specimens from
subjects with HIV infection, and 66 seronegative controls.
mRNAs from two rate-limiting enzymes of GABA synthesis
(glutamic acid decarboxylase 1 and 2; GAD1 and GAD2) and
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a gap junction-associated transcript expressed selectively in
GABAergic neurons (GJD2) were assayed using qPCR. All
three GABA-associated mRNAs were significantly decreased
in the dorsolateral prefrontal cortex (DLPFC) of HIV-positive
subjects. Abnormal expression was distributed widely in the
CNS including neocortex, neostriatum and cerebellum. Pa-
tients with and without HIV encephalitis had significantly
lower GABAergic mRNAs. Patients who died prior to and
after the era of HAART both had significantly lower
GABAergic mRNAs. Low GABAergic mRNAs were corre-
lated significantly with higher expression of mRNA markers
produced by endothelial cells including PECAM1 and VWF,
and with high expression of dopamine receptor type 2 mRNA
(DRD2L). Low GABAergic mRNA expression was specifi-
cally correlated with worse performance on testing for verbal
fluency. Immunoblotting and immunohistochemistry showed
protein-level changes in the HIV-infected brain specimens
including loss of GAD67 and parvalbumin staining intensity,
higher DRD2 expression in some GABAergic interneurons,
and swelling of endothelial cells. We conclude that abnormal
GABAergic tone is prevalent in HIV infected patients, and it
has a broad anatomical distribution in the CNS. Novel asso-
ciations with changes in dopamine transmission and endothe-
lial cell markers suggest roles in synaptic plasticity and con-
nection to the neurovascular unit.
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Thanks to an increasing panel of antiretroviral drugs, HIV
replication can be effectively controlled in infected patients.
However, there are limitations to ART, as immune activation
is not fully contained and penetration of most drugs into the
central nervous system (CNS) is inefficient. Thus, while
NeuroAIDS cases have diminished, HIV-associated
neurocognitive disorders (HAND) have become a far more
prominent problem. HIV neurovirulence has been associated
with viral tropism for macrophage/microglia (MG)/monocyte
lineages, but there is as yet a paucity of reliable animal models of
neurotropic HIV. To address this gap, we generated an MG-
tropic SHIV, named SHIV-Bo159N4p2. The resulting virus is
highly fusogenic and replicates to high levels in monocyte-
derived macrophages (MDM) andMG.We tested its replicative
capacity under the cover of depletion of CD8 cells or CD8 and
CD20 B cells in rhesus or pigtailed macaques (PMs). These
viruses replicated very well in vitro and in vivo (upon intrave-
nous or intrarectal inoculation) and reached peak viral loads in
plasma and CSF (10^6 to 10^9 copies/ml in plasma vs 10^5 to
10^8 copies/ml in CSF). Early-stage viruses were sensitive to
broadly neutralizing antibodies, soluble CD4 (sCD4) and in-
duced cross-clade neutralizing antibody responses. The late-
stage viruses differed in their sensitivity to sCD4 and broadly
neutralizing antibodies but remained R5 tropic. Notably, under
double depletion (CD8+CD20), 8 out of 11 PMs rapidly
progressed to disease within 2-4 months, while 2 out of 2 PMs
progressed to disease in < 2 years without depletion. Patholog-
ical changes in the brain in most PMs included astrogliosis,
chronic meningitis, perivascular cuffing or inflammation, gliosis
and few infectedMG, suggesting that these viruses cause milder
forms of neurological diseases. In summary, macrophage/MG-
tropic SHIVs will be valuable tools to study milder forms of
neurological disorders in a biologically relevant primate model.
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Studies suggest that uninfected and HIV infected CD14+
CD16+ monocytes transmigrate across the blood brain barrier
(BBB), mediating viral entry into the CNS and contributing to
chronic neuroinflammation that results in HIV associated
neurocognitive disorders (HAND) in greater than 50% of
HIV infected people. In some HIV infected drug abusers,
HAND is reported to be more severe. Increased extracellular
CNS dopamine is a common mechanism that occurs acutely
in response to intermittent drug use.We report that the number
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of peripheral CD14+CD16+ monocytes is increased in HIV
infected drug abusers. To study the effects of dopamine on
chemokine mediated CD14+CD16+ monocyte influx into the
CNS, uninfected peripheral blood monocytes were cultured
non-adherently with M-CSF to expand the number of CD14+
CD16+ cells. Cultured monocytes expressed CXCR4 and the
transmigration of these cells in response to CXCL12 and/or
dopamine was characterized using our human BBB model.
Unexpectedly, dopamine alone increased CD14+CD16+
monocyte transmigration. In contrast, dopamine had no effect
on T cells. Dopamine receptors D1R and D5R are higher,
while D4R is lower, in mature monocytes when compared to
T cells. The D1R/D5R agonist SKF 38393 increased CD14+
CD16+ monocyte transmigration, indicating the involvement
of these receptors in dopamine induced transmigration. Al-
though dopamine does not cross the BBB, CD14+CD16+
monocyte transmigration may be increased by dopamine me-
diated effects on BBB cells and/or on the transmigration
process once monocytes have penetrated the BBB in response
to chemokines. Mature monocytes were treated with dopa-
mine to determine the direct effects of dopamine on cellular
processes involved in transmigration. Dopamine increased
migration and pseudopodia formation, a component of cellu-
lar polarization involved in movement. Thus, the combination
of higher numbers of circulating CD14+CD16+ monocytes
and elevated dopamine in HIV infected drug abusers may
result in increased transmigration of these cells into the
CNS, contributing to the severity of HAND.
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Background: Whether active monocyte/macrophage traffic
with HIV infection is required for pathogenesis has not been
directly demonstrated.
Methods: Here we used a VLA-4 blocking antibody, Tysabri
(30 mg/kg once a week for three weeks), and treated
SIVmac251 infected, CD8+ lymphocyte depleted monkeys
with high viral load and CNS injury on 28 days post infection
(dpi) to stop monocyte/macrophage traffic (n=4). Additional-
ly, we treated another cohort of animals at the time of infection
(day 0, n=6) to stop productive infection of the brain and gut,
but not lymph nodes. In animals treated at 28 dpi, metabolite
concentrations of n-acetylaspartate over creatine (NAA/Cr)
were assessed biweekly by 1H MR spectroscopy (MRS).
Results: With Tysabri treatment at 28 dpi we found a stabiliza-
tion of neuronal injury (NAA/Cr) in frontal and parietal cortex.
Tissue analysis revealed significantly lower numbers of activat-
ed resident macrophages (CD68+), recently recruited
monocytes/macrophages (MAC387+, BrdU+), and productive-
ly infected cells (SIV p28+, RNA+) in the brain and small
intestine of Tysabri treated macaques when compared to con-
trols. SIV DNA was undetectable in all but one of 24 brain
tissue samples analyzed from 0 dpi Tysabri treated animals,
whereas similar concentrations of proviral DNAwere isolated
from gut tissue of Tysabri treated and untreated control ma-
caques. Animals treated with Tysabri had low to no LPS and
soluble CD163 in plasma. Ex vivo PBMCs from treated ma-
caques exhibited impaired adhesive and transmigratory capa-
bilities in response to proinflammatory stimulation.
Conclusions: Our studies using Tysabri at 28 days post-infection
in SIV-infected macaques demonstrate that stopping monocyte
traffic stabilizes CNS disease. Treating animals at the time of
infection blocked traffic of virus to brain, and reduced the number
of productively infected cells in the small intestine, raising the
possibility that Tysabri may be an effective agent for preventing
the formation of reservoirs during early HIV infection.
P37
Effect of Natalizumab treatment on peripheral blood
mononuclear cells subsets in MS patients
Silvia Carluccio1, Simone Dallari1, Serena Delbue1, Matteo
Gastaldi2, Diego Franciotta2, Roberto Bergamaschi2, Elena
Colombo2, Lucia Signorini1, Francesca Elia3, Pasquale Ferrante1,4
(presenting author: silvia.carluccio@unimi.it)
1Department of Biomedical, Surgical and Dental Sciences,
University of Milan, Italy;
2Mondino Neurological Institute, Pavia, Italy;
3Fondazione Ettore Sansavini, Lugo, Italy;
4Cittá Studi Clinical Institute, Milan, Italy
Natalizumab is a humanized monoclonal antibody against the
alpha4 subunit of VLA-4, a major integrin involved in the
transendothelial migration. Despite several trial studies
showed its efficacy in the treatment of Multiple Sclerosis
(MS), Natalizumab is not used as first-line drug since it was
reported to increase the risk of developing Progressive
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Multifocal Leukoencephalopathy (PML). Aim of this study
was to determine the immunological changes in Natalizumab-
treatedMS patients over the time, in order to better understand
the effects of the treatment on peripheral blood mononuclear
cells (PBMCs) subsets. For this purpose, the relative frequen-
cy of different leukocyte subsets and their expression of the
alpha4 and beta2 integrins were investigated.The analysis
were performed by flow cytometry on PBMCs recovered
from blood samples of 11 MS patients treated with
Natalizumab, followed up to two years. Eleven MS patients
treated with conventional therapy and 11 healthy subjects
were also enrolled as control groups.The analysis of the rela-
tive frequencies showed a decrease of the monocyte popula-
tion and an increase of the lymphocyte populations, in partic-
ular CD19+ and CD34+ cells. Within the monocyte popula-
tion, we could detect a significant decrease of not classic
CD14+CD16+, and an increase of classic CD14+CD16-,
associated with the course of the treatment. The integrins
expression was assessed by evaluating the Relative Fluores-
cence Intensity, which allowed to detect significant variations
within all the CD14+ subpopulations and the CD34+ popula-
tion. Additionally, a patients’ stratification based on the uri-
nary JCV and BKV DNA excretion was done to define
whether the viral status could affect the natalizumab treatment
and viceversa: CD3+ cells relative frequency increased in
patients excreting the viruses, while CD19+ relative frequency
decreased.
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Human T-cell lymphotropic virus type 1 (HTLV-1) is a retro-
virus that is the etiologic agent in a clinical neuromyelopathy
known as HTLV-1 associated myelopathy/tropical spastic
paraparesis (HAM/TSP). Quantification of the amount of
virus in a patient samples is critical for monitoring infection,
evaluating the efficacy of therapeutic agents, and assisting
with clinical diagnosis. Real-time PCR (qPCR) is the standard
method for determining HTLV-1 proviral load (PVL). How-
ever, qPCR is dependent upon well-defined standards and
calibration to a standard curve, precluding precise and accu-
rate quantification particularly at low cell concentrations. In
this study, we use a third generation PCR technique, digital
droplet PCR (ddPCR), which allows for direct quantification
of PVL. DNA samples are partitioned into thousands of
nanoliter-sized droplets, amplified on a thermocycler, ana-
lyzed for fluorescent signal, and normalized to a housekeeping
gene. Poisson distribution statistics are used to determine
absolute copy numbers independently of a standard curve.
We found that the intra-assay and inter-assay reliability of
ddPCR are robust and more consistent than those of qPCR.
Moreover, ddPCR yields similar patient PVL by quantifying
different viral genes. Our preliminary data suggests ddPCR
can also be used to examine viral gene expression, a key
player in the pathogenesis of HAM/TSP and an important
parameter to monitor during therapeutic interventions in this
condition. The reliability and precision of ddPCR for HTLV-1
quantification should be widely acknowledged as it might be
an important tool to further understand the clinical correlates
of the viral load in the context of HAM/TSP and other HTLV-
1 related conditions; however, further investigation is required
to determine the efficacy of ddPCR for mRNA analysis.
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HIV associated neurocognitive disorder (HAND) is a devas-
tating consequence of HIV infection in the current antiretro-
viral therapy (ART) era. The pathogenesis of HAND is a
multifactorial sequence of events including the transmigration
of HIV infected monocytes that cross the blood brain barrier
(BBB) resulting in infection of the central nervous system
(CNS) resident cells such as macrophages, microglia, and a
small population of astrocytes. Infection activates inflamma-
tion and subsequent cellular dysfunction and apoptosis. In
addition, viral reservoirs are generated within the CNS, and
upon activation, propagate viral infection and inflammation
years after primary infection. Thus, elimination of these cell
reservoirs is essential for the eradication of HIV from the brain
and its subsequent affects in pathogenesis of HAND. Our
preliminary data indicates that HIV infected microglia and
astrocytes are protected from cell death despite intracellular
pro-apoptotic signaling from mitochondrial dysregulation.
Mitochondrial release of cytochrome c into the cytoplasm is
normally induced by pro-apoptotic stimuli and is followed by
cell death. However, infected microglia and astrocytes resist
cell death even when cytochrome c is released from the
mitochondria into the cytoplasm. The mechanism by which
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HIV protects infected cells from cytoplasmic cytochrome c is
currently unknown, and understanding these mechanisms
may yield novel pharmaceutical targets for the treatment of
HAND. Key negative regulators of apoptosis are heat shock
proteins (HSP), which inhibit the pathway by which cyto-
chrome c induces cell death. Our hypothesis is that HIV
infected cells “hijack” heat shock proteins to avoid apoptosis
induced by cytoplasmic cytochrome c. Targeting a pathway
utilized specifically by HIV infected cells will generate a
potential drug target for treatment of HAND.
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Background: The risk of JC virus (JCV) reactivation and
progressive multifocal encephalopathy (PML), while on
natalizumab, may increase with duration of exposure to the
drug. We sought to determine the prevalence of JCV
reactivation and potential changes in JCV-specific cellular
immunity during prolonged treatment.
Methods: We enrolled 39 JCV-seropositive multiple sclerosis
(MS) patients, including 32 on natalizumab monotherapy for
18-20 months (n=14), 22-25 months (n=7) and > 36 months
(n=11), 2 on interferon-beta monotherapy >36 months and 5
untreated MS patients as controls. We performed QPCR in
CSF, blood and urine for JCV DNA and we determined JCV
specific T-cell responses using enzyme-linked immunospot
(ELISpot) and intracellular cytokine staining (ICS) essays,
ex vivo and after in vitro stimulation with JCV peptides.
Results: JCV DNA was detected in the CSF of 3/35 (8.6%)
subjects tested (1 in 18-20 and 2 in >36 months on
natalizumab), who had no symptoms or MRI lesions consis-
tent with PML. None of the subjects had JCV DNA in plasma
but viruria was detected in 8/39 (20.5%) patients. JCV-
specific T cells were detected more frequently by ICS than
ELISpot ex vivo [26/39(66.7%) vs 6/39(15.3%);p<0.001] and
after in vitro stimulation [39/39 (100%) vs 33/38 tested
(86.8%);p=0.03]. Both assays were significantly more fre-
quently positive after in vitro stimulation than ex vivo
(p<0.001). JCV-specific CD4+ T-cells were more frequently
detected than CD8+ T-cells after in vitro stimulation
[39/39(100%) vs 34/39(87.2%);p=0.05]. No differences in
TΓÇôcell responses were observed between patients with
and without viruria. Testing of JCV DNA in peripheral blood
mononuclear cells is in progress.
Conclusions: Asymptomatic JCVreactivationmay occur in CSF
of natalizumab-treated MS patients. In vitro stimulation with
JCV peptides allows enhanced detection of JCV-specific cellular
immunity which is highly prevalent in MS patients regardless of
treatment, and is mediated by CD4+ and CD8+ T-cells.
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Microglial cells, the resident macrophages of the central nervous
system (CNS), play important roles in maintaining homeostasis
in the CNS and in the pathogenesis of HIV-associated neuro-
logical disorders (HAND). Brain imaging reveals increased
microglial activation in patients with chronic HIV-1 infection,
and in vitro studies suggest that altered microglial function may
affect neuronal health. The role of miRNAs in regulating mi-
croglia activities in the context of HAND remains to be defined,
although altered miRNA profiles in blood mononuclear cells of
patients with chronic HIV-1 infection have been reported. Fur-
thermore, differential expression of selected miRNAs in the
cerebrospinal fluid of HIV+ patients with and without enceph-
alitis has been demonstrated. To date, no study has profiled
miRNA changes in primary human microglia upon HIV-1
infection and exposure to HIV-1 envelope proteins. To address
this, we infected primary human fetal microglia (PHFM) with
macrophage-tropic HIV-1 pseudotype (BAL), vesicular stoma-
titis virus-G pseudotype (VSV-G) or incubated PHFM with
HIV-1 envelope glycoprotein gp120. RNAs was extracted from
virus/envelope treated cells and mock treated cells at various
time points. ABI Openarray assay was performed on the
extracted RNAs to profile miRNA changes, and these were also
examined using TaqMan quantitative Real-Time PCR (qRT-
PCR). BAL infection resulted in 4-fold increase in miR-146a
levels at 48hr post infection and gp120 exposure did not have
significant effect on miR-146a levels. In future studies, we will
elucidate whether observed changes inmiRNA levels contribute
to altered microglial function during the course of HIV infection
in the CNS.
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Viruses, such as human immunodeficiency virus, hepatitis A,
poliovirus, coxsackievirus B3, and foot-and-mouth disease vi-
rus, use a variety of mechanisms to suppress the human im-
mune system in order to evade clearance by the host. Therefore,
investigating how a few changes in the viral genome of a non-
lethal virus can lead to an alteration in disease, from survivable
to immunosuppression and death, would provide valuable in-
formation into viral pathogenesis. In this study we provide a
model of a murine virus [DA stain of Theiler’s murine enceph-
alomyelitis virus (TMEV)] which in its natural host (the mouse)
causes, when administered via a peripheral route (intraperito-
neal - i.p.), an asymptomatic infection followed by viral clear-
ance with lasting immunity. C57BL/6 mice infected with the
DA strain of virus via the intracerebral (i.c.) route develop acute
encephalitis; mice survive the acute disease and clear the virus.
A mutant of the DA strain of TMEV was inadvertently created
as a result of transcription error(s) by the T7 polymerase while
using a modified full-length infectious cDNA clone of the DA
virus as template. The H101 mutant virus encodes a point
mutation (T101I) inVP1 (calledH101). In addition, in sequenc-
ing the H101 viral genome, there were also several nucleotide
substitutions in the 5’ untranslated region as well as additional
amino acid substitutions in the capsid protein coding region,
suggesting that there are a number of perturbations in the viral
genome. C57BL/6 mice infected with the H101 mutant virus
via a peripheral route become immunosuppressed by killing T
cells. This study provides experimental evidence that a virus
that is cleared by its natural host can become lethal due to just a
few changes in the viral genome.
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Transcriptional control of the human immunodeficiency
virus type 1 (HIV-1) promoter or long terminal repeat
(LTR), is achieved by interactions with cis-acting ele-
ments present both upstream and downstream of the
transcriptional start site. In silico transcription factor
binding analysis of the HIV-1 subtype B LAI LTR
revealed a potential downstream CCAAT enhancer bind-
ing protein (C/EBP) binding site. This element is pres-
ent immediately downstream of nucleosome 1 in the
viral promoter, which suggested that it may have a
functional role in transcriptional regulation because re-
modeling of this nucleosome is a crucial event in tran-
scription in productively infected cells. Analysis across
HIV-1 subtypes has indicated that the LTR downstream
C/EBP binding site displayed a high degree of conservation in
terms of both nucleotide sequence and physical location in the
LTR. Interestingly, this element overlaps with a previously
identified AP3-like element, which has been shown to bind
members of the nuclear factor of activated T cells (NFAT)
family of proteins. NFATc2 exhibited a higher relative affinity
for this element as compared with members of the C/EBP
family (C/EBP alpha and beta). The downstream C/EBP
element was able to compete efficiently with the low-affinity
upstream C/EBP binding site I with respect to C/EBP binding,
suggesting utilization of both NFAT and C/EBP. Moreover,
cyclosporine A treatment, which has been shown to prevent
dephosphorylation and nuclear translocation of NFAT iso-
forms, resulted in enhanced C/EBP beta binding. A down-
stream C/EBP binding site knockout mutant also demonstrat-
ed reduced LTR-driven transcription under both basal and
interleukin-6-stimulated conditions, indicating that interac-
tions at this site positively regulate HIV-1 transcription in cells
of the monocyte-macrophage lineage. This work is supported
by NIH/NINDS R01 NS32092, NIDA R01 DA19807, NIMH
P30 MH092177, and NIMH T32 MH079785.
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The DrexelMed HIV/AIDS Genetic Analysis Cohort in Phil-
adelphia, PA currently follows over 500 HIV-1-infected indi-
viduals longitudinally to examine viral genetic variation in
conjunction with clinical and neurological disease severity
and the impact of comorbidities like drugs of abuse on these
parameters. This substantial cohort allows for a unique anal-
ysis of neurological decline in the context of substance abuse.
Along with standard clinical parameters such as CD4+/CD8+
T-cell count, viral load measurements, and drug testing, a
modified version of the Hopkin’s Dementia Bedside Test
(TMHDS) was performed. Due to the longitudinal nature of
the DrexelMed cohort, it has been possible to investigate the
complex effects of drug abuse on HIV-1-infected individuals.
The complex nature of drug abuse in an urban cohort compli-
cates the traditional method of grouping patients into mono-
use categories. Instead we abandoned these traditional
methods in favor of Markov Chains. These chains model
patients as “stateful machines” in which the change in HIVD
score at the next visit is a function of parameters measured at
the current visit. The current viral load, CD4+/CD8+ T-cell
counts, adherence to HAART therapy, and drug testing
results were included in the model. Cocaine use was
found to have a detrimental effect on the TMHDS score
while cannabinoids exhibited a small but seemingly
measurable protective effect. As this study progresses,
we will work to develop neurological testing protocols with
increased sensitivity that will allow us to better understand the
effects of poly-abuse on neurocognitive decline. This work is
supported by NIH/NINDS R01 NS32092, NIDA R01
DA19807, NIMH P30 MH092177, and NIMH T32
MH079785.
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Background: Natalizumab blocks trafficking of leuko-
cytes to the brain, and has been associated with
reactivation of JC virus(JCV) leading to progressive multifo-
cal leukoencephalopathy (PML) in multiple sclerosis (MS)
patients. JCV can also infect cerebellar granule cell neurons
resulting in JCVgranule cell neuronopathy (JCV GCN).
Case report: A 32 year-old JCV-seropositive gentleman with
MS who received 63 infusions of natalizumab monotherapy
presented with changes in his handwriting, speech and gait.
Initial MRI did not identify any new lesions. CSF JCV PCR
was positive 3 months after symptoms onset and subsequent
MRIs showed progressive cerebellar atrophy. Natalizumab
was discontinued and he received plasma exchange and IV
steroids, followed by mirtazapine. He developed progressive
hyperintensities in the pons and cerebellar peduncles on T2-
weighted images on MRI, and contrast-enhancement, sugges-
tive of immune reconstitution inflammatory syndrome (IRIS).
CSF JC viral load was 16,489 copies/ml. Intracellular cyto-
kine staining showed a robust cellular immune response me-
diated by JCV-specific CD4+ and CD8+ T-cells.
Molecular analysis of CSF JCV strains revealed three different
mutations in the C-terminus of the VP1 gene, consistent with
previously reported GCN type JCV strains. He was treated
with IV steroids, followed by a decrease in contrast enhance-
ment in his cerebellum on MRI. His neurological function
stabilized concomitant with negative JCV CSF PCR. Repeat
MRI/MR spectroscopy showed stable low grade cerebellar
enhancement and a Lip1/Cr ratio <1.0 in cerebellum consis-
tent with subsiding IRIS. However, there were more extensive
T2 signal changes in the pons and cerebellar peduncles.
Conclusion: This is the second patient with natalizumab-
associated JCV GCN IRIS. Contrary to the initial case-
report 1, 2, this patient developed contrast enhancement in
the cerebellar cortex on MRI and extension of the lesions in
the cerebellar white matter and pons. JCV GCN is a novel
complication of natalizumab therapy and should be suspected
in any MS patient developing cerebellar dysfunction.
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West Nile virus (WNV) is a mosquito-borne pathogen capable
of infecting the central nervous system (CNS) and causing
lethal encephalitis in human hosts. However, the mechanisms
by which WNVaccesses and infects the CNS are mysterious,
as pathogens are normally excluded from the CNS by the
blood brain barrier (BBB). The BBB is a complex assortment
of vascular endothelial cells joined by tight junctions that
prevent circulating pathogens from escaping the vasculature
in the CNS and accessing parenchymal nervous tissue. Detec-
tion of WNV in the circulation by host tissues elicits innate
immune responses, including the production of type-I inter-
feron (IFN), which has been shown to promote and preserve
BBB integrity in the context of CNS autoimmunity. Here, we
utilize an in vitro model of the BBB to demonstrate that
pathogen detection of WNV in the vascular endothelia of the
BBB promotes barrier integrity via type-I IFN, rescuing bar-
rier dysregulation by inflammatory cytokines and limiting
transendothelial trafficking of WNV via modulation of endo-
thelial Rho-GTPase signaling. Similarly, mice with dimin-
ished type-I IFN signaling (IFNAR-/-, IRF7-/-) exhibit en-
hanced BBB permeability after peripheral WNV infection and
earlier entry of virus into the CNS. Together, these data are the
first to show a functional role for type-I IFN at the BBB in the
context of a neurotropic viral infection, suggesting new roles
for type-I IFN in the treatment of neuroinflammatory and
infectious diseases.
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Immunosuppression caused by pathologic agents such as
HIV-AIDS or by regiments used for the treatment of different
types of diseases such as multiple sclerosis puts patients in
high risk group of developing progressive multifocal
leukoencephalopathy (PML), a fatal demyelinating disease
of the white matter caused by human neurotropic polyomavi-
rus, JCV. The virus establishes a latent infection and
reactivates under immunosuppressive conditions with an un-
known mechanism. Immune-dependent reactivation of JCV
and the development of the disease suggest that JCV gene
expression and replication are tightly controlled by the im-
mune system in latently infected cells potentially mediated by
immune mediators at the tissue level. We have developed an
in vitro model to study the role of immune-mediators secreted
by active immune cells in the viral gene expression and
replication. PMBSc from peripheral blood were cultured and
activated in tissue culture and conditioned media (CM) was
collected to treat glial cells infected with JCV. A series of
experiments suggested that CM from induced but not from un-
induced PBMCs inhibited the propagation of the virus sug-
gesting immune-mediated control of viral life cycle. Further
studies revealed that soluble immune mediators from PBMCs
possessed a dual control on T-antigen expression at transcrip-
tional and posttranscriptional level. We recently identified the
alternative splicing factor, SF2/ASF, as a potential regulator of
JCV as its overexpression in glial cells strongly suppresses
viral gene expression and replication. Results from our pre-
liminary studies suggest that immune mediators secreted from
PBMCs induce the expression of SF2/ASF, and inhibit the
replication of JCV. These observations suggest operation of a
novel immune signaling pathway between peripheral immune
cells and glial cells that controls the immediate early stage of
JCV gene expression during the course of viral reactivation.
This work wasmade possible by grants awarded byNIH to IKS.
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Background: The efficacy of natalizumab in the treatment of
multiple sclerosis (MS) is high, but 372 cases of progressive
multifocal leukoencephalopathy (PML) have been reported
among treated patients. The risk of PML is calculated by
assessing JC virus (JCV) seropositivity in natalizumab-treated
MS patients.
Methods: In total, 42 natalizumab-treated MS patients and 45
MS patients treated with conventional therapies (controls)
were enrolled in a case-control study. Urine and blood sam-
ples were collected monthly for up to 60 months from the
natalizumab-treated patients and once from the controls; these
samples were used to monitor JCV and BK virus (BKV)
replication. Viral loads were assessed using quantitative real-
time PCR (qPCR) assays, and serum anti-JCVantibodies were
measured with the Stratify and/or Stratify DxSelect tests.
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Results: JCV DNA was found in 229 of 741 (30%) urine
samples overall and at least once in 21 of 42 (50%) urine
samples from natalizumab-treated patients. However, JCV
DNAwas also detected in 11 of 45 (24.4%) control samples
(p<0.05). In the natalizumab-treated patients, JCVDNA shed-
ding in the urine significantly increased up to month 24 of
treatment (45.2%, R2=0.86). BKV was found in the urine of
59.5% (25/42) natalizumab-treated patients and in a total of
126 of 741 (17.1%) urine samples overall. In contrast, viral
genomes were not detected in the blood. Additionally, JCV
viruria and seropositivity did not correlate with each other, and
three viruric patients were seronegative according to the Stratify
and Stratify DxSelect tests.
Conclusions: Our findings demonstrate that natalizumab ther-
apy may increase the rate of JCVurinary shedding and that the
correct identification of JCV carriers cannot solely rely on
serological tests. To correctly stratify patients by the risk of
PML, monitoring the presence of JCV DNA in the urine is
needed.
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Neuronal dysfunction and degeneration are the causative
mechanisms for the HIV-Associated Neurocognitive Disor-
ders (HAND) in the era of highly active antiretroviral therapy
(HAART). In this study we assessed the effects of exosomes
derived from PMA activated promonocytic cells U1 that are
latently infected with HIV-1 on human fetal neurons.
Exosomes secreted by U1 cells were found to be enriched in
as many as 20 micro-RNAS, potentially affecting expression
of several essential genes in neurons. Neuronal cultures treat-
ed with U1 exosomes were found to be severely compromised
in their ability to maintain existing neuronal network as well
as their ability to form neurites in a scratch-wound assay.
Neuronal cultures treated with U1 derived exosomes showed
low levels of superoxide dismutase activity indicating height-
ened oxidative stress. Analysis of the cytokine/chemokine
profile in U1 exosomes revealed attenuated levels of MCP-
1, MIP-1alpha, MIF, RANTES and IL-4 in comparison to
U937 derived exosomes. Similar analysis of medium obtained
from exosome-treated neuronal cells revealed increased ex-
pression of MCP-2, MCP-3, MIP-3alpha, NAP-2 and uPAR
in cultures treated with U937 exosomes. Furthermore, we also
analyzed the phosphorylation status of mitogen-activated
protein kinases (MAPKs) and other intracellular proteins and
kinases, such as Akt, GSK-3, p70S6 Kinase, mTOR, p53, and
CREB that are important regulators of signal transduction and
cell proliferation, in neurons treated with U1 exosomes using
antibody arrays. These studies demonstrated that many sig-
naling pathways that are known to be crucial for cell survival
such as Akt, mTOR, PI3K were found to be negatively affect-
ed in U1 exosome treated neurons. Collectively, these obser-
vations demonstrate that exosomes derived from HIV-1
infected cell can cause neuronal dysfunction and degeneration
by targeting multiple pathways. Supported by Comprehensive
NeuroAIDS center (CNAC) developmental core grant to
PKD. The study also utilized services offered by core facilities
of CNAC (NIMH Grant#P30MH092177) to KK.
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Neuroinflammation mediated by pro-inflammatory cytokines
such as interleukin (IL)-1 beta induced by HIV-1 infection of
macrophages, microglia, and astrocytes in the CNS play crit-
ical role in the pathogenesis of NeuroAIDS. Dysregulation of
inflammation-associated microRNAs such as miR-146a with-
in the brain can accelerate the development of HIVAssociated
Neurocognitive Disorders (HAND). Thus, we investigated the
role of post-translational modification of RelA in miR-146a
gene regulation by IL-1 beta in human fetal brain astrocytes
and in astroglial cell lines. Our studies demonstrate that IL-
1beta-induced phosphorylation of IKKbeta, IkBalpha and
p65 at serine 536 regulate NF-kappaB activation in human
fetal astrocytes and in astroglial cell lines. Additionally, our
results using phosphorylation defective mutants of p65 indi-
cate that phosphorylation status of serine residues 276 and 536
differentially regulate IL-1beta induced transcriptional expres-
sion of miR-146a. To demonstrate the role of mitogen- and
stress-activated protein kinase1 (MSK1) that phosphorylates
S276 in the regulation of mir-146a by IL-1 beta we employed
a pharmacological inhibitor of MSK1, H-89. Our studies
demonstrate that H-89 (5 and 10 microM) dose dependently
inhibited miR-146a expression. Collectively, our observations
demonstrate that IL-1beta activates both canonical and
noncanonical NF-kappa B pathways to regulate mir-146a
expression in astrocytes. Therefore, pharmacological inhibi-
tors that target NF-kappa B pathways may have therapeutic
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potential for the treatment of neuroinflammation. This work is
supported by NIH/NIDA grant to PKD. The study also uti-
lized services offered by core facilities of the Comprehensive
NeuroAIDS center (CNAC) NIMH Grant # P30MH092177.
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Currently, there are no defined surrogate measures to deter-
mine which HIV+ patients are likely to develop cognitive
impairment or to track the effectiveness of potential
neurotherapeutics. Here, we analysed CSF samples taken
from HIV+ patients with differing neurocognitive states using
1H-NMR spectroscopy and multivariate analysis to identify
novel metabolomic biomarkers for cognitive impairment.
CSF samples from 100 HIV-infected patients were collected
at 2 time points with four distinct neurocognitive states that
were defined by temporal changes in cognitive status. These
neurocognitive states were stably-normal, stably-abnormal,
improving, and worsening. 1D-NOESY 1H-NMR spec-
troscopy was performed on these samples using a 16.4T
NMR system. Multivariate Partial least squares (PLS) regres-
sion models showed significant separations between
neurocognitive states with q2 values = 0.61 (stably-normal),
0.84 (stably-abnormal), 0.47 (worsened) and 0.52 (improved).
The metabolites that underpinned these changes were distinct
in each group, but were generally connected to amino acid,
and energy metabolism. Using a classification and regression
tree analysis we identified changes in 5 energy metabolites
(pyroglutamate, citrate, creatine, alanine, and acetate) that
were prognostic indicators for declines in cognitive status
(sensitivity 100%, specificity 88%), and 5 metabolites that
were prognostic indicators for improved cognitive status
(glutamate, pyroglutamate, creatine, myoinositol, beta-
glucose (sensitivity 91%, specificity 92%). Linear regressions
showed that increased levels of specific energy metabolites
were associated with poor performance on tasks that measure
executive, learning, recall and motor functions, but were not
related to working memory performance. These findings sug-
gest that declines in cognitive function are accompanied by a
compensatory increase in specific energy metabolites. CSF
levels of these energy metabolites may be useful surrogate
measures for temporal shifts in cognitive status, and reveal
new insights into the neuropathogenesis of HAND.
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Herpes simplex virus type 1 (HSV-1) is a ubiquitous human
pathogen which causes recurrent mild orofacial lesions in
infected individuals. Acute infection initiates in mucosal sur-
faces where the virus replicates within epithelial cells. Fol-
lowing propagation of virus at the site of infection, innervating
sensory neurons are infected and a latent infection is
established which persists for the lifetime of the host. The
immune system is critical for controlling initial virus replica-
tion in the periphery and limiting infiltration into the nervous
system.We investigated the mechanism that immune cells use
to detect productive viral replication in the periphery. TLR-2
knockout (TLR2-/-) mice were more vulnerable to HSV-1-
induced mortality than wild-type (WT) controls. Although
natural killer cells were normal, dendritic cell and CD8+ T-
cell activation was impaired in TLR2-/- mice. We observed a
minor decrease in CD8+ T-cells responding to virus infection
in the knockout animals, but the responding cells exhibited
impaired production of interferon gamma. Both WT and
knockout animals supported comparable HSV-1 replication
in the periphery, but the knockout mice had greater infiltration
into the nervous system and suffered greater mortality. These
results demonstrate the important role of TLR-2 in priming
immune cells and control of acute HSV-1 infection. In the
future, we will investigate the role of TLR-2 in maintaining
immune control of HSV-1 latency by CD8+ T-cells. We will
confirm that CD8+ T-cells in the trigeminal ganglia belong to
the recently described Tissue Resident Memory (TRM) class
of memory T cells. We will explore the homing mechanisms
and proliferative capacity of TRM cells for the purpose of
enhancing CD8+ T-cell levels in the trigeminal ganglia. In-
creased presence of CD8+ T-cells is a possible therapeutic
treatment option for reducing reactivation events.
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Objective: We studied the frequency and clinical features of
HIV-related neurologic complications in a Romanian cohort
of HIV clade F infected subjects.
Design: This is a retrospective longitudinal study of
children and adolescents with HIV associated neurolog-
ical complications followed between January 1996 and
June 2010.
Methods: All patients with HIV encephalopathy (HIVE) or
HIV related opportunistic infections were included. We eval-
uated demographics, viral loadmarkers and brain imaging and
hystology, to describe the clinical dynamics in this unique
cohort.
Results: During the 14.5 year surveillance period a total
number of 275 children and young adolescents were diag-
nosed with neuroAIDS defining diseases representing 49.2%
out of 559 subjects. Although the number of HIV associated
CNS complications decreased after introduction of cART, the
frequency among AIDS defining diseases increased from
44.5% before cART, to 54.1% thereafter. Unique features
were observed in PML patients, including cerebellar and
brainstem location of lesions and improved survival in cART
regimens with good cerebrospinal fluid HIV viral control.
Furthermore, we describe a case series of 34 patients diag-
nosed with a fatal clinical entity: subacute myoclonic measles
encephalitis (SMME) that occurred during two consecutive
outbreaks in Romania.
Conclusions: We found a high frequency of HIV-related neu-
rological complications in a cohort of parenterally infected
children that, interestingly, increased in the cART era.
We also describe a new AIDS defining neurologic compli-
cation of measles in severe immunosuppressed children:
SMME. The frequency of almost 50% of neurological
AIDS complications suggests a neurotropic potential for HIV
clade F.
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Intrathecal antibody synthesis is a well-documented phenom-
enon in infectious neurological diseases as well as in demye-
linating diseases. Intrathecal antibody synthesis against
HTLV-1 has been reported in HAM/TSP, but little is known
about the role of B cells and humoral immune responses in the
central nervous systems (CNS) of HAM/TSP patients. Here
we demonstrate profiles of HTLV-1-specific antibodies in
cerebrospinal fluid (CSF) of HAM/TSP patients. Of 36
HAM/TSP patients, antibody responses against Gag and Tax
were detected in CSF of all the patients. CSF/Serum anti-Gag
antibody ratio was elevated more than anti-Tax (anti-Gag:
mean 1.20, anti-Tax: mean 0.85), and was significantly corre-
lated with proviral loads in PBMC. More importantly HAM/
TSP patients with lesions or atrophy in spinal cord showed
higher CSF/Serum anti-Gag antibody ratio. Antibody re-
sponse against Env was detected in CSF of 94.4% of patients,
but CSF/serum anti-Env ratio was significantly lower than
those of anti-Gag and anti-Tax (mean 0.18). Interestingly,
CXCL13 (B cell attracting chemokine-1) and IL-21 were
increased in CSF of HAM/TSP patients compared to HTLV-
1 positive asymptomatic carriers, which was associated with
higher HTLV-1-specific antibody responses in CSF. In ex vivo
experiments, CD4+ T cells of HAM/TSP patients showed
significantly higher IL-21 expression than those of healthy
normal donors. In addition, IL-21 stimulated B cells differen-
tiate into plasma cells and produce HTLV-1-specific antibod-
ies in the cultured B cell of HAM/TSP patients. These results
highlight the importance of the B cell compartment in HAM/
TSP where production of HTLV-1-specific antibody may be
required to control viral persistence and/or may be associated
with HAM/TSP disease progression.
P55
Raltegravir Decreases Interleukin-8 Production in
HIV - Infected Microglia
Tatro Erick1, Benchawanna Soontornniyomkij1, Scott
Letendre2, Cristian Achim1
(presenting author: etatro@ucsd.edu)
S26 12th ISNV, Washington, DC, USA
1Department of Psychiatry, University of California San
Diego;
2Department of Medicine, Division of Infectious Diseases,
University of California San Diego
Background: Despite successful suppression of HIV-1 repli-
cation with combination antiretroviral therapy, chronic im-
mune activation persists in some patients, a process that may
be mediated through latently infected cells in various com-
partments, including the central nervous system. Raltegravir, a
potent HIV integrase inhibitor was previously shown to inhibit
immune activation in peripheral blood. The goal of the present
study was to determine how raltegravir influences pro-
inflammatory cytokine production in HIV-infected mono-
cytes, microglia, and assess toxicity in neuron-glia cultures.
Methods: Primary humanmonocyte derivedmacrophages and
microglia from fetal brain tissue were grown in culture and
infected with m-tropic HIV (BaL). Infected cultures were
treated with 20 nM raltegravir or vehicle (saline). Supernatant
was removed periodically for 9 days and pro-inflammatory
cytokines were quantified using Mesoscale Discovery 7-plex
platform. Primary neuron-glia cultures were exposed to 0, 20,
100 nM raltegravir for 7 days, then stained for beta-III tubulin
and glial fibrillary acidic protein, and immunofluorescence
quantified.
Results: In both microglia and monocyte derived macro-
phages, the rate of interleukin-8 secretion was significantly
lower for HIV-infected cells treated with raltegravir (132 pg/d)
compared to Control (245 pg/d), HIV-infected (232 pg/d), and
raltegravir alone (268 pg/d), as determined by analysis of
covariance and Tukey's Honestly Significant Difference test;
p < 0.001. TNF-alpha, interferon-gamma, IL10, IL12,IL1, and
IL6 were not significantly different. In the neuron-glia cul-
tures, at 20 nM, there was significantly more beta-III tubulin
area. There was a stepwise decrease in GFAP area at 20 and
100 nM raltegravir.
Conclusion: Raltegravir, in the context of HIV infection, leads
to diminished production of the potent pro-inflammatory
chemoactractant, IL-8 in both monocytes and microglia. The
data suggest that raltegravir inhibits astrogliosis and may be
neuroprotective. Further study on mechanisms, including
NF-kappa B nuclear translocation are underway.
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Cell to cell communication is essential for development
of multicellular systems, and is coordinated by soluble
factors, membrane associated proteins, gap junction
channels and the recently described tunneling nanotubes
(TNT). We and others reported that TNT can be used
for pathogens, such as HIV between communicated
cells. However, the characterization of these processes,
especially in primary cells, and their role in HIV infec-
tion has not been fully characterized. Our current data
indicates that TNT are composed of several smaller
TNT. TNT in macrophages are not continuous tubes,
rather TNT establish contact with others macrophages by a
synaptic type of contact. We identify several blockers of
TNT that reduces spread of HIV between HIV infected
and uninfected cells by transfer viral genetic material
between communicated cells. Blocking formation of
TNT using mild actin blockers or siRNA reduced the
spread of HIV among connected cells. Thus, we char-
acterize that TNT play a key role in the spread of HIV
among connected cells.
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Viral infection and inflammation in the central nervous system
(CNS) can induce significant illness and neuropathology,
particularly in the very young. Though neonates are capable
of mounting both innate and adaptive immune responses, they
are often unable to control viral infections in the brain and
suffer extensive neuronal loss and tissue damage. In order to
study how the neonatal immune response interacts with
infected CNS neurons, our laboratory uses a transgenic mouse
model (NSE-CD46) of neuron-restricted measles virus (MV)
infection. NSE-CD46 mice express the human isoform of
CD46, a MVreceptor, under the control of the neuron specific
enolase (NSE), allowing for infection only in CNS neurons.
Here, we show that the adaptive immune response is detri-
mental in neonates during a viral infection in CNS neurons, as
neonates lacking T- and B-cells (CD46+/RAG2-KO mice)
survive longer than immunocompetent pups. CD46+/RAG2-
KO neonates also control viral load more effectively than
immunocompetent NSE-CD46 neonates. These results are in
contrast to adult NSE-CD46 mice, which survive the infection
and clear the virus from the brain in a T-cell dependent
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manner, whereas CD46+/RAG2-KO adult mice succumb to
the infection. In addition, neonatal mice that lack interferon-
gamma (IFNg), which is required for viral clearance from the
adult brain, lose nestin-positive precursor cells in contrast to
NSE-CD46+ neonates despite higher levels of T-cell infiltra-
tion in CD46+/ IFNg-KO neonates. These findings suggest
that certain pro-inflammatory cytokines can protect neural
cells during a neonatal CNS infection, but that the full
adaptive response is associated with greater neuropathol-
ogy. Current work addresses defects in the neonatal T-
cell response and the potential role of IFNg-producing natural
killer cells in limiting viral spread. Through these stud-
ies, we aim to better define the protective and cytotoxic roles
of innate and adaptive immune cells during a neonatal CNS
infection.
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Injection and non-injection illicit drug use and abuse remain
significant cofactors for HIV infection and transmission. Co-
caine is one of the most widely abused drugs in the United
States, which both impair the normal functioning of brain cells
and also activate human immunodeficiency virus (HIV) ex-
pression in central nervous system (CNS). As a result, HIV-
infected individuals who abuse cocaine experience more se-
vere and rapid onset of NeuroAIDS than non-abusing indi-
viduals. It has been known that cocaine affects the expression
of numerous cellular genes by modulating various signaling
and epigenetic pathways. Some of those pathways also influ-
ence the expression of integrated HIV proviruses and eventu-
ally end up enhancing HIV replication and transmission. It is
known that cocaine activates NF-kappaB, and given the im-
portance of NF-kappaB during HIV transcription, it is imper-
ative to understand the underlying molecular mechanisms that
ultimately result in the enhanced HIV gene expression. Our
results establish that cocaine activate specific protein kinases,
which in turn induce selective posttranslational modifications
in NF-kappaB. To further extend our understanding about the
regulation of HIV gene expression via cocaine induced
NF-kappaB systems, we have employed a multi-level ap-
proach to characterize the effect of cocaine on the chromatin
state of provirus by running several ChIP (Chromatin
Immunoprecipitation) assays. Overall, our results demonstrate
the exchange of various key epigenetic modifications and
associated factors at HIV LTR following cocaine treat-
ment. In summary, our data provide direct evidence that
cocaine enhances HIV gene expression not only by
activating transcription factors such as NF-kappaB, but
also by inducing various selective epigenetic modifica-
tions. These events eventually support the establishment
of transcriptionally active chromatin structure at HIV LTR
and facilitate HIV transcription.
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JC virus (JCV) is the etiological agent of the human
CNS demyelinating disease progressive multifocal
leukoencephalopathy (PML). Attempts to identify risk factors
for PML are hampered by the lack of an animal model and the
limited cell types in culture that are susceptible to JCV infec-
tion. To understand JCV pathogenesis, it was necessary to
develop a new system to identify transcription regulators
important in the JCV lifecycle and development of PML.
Traditional techniques of protein over-expression and knock-
down are hampered by off-target effects when transcription
regulators important in viral gene expression are targeted,
limiting the ability to discern direct from indirect effects (over-
or under-expression of genes regulated by the transcription
regulator of interest). Using multiple cell culture models with
differing permissiveness to JCV, cellular gene expression in
both uninfected and infected cells was characterized. Multiple
known and novel transcription regulators with potential JCV-
regulatory roles were identified by transcriptome profiling of
SV40 T antigen immortalized human fetal brain cells
displaying characteristics of either CNS stem cells or radial
glia. Several of these factors overlappedwith factors identified
during differentiation of less permissive human fetal neural
progenitor (progenitors) cells to highly permissive progenitor-
derived astrocytes (PDAs). Lymphoid Enhancer Factor 1
(LEF1) was identified as a potential novel negative regulator
of JCV transcription, and potential binding sites for LEF1 in
the JCVregulatory region were identified using computational
promoter analysis. Progenitor-derived neurons (PDNs) and
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PDAs were used to confirm LEF1 as important for JCV
transcription. Chromatin immunoprecipitation revealed that
LEF1 bound the JCV promoter to a greater extent in JCV-
repressive neurons than in JCV-permissive astrocytes. These
results demonstrate that human fetal brain derived CNS
stem cell models combined with bioinformatic ap-
proaches can facilitate the identification of factors respon-
sible for JCV multiplication and potential development
of PML.
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The molecular mechanisms involved in HIV-induced
synaptodendritic injury, the structural basis for HIV-
associated neurocognitive disorders, have yet to be fully elu-
cidated. In this study, we propose that HIV proteins and
inflammatory cytokines induce dendritic injury by altering
the neuronal expression of the protein ferritin heavy chain
(FHC), a known negative regulator of the CXCL12/CXCR4
signaling pair. Previous work from our lab suggests the im-
portance of CXCL12 in increasing dendritic spine density, as
well as modulating the expression of specific glutamate re-
ceptor subunits (NR2B). Additionally, we have found that
opiates, including morphine, can negatively regulate CXCR4
signaling through FHC. In vivo data from brain tissue of
HIV+/drug abusers (and SIV-infected/morphine-treated ma-
caques) show an increase in neuronal FHC and a subsequent
decrease in CXCR4 activation (Ser339 phosphorylation).
Thus, we sought to investigate whether components of HIV
infection could modulate FHC. Our results suggest that TNF-
alpha and IL-1 beta, as well as the HIVenvelope glycoprotein
gp120, upregulate FHC in neurons. Both of the cytokines
altered neuronal FHC in the presence or absence of glia;
however, gp120 (X4-or R5-using) only caused significant
increases in neuronal/glial bilaminar co-cultures, suggesting
that glia are required for the changes in FHC protein levels by
gp120. In support of this, the presence of an IL-1 beta neu-
tralizing antibody (or receptor antagonist) in gp120-treated
bilaminar cultures abrogated this effect. In two in vivo models
of HIV infection (gp120-ICV injected and HIV-Tg rats), we
saw a significant reduction in cortical neuron dendritic spine
density compared to age-matched controls. Overall, these
studies suggest that the effects of gp120, proinflammatory
cytokines, and opiates may converge on dendritic spines,
through FHC, and augment synaptic injury in HIV/drug abuse
patients.
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Perturbations in brain lipid metabolism with accumulation of
the bioactive lipid ceramide occur early in the course of
human immunodeficiency virus 1 (HIV-1)-associated
neurocognitive disorders (HAND). Elevations of ceramide
are thought to contribute to neuronal dysfunction through
biophysical effects that alter membrane excitability and mo-
lecular response to stress. Ceramide can be rapidly generated
in response to inflammatory stimuli and by the HIV-1 coat
protein gp120 through actions mediated by the sphingomyelin
phosphodiesterase neutral sphingomyelinase 2 (nSMase2).
Expression and activity of nSMase2 is elevated in brain tis-
sues from HIV-1 infected patients in conjunction with cogni-
tive impairment, suggesting that inhibition of nSMase2 may
preserve neuronal function by preventing increases in cer-
amide. Indeed, both chemical and genetic modulation of
nSMase2 expression or activity are neuroprotective, making
this enzyme an attractive therapeutic target. There are a few
known inhibitors of nSMase2 that include natural products
and small molecules, but these compounds lack specificity, are
insoluble and/or exhibit low potency. To identify novel inhib-
itors specific against human nSMase2, we screened pharma-
cological active compounds, approved drugs, and inhibitors of
acid sphingomyelinase in 384-well format. Enzyme activity
was monitored as increases in the fluorescence emission of a
product generated after three consecutive coupled reactions
that involved alkaline phosphatase, choline oxidase, and
horseradish peroxidase. Hits were confirmed using a direct
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assay with 14C-labeled sphingomyelin (SM) as substrate.
Several inhibitors with low micromolar potency were
identified from distinct chemical series. The identified
compounds are being optimized in structure-activity re-
lationship studies. Small molecule inhibitors of nSMase2
may be useful therapeutic agents that could dampen the
neuromolecular response to HIV-1-infection and associ-
ated inflammation.
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The brains of human immunodeficiency virus-1 (HIV-1) pa-
tients show signs of chronic inflammation including microglia
activation which, in part, leads to neurodegeneration and the
manifestation of HIV-1-associated neurocognitive disorders
(HAND). Activated microglia and macrophages release ex-
cess glutamate which causes excitotoxicity that ultimately
results in neuronal dysfunction and death. Two proteins, the
cystine/glutamate antiporter (xCT), and the phosphate-
activated glutaminase, are thought to be partially responsible
for the excess glutamate released from activated microglia.
xCT is a sodium independent amino acid transporter that
imports extracellular cystine and exports intracellular gluta-
mate. Glutaminase is a mitochondrial enzyme that catalyzes
the production of glutamate from glutamine. Both have shown
increased activity and/or expression levels following infection
of microglia or macrophages with HIV-1, or activation with
the viral protein Tat. We developed a cell-based phenotypic
assay in 96-well format to screen novel xCT and glutaminase
compounds for their ability to inhibit glutamate release from
lipopolysaccharides (LPS)-activated microglia. Primary mi-
croglia obtained from newborn rats cultured for 10-21 days
were treated with 1-1000 ng/mL LPS, which induced the
production/release of glutamate in a dose-dependent manner
(2-20 fold increase in extracellular glutamate). Response was
time- (16-24 h) and cell number-dependent (10,000-50,000
cells/well). The prototype xCT inhibitor erastin and the
glutaminase inhibitor DON showed dose dependent inhibition
of glutamate release/production with EC50 values of 14 ± 3
nM and 1.5 ± 0.4 microM, respectively. Commensurate
with its weaker xCT inhibitory capacity, sulfasalazine
was significantly less potent than erastin (362 ± 60 nM).
Phenotypic assays following excess glutamate release induced
by microglia activation represent a novel way to screen for
agents to treat neuroAIDS and other neuroinflammatory
disorders.
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Human immunodeficiency virus (HIV)-infection con-
tinues to be a major clinical manifestation in the com-
bination antiretroviral therapy era (cART), that is en-
hanced in opioid-drug abusers. The gastrointestinal (GI)
mucosa plays a major role in HIV-infection as HIV is
mostly transmitted across mucosal surfaces. The enteric
nervous system (ENS) controls several GI processes
including motility and secretion which are specifically
affected in HIV-infected patients. Morphine and other
opioids directly affect the ENS, causing severe consti-
pation. Because the virus does not infect neurons, it is
suggested that viral toxins, such as Tat, modulate neu-
ronal function in HIV-1-infected patients. Tat has been
shown to increase neuronal excitability but not much is
known about effects of Tat on enteric neurons in com-
bination with drug abuse. Recent experimental studies in
our lab have shown that Tat increases enteric neuronal
excitability by shifting the voltage-dependence of acti-
vation of sodium channels to more negative potentials.
In contrast, morphine alone decreases the availability of
sodium channels in enteric neurons reducing excitability.
Voltage gated sodium channels (VGSCs) are responsible for
the generation and propagation of action potentials in neurons.
In order to determine the effects of Tat (100 nM) in combina-
tion with morphine (0.3 uM, 3 uM) on the voltage dependence
of steady-state activation/inactivation of sodium channels, we
used a double-pulse protocol in which a variable conditioning
pulse was applied from -100 mV to +50 mV in 10 mV steps
for 50 ms followed by a test pulse. In Tat-treated neu-
rons, the sensitivity to morphine was significantly en-
hanced. The V0.5 for steady-state inactivation was
shifted in Tat-treated neurons at 0.3 uM morphine with
50% decrease in maximal availability at -100 mV. Morphine
did not alter the steady-state activation. Taken together,
data suggest that Tat increases the sensitivity tomorphine in
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enteric neurons that may exacerbate the deleterious effects of
morphine on GI motility.
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Elevated levels of interferon-alpha (IFNalpha) in the central
nervous system (CNS) are linked to cognitive dysfunction in
patients with inflammatory CNS diseases such asHIV-associated
dementia. Previous studies showed that IFNalpha treatment of
neuronal cultures caused a dose dependent decrease in dendritic
branching and length, that was prevented after pre-treatment with
IFNalpha neutralizing antibodies. Antagonists to NDMA recep-
tor were also found to be partially protective against IFNalpha
induced neurotoxicity. To begin to determine the mechanism of
IFNalpha induced neurotoxicity, the cell signaling pathway in-
volving IFNalpha receptor (IFNAR) was evaluated. We demon-
strate increased interferon stimulating gene 15 (ISG15) ex-
pression, an indicator for JAK-STAT cascade activation,
after IFNalpha stimulation. Inhibiting IFNAR was found to
partially protect neurons from IFNalpha neurotoxicity, but not
as efficiently as neutralizing antibodies to IFNalpha. Our
preliminary studies suggest that IFNalpha is in part acting
through its receptor as well as NMDAR to reduce dendritic
arborization in neurons. Further studies are needed to deter-
mine what other signaling pathways may be involved in
IFNalpha induced neurotoxicity. Determining the mech-
anism of IFNalpha neurotoxicity could lead to therapies
for cognitive dysfunction during neuroinflammation.
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Macrophages are one of the principle cell types infected with
HIV, and the primary source of virus in many tissues,
including the CNS. Within the brain, macrophages are ex-
posed to the neurotransmitter dopamine. Dopamine is elevat-
ed by the use of drugs of abuse such as cocaine and metham-
phetamine. We showed previously that macrophages express
dopamine receptors and other dopaminergic proteins, and that
exposure to dopamine increases HIV replication in macro-
phages and alters their cytokine production and MAPK sig-
naling. Our current data demonstrate that the dopamine medi-
ated increase in HIV replication is due to an increase in the
ability of HIV to enter macrophages. This effect is dose
dependent, occurring at greater than 10 nM dopamine, and is
not affected by dopamine metabolites. A pan-dopamine re-
ceptor antagonist abrogated the effect, indicating that dopa-
mine receptor activation is necessary for increased entry.
Infection in the presence of D1-like or D2-like dopamine
receptor agonists shows that the increase can be induced by
activation of both dopamine receptor subtypes. Antagonizing
CCR5 with TAK779 completely blocks entry, indicating that
dopamine mediates is effects through the CCR5 entry process.
However, the increased susceptibility to entry is not due to an
increase in surface CCR5. These data demonstrate that the
macrophage dopaminergic system plays an important role in
HIV infection of these cells. The development of neuroinflam-
mation and HAND may be accelerated by the effects of
dopamine on macrophages, and that these effects maybe
exacerbated by drug abuse. In addition, although different
drugs of abuse act through distinct pharmacologic mecha-
nisms, dopamine mediates the addictive and reinforcing ef-
fects of many drugs of abuse and may be a common mecha-
nism by which drugs of abuse contribute to HIV associated
neuropathogenesis.
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HIV DNA that is integrated into human genomic DNA
(HIVint) may become transcriptionally repressed and immu-
nologically inert in infected people in whom virus replication
is suppressed with highly active antiretroviral therapy
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(HAART). The “latent” pool of HIVint represents a key
obstacle to curing HIV infection because it re-seeds the body
with replicating HIV when HAART is stopped. Little is
known about the neuroimmunological factors involved in
supporting the latent pool of HIVint in the brain.Wemeasured
HIVint in genomic DNA extracted from the frontal neocortex
of 40 HIV infected patients using the O’Doherty Alu-Gag
two-step assay. Cases were divided into two equal groups
having either a high proportion of HIVint (> 3% of the
replication rate in brain) versus low (< 3%). The groups had
equivalent rates of HIV transcription (HIV RNA load) in the
brain specimens. A panel of neuroimmune marker mRNAs
was quantified using qPCR in the groups. The group with high
HIVint had significantly greater expression of interleukin 10
(IL10) and interferon regulatory factor 4 (IRF4) mRNAs.
Several other neuroimmunological marker mRNAs were not
significantly different. These two proteins are associated
with in vitro polarization of macrophages towards M2
phenotypes. When typical M2 marker mRNAs including
CD163 were assayed, they were not expressed at signifi-
cantly higher rates in the specimens with high HIVint.
Conclusion: High HIVint in the brain is associated with
IL10 and IRF4 expression, which play key roles in M2
macrophage polarization.We suggest that HIVint accumulates
preferentially in a numerically minute subtype of M2 polar-
ized macrophage in the brain. To identify the cellular sources
of latent HIV in the brain, we are screening specimens for M2
surface markers that specifically segregate with high HIVint
load.
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Background: Insulin resistance is present in HIV-seropositive
people using combined antiretroviral treatment (cART) and as-
sociated with HAND. However, the mechanisms involved are
not well understood. Recently, we reported that higher plasma
soluble Insulin Receptor (sIR) levels are associated with the
presence and severity of HAND in our cohort of HIV-
seropositive women on cART. In this study, we investigated if
soluble insulin-like growth factor-1 receptor (sIGF1-R) in the
plasma of HIV-infected woman is associated with HAND and
correlates with plasma sIR levels. Methods: Plasma sIGF1-R
levels were assayed in 34 HIV-seropositive women stratified by
HAND into normal cognitive (NC; n=11), asymptomatic impair-
ment (AI; n=8), or symptomatic impairment (SI; n=15) and five
(5) controls without history of diabetes. Soluble sIGF1-R levels
(full-length or intact) were quantified by ELISA. Patients were
also characterized for plasma sIR and TNF-alpha levels as deter-
mined by ELISA. Nonparametric statistics were used. Results:
Higher levels of plasma sIGF1-R were associated with worse
cognitive performance (p=0.006) amongHIV-seropositive wom-
en stratified by HAND. No significant differences were observed
in sIGF1-R levels between controls and HIV-seropositive wom-
en with NC. However, significant differences were seen between
the NC and AI (p=0.001) and between the NC and SI groups
(p=0.027). A positive correlation was observed between plasma
sIGF1-R and sIR levels (p=0.011). No correlations were ob-
served with age, viral-immune profile, antiretroviral therapy, or
TNF-alpha levels. Conclusions: This study provides evidence
that sIGF1-R secretion is increased in HIV-infected women and
may have a role in the progression of HAND. Our findings also
suggest that similar or coordinated cellular mechanisms may be
responsible for the secretion of both, sIGF1-R and sIR, to the
plasma of these patients and they could represent biomarkers for
the presence and severity of HAND. This work was supported
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Chronic neuroinflammation in HIV-1 infection is believed
to contribute to the development of HIV-associated
neurocognitive disorders (HAND). Previous work from our
laboratory and others suggest that the accumulation of activated
central nervous system (CNS)-associated macrophages and
resident microglia results from the invasion and differentiation
of peripheral blood monocytes. This process is significant to
the pathogenesis of HAND because these cells constitute the
principal cellular reservoirs of HIV-1 in the CNS. Importantly,
HIV infection results in altered monocyte/macrophage homeo-
stasis, evidenced by a skewed monocyte phenotype and acti-
vation status that may support the development and mainte-
nance of a neuroinvasive monocyte subset.We have previously
reported expansion of CD163+CD16+ monocytes in the pe-
ripheral blood of HIV+ patients that is phenotypically similar to
macrophages/microglia that accumulate in the CNS in HIV
infection; however, whether these cells are a source of new
infection remains unclear. Here, we test the hypothesis that
specific monocyte populations with predilection for invasion
are preferentially infected with HIV-1. We compared the cellu-
lar location of HIV-1 in the monocyte subsets isolated from the
peripheral blood of a cohort of chronically HIV-1 infected
donors with a documented history of combination anti-
retroviral therapy (cART) adherence, with and without detect-
able plasma viremia, based on CD163 and CD16 expression.
Further, we explored a therapeutic strategy targeting the
CD163+CD16+ monocyte subset using experimental and
FDA-approved tyrosine kinase inhibitors (TKIs) with selectiv-
ity for cfms, a type III receptor tyrosine kinase that has been
shown to promote this monocyte phenotype in vitro. We antic-
ipate that our studies will provide novel insights into the role of
altered monocyte/macrophage homeostasis in HIV disease
and identify a novel strategy for targeting long-lived cellular
reservoirs of HIV through restored immune homeostasis.
P69
Varicella Zoster Virus is a Major Cause of Giant Cell
Arteritis
Don Gilden1, Nelly Khmeleva2, Alexander Choe2, Philip
Boyer3, Denis Chatelain4, Charles Eberhart5, Robert Poppiti6,
PratimaAgarwal2, Anna Heintzman2, Victoria Pelak2, Vikram
D Durairaj7, Maria Nagel2
(presenting author: Don.gilden@ucdenver.edu)
1Department of Neurology and Microbiology, University of
Colorado School of Medicine;
2Department of Neurology, University of Colorado School of
Medicine;
3Department of Pathology, University of Colorado School of
Medicine;
4Department of Pathology, Centre Hospitalier Universitaire du
Nord, France;
5Department of Neuropathology, Johns Hopkins University
School of Medicine;
6Department of Pathology, Mount Sinai Medical Center,
Miami FL;
7Department of Ophthalmology, University of Colorado
School of Medicine
Giant cell arteritis (GCA) and multifocal varicella zoster virus
(VZV) vasculopathy with temporal artery (TA) infection have
overlapping clinical features and laboratory abnormalities. Our
analysis of TAs that were pathologically negative for GCA
(GCA-) revealed VZV antigen in 39/103 (38%) TAs. Viral
antigen was foundmostly, but not exclusively in the adventitia.
During our continuing search for VZV antigen in GCA- TAs,
abundant VZV antigen was found in multiple regions (skip
areas) of an artery. This led to additional pathological analysis
of sections adjacent to those containing VZV antigen. Re-
examination revealed pathological changes with inflammation
involving the arterial media and abundant multinucleated giant
cells characteristic of GCA. When we analyzed TAs that had
been pathologically confirmed to be GCA (GCA+), VZV
antigen was found in 17/26 (65%) TAs. Also, despite
formalin-fixation, the presence of VZV in TAs was further
confirmed by the detection of VZV DNA in 24/31 (77%) of
TAs that contained VZVantigen. None of 27 normal TAs from
subjects over age 50 contained VZV antigen or VZV DNA.
The detection of VZVantigen was noted in 65% of GCA+ TAs
in which inflammation with (1) multinucleated giant cells and/
or epithelioidmacrophages and (2) damage to themedia and/or
internal elastic lamina is present. In contrast, little or no in-
flammation in the adventitia of 38% of GCA- TAs indicates a
continuum of disease. Overall, after reactivation from latency
in ganglia, VZV travels transaxonally and initially infects the
arterial adventitia resulting in clinical features that lead to TA
biopsy even though the classic pathological features of GCA
described above have not yet developed. By the time GCA
pathology develops, ~65% of TAs contained VZV. VZV is a
major cause of GCA.
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Although antiretroviral therapy (ART) has significantly im-
proved clinical outcomes in HIV+ patients, the prevalence and
associated morbidity of HIV-associated neurocognitive disor-
ders (HAND) remain high (~50%). Thus, adjunctive neuro-
protective therapeutic targets that address the pathological
processes persisting in ART-treated individuals are needed.
Our lab has identified heme oxygenase-1 (HO-1), a sentinel
cytoprotective protein, as a host factor protective against HIV-
mediated neurodegeneration that is deficient in the CNS of
HIV+ individuals. In our current study, we quantified the
protein expression of HO-1 in the prefrontal cortex of HIV-,
HIV+, and HIV encephalitic brains (n=156). HO-1 protein
levels were deficient in the prefrontal cortex of HIV+ patients
compared to HIV- controls (p<0.01), with more severe HO-1
deficiency observed in HIV encephalitis patients (p<0.001).
Furthermore, this HO-1 deficiency correlated significantly
with CNS viral load as well as with brain parenchymal
markers of macrophage and innate immune activation. These
results suggest CNS HIV infection reduces HO-1 protein
expression in the prefrontal cortex. Notably, HO-1 deficiency
was significantly worse in patients with HAND compared to
HIV+ individuals with normal cognition and correlated with
neurocognitive impairment in executive and speed of process-
ing domains, suggesting this HO-1 deficiency may play a role
in neurocognitive impairment in HAND patients. Using our
in vitro model of HIV-mediated neurodegeneration in which
HIV-infected monocyte-derived macrophages (HIV-MDM)
release neurotoxic levels of glutamate, we have shown that
HIV infection of MDM drastically decreased the protein
expression of HO-1. Moreover, pharmacologic induction
of HO-1 decreased HIV-MDM neurotoxin production
and glutamate release; in contrast, inhibition of HO-1 in-
creased neurotoxin production. In summary, these findings
report HO-1 deficiency in the brains of HIV+ individuals
and identify HO-1 as a potential modulator of macrophage-
mediated neurodegeneration in HAND. Therefore, pharmaco-
logic inducers of HO-1 should be studied for the potential to
reduce the persistent prevalence of HAND in ART-treated
individuals.
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Varicella zoster virus (VZV) is a ubiquitous neurotropic
alphaherpesvirus. Primary infection typically causes child-
hood varicella after which virus becomes latent in ganglionic
neurons along the entire neuraxis. As cell-mediated immunity
to VZV declines with age or immunosuppression, VZV can
reactivate to cause zoster and other serious neurologic and
ocular diseases. Unfortunately, few models are available to
study VZV latency since the virus infects only humans and
latency is established only in neurons. We have successfully
maintained normal human neural progenitor cells (NHNP) in
tissue-like assemblies (TLAs) in 3-dimenstional (3D) cultures
for up to 6 months. NHNP TLAs are a mixture of cells
expressing markers for neuronal progenitor cells (CXCR4,
CD90 and nestin), terminally differentiated neurons (beta-
III-tubulin) as well as non-neuronal cells (GFAP). VZV
infected NHNP-TLAs remained viable for 3 months during
which time VZV DNA replicates, VZV genes (ORFs 9, 40
and 63) are transcribed and infectious VZV is sporadically
released. The ability to maintain VZV infected NHNP cells in
culture for an extended time provides a unique opportunity to
study molecular interactions between VZVand neurons to an
extent previously unattainable.
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JC virus (JCV) is a ubiquitous human polyomavirus and the
etiological agent of progressive multifocal leukoencephalopathy
(PML). In addition to its role in PML, which has been observed
with increasing frequency in Multiple Sclerosis patients on
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monoclonal antibody therapy, JCV has been association with
several human cancers. JCV infection most likely occurs in
childhood and it has been hypothesized that the virus is able to
persist within the bone marrow. However, identification of the
bone marrow cell population that harbor the persistent virus and
may therefore facilitate spread of the virus into different organs,
including the brain, has been hampered by the heterogeneity of
cell populations within the bone marrow. We recently isolated a
distinct population of non-hematopoietic bone marrow derived
cells from JCV T-antigen transgenic mice. These cells are of
neural crest lineage, and we demonstrate that the expression of
JCV T-antigen can be activated in this population of bone
marrow cells upon exposure to a neural environment. JCV T-
antigen positive cells exhibit neural crest characteristics and
demonstrate p75, SOX-10 and nestin positivity. JCV T-antigen
positive cells could be successfully cultured long-term while
maintaining their neural crest characteristics. Furthermore, when
these cells are induced to differentiate into neural crest deriva-
tives, JCV T-antigen expression is downregulated in cells dif-
ferentiating into bone and maintained in glial cells expressing
GFAP and S100. We conclude that JCV T-antigen can be stably
expressed within a fraction of bone marrow cells differentiating
along the neural crest/glial lineage when cells are cultured
in vitro. Thus, we identify a previously unrecognized bone
marrow-derived neural crest stem cell population permissible
for JCV early gene expression suggesting the possibility that
these cells could support viral infection and thus provide clues
toward understanding the role of the bone marrow in JCV
persistence and reactivation.
P73
Novel Neuroprotective GSK-3beta Inhibitor Restricts
Tat-Mediated HIV-1 Replication
Irene Guendel1, Rachel Van Duyne1,2, Kylene Kehn-Hall1,
Mohammed Saifuddin1, Ravi Das1, Elizabeth Jaworski1,
Gavin Sampey1, Svetlana Senina1, Leonard Shultz3, Aarthi
Narayanan1, Hao Chen4, Sergey Iordanskiy1, Benjamin
Lepene5, Chen Zeng4,6, Fatah Kashanchi1
(presenting author: fkashanc@gmu.edu)
1Department of Molecular and Microbiology, National Center
for Biodefense & Infectious Diseases, George Mason
University;
2The Department of Microbiology, Immunology and Tropical
Medicine, The George Washington University School of
Medicine;
3The Jackson Laboratory;
4Department of Physics, The George Washington University;
5Ceres Nanosciences, Inc;
6Department of Physics, Huazhong University of Science and
Technology
The implementation of new antiretroviral therapies targeting
transcription of early viral proteins in post-integrated HIV-1
can aid in overcoming current therapy limitations. Using high
throughput screening assays, we have previously described a
novel Tat-dependent HIV-1 transcriptional inhibitor named
6BIO. The screening of 6BIO derivatives yielded unique
compounds that show potent inhibition of HIV-1 transcrip-
tion. We have identified a second generation derivative called
18BIOder as an inhibitor of HIV-1 Tat-dependent transcrip-
tion in TZM-bl cells and a potent inhibitor of GSK-3beta
kinase in vitro. Structurally, 18BIOder is half the molecular
weight and structure compared to its parental compound
6BIO. More importantly, we also have found differential
GSK-3beta complex present only in HIV-1 infected cells. In
uninfected cells GSK-3beta was present in a complex with a
molecular weight of ~300 kDa, which is likely to be com-
posed of either homo- or hetero-dimers of GSK-3beta in
conjunction with possible chaperone proteins or other bound
proteins. However, HIV-1 infected cells displayed an extend-
ed set of smaller molecular weight complexes in addition to
the dominant ~300 kDa complex. 18BIOder preferentially
inhibits this novel kinase complex from infected cells at
nanomolar concentrations. We observed efficacy of 18BIOder
in HIV-1 replication inhibition in humanized mouse model at
both 1.0 and 10 mg/kg as measured through reverse transcrip-
tase activity from treated animals. Longitudinal measurements
over a span of 29 days showed effective viral suppression at
1.0 mg/kg 18BIOder shortly after treatment. When left
untreated the virus would resume replication, a comparable
response to cART which require daily dosage for effective
plasma control of viral load. Finally, we observed that neuro-
nal cultures treated with Tat protein are protected from Tat-
mediated cytotoxicity when treated with 18BIOder. Overall,
our data suggest that HIV-1 Tat-dependent transcription is
sensitive to small molecule inhibition of GSK-3beta.
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HIV-1 invades the central nervous system (CNS) and estab-
lishes infection in brain by infecting monocytes/macrophages
and microglia. HIV-1 infected monocytes/ macrophages re-
lease cytokine/chemokines that recruit other cells into brain.
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In this study we focused on the highly expressed chemokine
CXCL5, which is a potent chemoattractant of neutrophils.
Neutrophils maintain innate immune surveillance under nor-
mal conditions, whereas, during inflammation they cause
tissue damage. To investigate the role of CXCL5 as well as
neutrophils in HIV-1 infected brain monocyte-derived macro-
phages (MDMs) were infected with HIV-1 that showed a
significant upregulation of CXCL5 both at the RNA and
protein levels compared to uninfected/mock MDM culture.
The significant upregulation of CXCL5 in HIV-1 infected
MDMs was partly influenced by overexpression of IL-1beta,
as neutralizing antibody against IL-1beta reduced the expres-
sion of CXCL5 more in HIV-1 infected MDM compared to
mock infected. The increased production of CXCL5 was also
in part regulated by the phosphorylation status of ERK1/2 and
p38. The association of ERK1/2 and p38 with CXCL5 pro-
duction was confirmed by blocking these MAPKs that
prevented the elevation of CXCL5 in HIV-1 infected MDMs
than in uninfected cultures. Functional analyses suggest that
increased level of CXCL5 was directly correlated with infil-
tration of neutrophils in chemotaxis assay. Furthermore, in-
creased level of CXCL5 and enhanced infiltration of activated
neutrophils expressing myeloperoxidase (MPO) were also
observed in brain tissues from HIV-1 positive subjects. To
assess the consequence of MPO on neurons during HIV-1
infection, primary neurons were treated with HIV-1 infected
or control MDM supernatants in the presence or absence of
MPO. Results indicate that MPO reduced neuronal survival in
a dose dependent manner. Collectively, our results suggest
that CXCL5 has a profound effect on impairment of innate
immune functions in HIV-1 infected brain through neutrophil
infiltration that affects the final outcome of HIV-1 infection.
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We recently reported that 60% of subjects with HCV and
virally-suppressed HIV infection (coinfection) were cogni-
tively impaired. Importantly, we showed that peripheral
monocytes in coinfection had a distinct type-I interferon
(IFN) activation profile. Since HCV is not considered neuro-
tropic, it suggests that indirect viral mechanisms may be
responsible for neural cell dysfunction. Several lines of evi-
dence indicate that exosomes facilitate cell-to-cell communi-
cation wherein host RNA, including miRNAs and proteins
can be transferred to recipient cells. We hypothesized
that IFN-activated monocyte/macrophages mediate
neurocognitive impairment in coinfection by the transfer of
exosomal miRNAs to neural cells that subsequently
dysregulate their function. In support of our hypothesis, we
show that monocyte-derived exosomes are internalized by
primary human astrocytes. In addition, miRNA profiling of
exosomes shed by monocytes from HIV/HCV-infected sub-
jects revealed that the vesicles were highly enriched in miR-
223. Further, we developed an in vitro model that recapitulat-
ed the activation state of monocytes from coinfected subjects.
IFN-activated monocyte-derived exosomes were greatly
abundant inmiR-223 as well, andwhen incubatedwith human
astrocytoma cells, resulted in significant elevation of intracel-
lular miR-223 levels. These results suggest that monocyte-
derived exosomes can transfer miRNAs to neural cells, po-
tentially altering the cellular environment of the latter. The
transfer of miRNAs from activated monocytes to astrocytes
via exosomes may explain, in part, the neurological abnor-
malities associated with coinfection.
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Discovering the cause and potential therapies for HIV-
associated neurocognitive disorders (HAND) will be of in-
creasing importance as the HIV population continues to age.
HAND is marked by impaired attention and memory as well
as decreased cognitive flexibility. The viral envelope glyco-
protein, gp120, has been implicated in the development of
HAND. Previous studies have shown deficits in the
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acquisition phase of the Morris Water Maze task following
intra-cerebroventricular (ICV) infusions of gp120 in rats. The
present work sought to extend those findings to other domains
of cognitive function. Adult male Fischer-344 rats were im-
planted bilaterally with cannulae into the lateral ventricles.
After recovery from the surgery, daily infusions of gp120 (50
ng/microliter) or the bovine serum albumin (BSA) vehicle
solution were administered for 7 days. Animals were food
restricted the day after their final infusion and were tested in an
attention set-shifting task, adapted from Birrell and Brown
(2002), 20 days later. To succeed in this task, the animal must
discriminate between sensory cues to determine the location
of a food reward. Subjects are also required to ignore cues that
were rewarded on previous trials but which are no longer
indicative of reward location. Animals exposed to gp120 were
significantly impaired in reversal learning (within modality
shift) and in their ability to make an extra-dimensional shift
(cross-modality switch), suggesting behavioral inflexibility.
Establishing a rat model of HAND that mimics the cognitive
deficits observed in the clinical population will provide in-
sights regarding mechanisms as well as guide the develop-
ment of potential therapies. This work is supported by NIH/
NIMH R21 MH097623 and NIMH T32 MH070785.
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Human immunodeficiency virus type 1 (HIV-1) remains a
worldwide epidemic and a vaccine or therapy capable of
eradicating the virus is not available. Although HIV-1 infec-
tion is generally associated with the widespread destruction of
T-cells, monocytes and macrophages play an important role in
the infection process, serving viral reservoirs capable of har-
boring latent virus as well as disseminators of the virus
throughout the body. A novel therapeutic avenue against
HIV-1 would be to target host factors, such as transcription
regulators, that are involved in the host response to viral
infection but can be bypassed in normal cellular functioning
and this approach could circumvent the current limitations of
antiretroviral therapy. We hypothesized that transcription reg-
ulator proteins - including transcription factors and cofactors,
promoters, enhancers, repressors and proteins involved in
chromatin structure and modification - were differentially
expressed in HIV-1-infected macrophages. To test this hy-
pothesis, we used a novel proteomic platform, SWATH-MS,
for the targeted and quantitative proteomic analysis of tran-
scription regulators capturing quantitative proteomic data spe-
cifically selected for transcription regulator proteins using an
in-house generated database composed of both known and
putative transcription regulators. Using this SWATH-MS ap-
proach, we identified and quantified 510 transcription regula-
tors in uninfected and HIV-1-infected monocyte-derived mac-
rophages. We then applied novel statistical testing to our
proteomics data using methods previously established for
intensity-based microarray data analysis; we identified 61
transcription regulators that were significantly (p < 0.05)
altered following HIV-1 infection. Bioinformatic analysis of
these altered transcription regulators revealed functional en-
richment of proteins involved in chromatin structure and
epigenetic modifications. Our findings highlight a novel sub-
set of transcription regulator proteins that are involved in HIV-
1 infection demanding further investigation. In addition, our
study provides a new experimental paradigm that can be
readily applied by a broad group of scientists for understand-
ing the host response to microbial infection.
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Several viruses can infect the mammalian nervous system,
some with devastating consequences, and others with little
or no overt pathology. Adoptive immunotherapy is an ap-
proach that involves administration of anti-viral T cells and
has shown promise in clinical studies for the treatment of
CMV, EBV, and adenovirus infections. Our laboratory models
adoptive immunotherapy by transferring anti-viral memory T
cells into mice persistently infected from birth with lympho-
cytic choriomeningitis virus. Here, we demonstrate that mem-
ory T cells can completely purge the brain of persistently
infected mice without causing blood brain barrier breakdown
or severe tissue damage. This is accomplished by a tailored
release of chemoattractants that recruit adaptive immune cells,
but few pathogenic innate immune cells such as neutrophils
and inflammatory monocytes. Interestingly, memory T cells
enlist the support of nearly all brain resident myeloid cells
(microglia) by converting them into CD11c-expressing
antigen-presenting cells (APCs). Two-photon imaging studies
revealed that anti-viral CD8 T cells are more likely to decel-
erate and form stable interactions with brain-resident APCs
than CD4 T cells. Importantly, microglia do not undergo cell
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death following T cell engagement and appear to protect
themselves by upregulating serine protease inhibitors like
Spi-6. We propose that non-cytopathic viral clearance from
the brain by therapeutic memory T cells results from tailored
chemoattractant production and interactions with resident my-
eloid cells protected by Spi-6.
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While the introduction of combined antiretroviral therapy,
cART, has greatly improved survival rates among AIDS pa-
tients, a substantial portion of HIV-1 infected individuals
remain at risk for the development of full blown AIDS as a
result of reactivation of latently infected cells, partly due to
nonadherence to medication and emergence of drug resistant
viruses. Moreover, HIV-1 positive long term survivors con-
tinue to develop comorbidities including an accelerated aging
process, neurocognitive disorders, heart failure, and others.
From the virological point of view, as none of the current
treatments suppress viral gene transcription, it is suspected
that low, yet continuous, levels of viral early proteins with
regulatory and pathogenic activities may contribute to the
development of these quality of life-threatening illnesses.
Sadly, all efforts toward the development of vaccines against
HIV-1 have not shown promising outcomes. Thus, curing of
AIDS by eradicating the HIV-1 genome in infected subjects
requires a novel strategy that is specific, highly effective,
irreversible, and sustained. Recently, we have adapted a ge-
netic approach using clustered regulatory interspaced short
palindromic repeat-associated system (Cas) and short comple-
mentary single-stranded RNA, called guide RNA (gRNA),
which specifically targets the U3 region of the HIV-1 long
term repeat (LTR) promoter and precisely excises a segment
of the viral regulatory sequence required for its expression. In
addition, the employment of single and multiplex gRNA in
our Cas9 system showed promising results that included erad-
ication of the entire HIV-1 genome in latently infected
microglial cells, thus abrogating viral gene expression and
reactivation. Based on this observation, we propose a working
model for the development of an RNA-guided Cas9 that acts
as molecular scissors and, by disrupting various regions of the
LTR and/or removing the entire viral genome, abrogates
reactivation of the virus in macrophages, microglia and
astrocytes which serve as viral reservoirs in the brain. This
work was supported by NIH grants R01 MH093271 and P30
MH092177 Comprehensive NeuroAIDS Center Grant
awarded to KK.
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HIV-1 Tat continues to be implicated as a causative agent of
HIV-1 associated neurocognitive disorder (HAND).We found
previously that Tat elevates endolysosome pH and alters the
structure and function of neuronal endolysosomes, a promi-
nent and early pathological feature of HAND. Here, we
showed that enlarged neuronal endolysosomes occur in an
inducible HIV-1 Tat transgenic model of HAND and deter-
mined underlying mechanisms whereby HIV-1 Tat induces
endolysosome dysfunction. Our observations that HIV-1 Tat
elevates endolysosome pH indicates that HIV-1 Tat escaping
from endolysosomes appears to be linked to proton leakage
out of endolysosomes and suggests that a proton-dependent
peptide transporter might be involved. Of the known proton-
dependent peptide transporters, we demonstrated that proton-
coupled oligopeptide transporter 2 (Pept2) is present on neu-
ronal endolysosomes and that siRNA knockdown of Pept2
blocked HIV-1 Tat-induced enlargement of endolysosomes.
Thus, Pept2 might be a proton-dependent peptide transporter
through which HIV-1 Tat affects endolysosome pH and it
might be involved in HIV-1 Tat escape from endolysosomes.
Elevation of endolysosome pH could also affect
endolysosome calcium homeostasis and we showed that ele-
vation of endolysosome pH not only induces calcium release
from endolysosomes but also activates a novel endolysosome-
dependent calcium influx across plasma membranes, a
phenomenon we have termed “acidic store-operated cal-
cium entry.” Given our observations that HIV-1 Tat
elevates endolysosome pH, increases calcium release
from intracellular stores, and enhances calcium influx
across the plasma membranes, HIV-1 Tat could activate
this novel endolysosome-dependent calcium regulatorymech-
anism. Pept2 may be involved in the actions of HIV-1 Tat on
neuronal endolysosomes and its contribution to the pathogen-
esis of HAND. (Supported by AG043338, GM103329,
NS065957).
S38 12th ISNV, Washington, DC, USA
P81
Irradiation-induced cellular stress activates virus
replication and apoptosis in HIV-1 infected macrophage
model cells and in the brain of infected humanized mice
Sergey Iordanskiy1, Rachel Van Duyne1,2, Gavin Sampey 1,
Kelsi Fry1, Fabio Romerio3, Fatah Kashanchi1
(presenting author: siord6@gmail.com)
1Department of Molecular and Microbiology, National Center
for Biodefense & Infectious Diseases, George Mason
University;
2Virus-Cell Interaction Section, HIV Drug Resistance
Program, National Cancer Institute NIH;
3Institute of Human Virology, University of Maryland School
of Medicine
The highly active antiretroviral therapy reduces HIV RNA in
plasma to undetectable level. However, the virus continues
persistence in resting T cells and CNS reservoirs, such as
perivascular macrophages, microglia and astrocytes. Selective
reactivation and eradication of HIV from CNS reservoirs is a
critical problem of current HIV therapy. The X-ray irradiation
(IR), well-defined stress signal, that is widely used for many
therapeutic purposes, has earlier been shown to be capable to
activate increased HIV-1 transcription, progeny virion forma-
tion and eventual apoptosis of infected cells. Here, using the
HIV-1 infectedmonocyte-derivedmacrophage (MDM)model
cells (PMA-activated U1) and NSG humanized mice infected
with dual-tropic HIV-1 89.6 strain, we examined the effect of
IR-induced cellular stress onHIV-1 replication and viability of
infected cells. Treatment of both PBMCs and MDM with
different IR doses led to dramatic increase of HIV-1 transcrip-
tion, as evidenced by presence of Pol II and reduction of
HDAC1 on HIV-1 promoter when using ChIP assay. This
coincided with increased level of intracellular HIV-1 RNA.
Incubation of IR-treated cells with proteasomal inhibitor
ALLN (Calpain inhibitor 1) resulted in the additional increase
of HIV-1 transcription probably due to Tat protein stabiliza-
tion. Interestingly, analysis of infectivity of progeny virions
using TZM-bl reporter cells showed decreased infectivity of
the virus produced by irradiated cells, suggesting that along
with activation of HIV-1 replication, IR increased production
of defective viral particles. Treatment of HIV-1 infected hu-
manized mice that did not display viral RNA in the plasma
and PBMCs with IR resulted in significant increase of
HIV-1 RNA in plasma, lung and especially brain tis-
sues. Taken together, our current data suggest that IR-
induced cellular stress activates HIV-1 expression in the
infected MDM in different MDM-rich tissues including
brain and facilitates the apoptotic death of infected cells
possibly via Tat-dependent phosphorylation of p53
protein.
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Human T-lymphotropic virus type 1 (HTLV-1) is the causative
agent of adult T-cell leukemia (ATL) and HTLV-1-associated
myelopathy (HAM)/tropical spastic paraparesis (TSP). The
HTLV-1 transactivator protein Tax controls many critical cel-
lular pathways including host cell DNA damage response
mechanisms, cell cycle progression, and apoptosis. Recently,
extracellular vesicles called exosomes have been shown to
play critical roles during pathogenic viral infections as deliv-
ery vehicles for host and viral components including proteins,
mRNA and miRNA. We hypothesized that exosomes derived
from HTLV-1 infected cells contain unique host and viral
proteins that may contribute to pathogenesis. We found that
exosomes derived from infected cells contained the oncogenic
Tax protein and pro-inflammatory mediator IL-6, as well as
the viral mRNA transcripts, tax, hbz, and env. We also ob-
served drastic reduction ofMCP-1 and RANTES in exosomes
from infected cells. Exosomes from infected cells deliver
functional proteins to naive recipient cells and induce ROS
production. Furthermore, we observed that exosomes released
from HTLV-1 infected Tax-expressing cells contributed to
enhanced survival of target cells when treated with FAS
antibody. IL-2 dependent CTLL-2 cells that received Tax
containing exosomes were also protected from apoptosis.
Similar experiments with PBMCs also showed protection of
the cells in 15 day cultures in the absence of PHA/IL-2.
Collectively, these results suggest that exosomes may play
an important role in extracellular delivery of functional
HTLV-1 proteins, especially Tax, and mRNA to recipient cells
and contribute to oncogenesis in the recipient cells.
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HIV-1 infection results in a chronic but incurable illness since
long-term HAARTcan keep the virus to an undetectable level.
Discontinuation of therapy rapidly increases virus burden.
Moreover, patients under HAART frequently develop various
metabolic disorders and also HIV-associated neuronal disease.
Today, the main challenge of HIV research is the elimination
of the residual virus in infected individuals. The current HIV-1
diagnostics are largely comprised of serological and nucleic
acid based technologies. Our goal is to integrate the nanopar-
ticle technology into a standard research tool that will allow
for highly sensitive detection of HIV infection. Our study
demonstrates that majority of HIV-1 virions and Tat/nef pro-
teins spiked in culture medium can be captured by
nanoparticles. Especially at low concentrations, the
nanoparticles provided dramatic increase in HIV-1 detection
levels over standard assays. To determine the binding speci-
ficities of different affinity baits, we incubated target mole-
cules with nanoparticles at room temperature. After short
sequestration, materials were either eluted using downstream
assay buffer or remained attached to nanoparticles prior to
analysis. The unique affinity baits of nanoparticles preferen-
tially bound HIV-1 materials while excluded albumin. The
specific capture of full-length Tat or Tat peptide spiked in cell
culture medium by nanoparticles NT082 and NT084 was
measured by WB. Intracellular Nef protein was captured by
NT080, while membrane-associated Nef was captured by
NT086. Whole HIV-1 virus capture was enriched by NT073
and NT086, while NT086 nanoparticle captured infectious
virus as demonstrated by Tat transactivation in TZM-bl cells.
We also demonstrated specific capture of exosomes derived
from HIV-1 infected cells and measured TAR-RNA by qRT-
PCR. Collectively, our data indicate that some nanoparticles
selectively capture specific target molecules of HIV-1 infec-
tion, and we propose to use this technology as a platform to
enhance HIV-1 detection by concentrating viral proteins and
infectious materials from infected samples.
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Background: While the effects of HIV-Tat protein on neuro-
glial function has been well studied, the role of Tat in medi-
ating persistent proinflammatory responses in the CNS in
virologically controlled individuals on ART is not well
known. Persistent, low level inflammation can be demonstrat-
ed in the majority of individuals with chronic HIV infection,
even when aviremic. Some patients who are well controlled
on ART develop an immune reconstitution inflammatory
syndrome (IRIS).
Methods: We immunostained brain biopsy tissue for Tat
and p24 antigen, and T cell markers from two HIV
patients on ART who developed CNS- IRIS and com-
pared it to autopsy brain tissue of seven HIV-infected
individuals with good virological control on ART but
without IRIS and one with HIV encephalitis (HIVE) with
no ART. Tat levels were also examined in the CSF of
patients on ART (n=31) and in peripheral blood mono-
nuclear cells (PBMC) infected with HIV and treated with
darunavir.
Results: Monocytic infiltrates strongly stained for Tat in both
patients with IRIS, however, p24 immunostaining was nega-
tive. In HIV patients without IRIS Tat was present in 2/7
individuals. The patient with HIVE had Tat and p24 express-
ing macrophages in microglial nodules and perivascular re-
gions. In IRIS patients, infiltrates consisted of CD3 + T-cells
which were predominantly CD8+ with few CD4+ cells and
occasional IL-17+ cells. Tat was detected in 13/31 CSF
samples by ELISA from HIV-infected individuals controlled
on ART. Tat was confirmed in a subset of CSF samples by
Western blot analysis. Darunavir blocked viral production
in HIV-infected PBMC, however Tat production was
unimpaired.
Conclusions: Robust production of Tat was noted in brain of
individuals with CNS-IRIS and in CSF of one third of indi-
viduals controlled on ART. While ART can control HIV
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replication it does not impact Tat production. Therapeutic
development to prevent Tat production is necessary.
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Background: Iron dysregulation in the brain is a consis-
tent and poorly understood feature of neurocognitive
disorders, and functional neuronal iron deficiency has
been implicated in certain dementias. We hypothesized
that HIV-Associated Neurocognitive Disorder (HAND)
pathophysiology involves brain iron deficiency, reflected
by increased transferrin receptor (TFR) RNA expression
in brain.
Methods: Subjects who died of HIV/AIDS and participated
in the National NeuroAIDS Tissue Consortium (NNTC)
Study underwent uniform autopsy/neuropathology protocols
and comprehensive neurocognitive assessments within 6
months antemortem. Total RNA was extracted and purified
from frozen brain tissue (frontal neocortex at Brodmann
Area 9); TFR messenger RNA was quantified by RT-PCR.
Associations of TFR RNA expression with HAND and
standardized, neurocognitive domain scores were assessed
using multivariable regression to adjust for potential
confounders.
Results: Among 300 evaluated decedents from the NNTC
Brain Bank (mean age 44, median CD4 cell count 109/ul),
HAND occurred in 243 (81%), ranging from mild
neurocognitive impairment (24%) to dementia (32%). TFR
RNA expression levels, available in 274 subjects (91%),
were unrelated to brain viral burden. TFR RNA expres-
sion in neocortex was associated with HAND (p<0.05;
p<0.01 for association with dementia) in unadjusted anal-
yses: TFR RNA levels were 15.4% higher in HAND cases
than controls [median (IQR) 0.90 (0.65, 1.20) vs. 0.78
(0.61, 1.0), respectively]. These associations persisted
after multivariable adjustment [odds ratio (OR) 5.8 (95%
CI 1.5-22.9, p<0.05) for all HAND cases; OR 2.3 (95%
CI 1.1-4.9, p<0.05) for dementia]. Speed of information
processing, attention working memory, and global stan-
dardized T-scores were negatively associated with TFR
RNA expression [all p≤0.05; beta-coefficient -4.27 (95%CI -
8.3 to -0.23) for global T-score].
Conclusions: TFR RNA expression in frontal neocortex is
independently associated with both mild and more severe
neurocognitive impairment among individuals dying of
HIV/AIDS, suggesting a role for brain iron deficiency in
HAND etiology and/or progression.
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Transcription of the HIV-1 promoter is controlled by a
series of ubiquitous and inducible cellular proteins, some
with the ability to enter the nucleus and interact with the
specific DNA sequences spanning the 5` long terminal
repeat, LTR. Here, we demonstrate the ability of Rad51,
a key regulator of the homologous recombination pathway
of DNA repair, to stimulate transcription of the HIV-1
promoter spanning within the long terminal repeat
(LTR). Our results show that activation of NF-kB path-
way by PMA treatment or overexpression of its subunit
p65, promotes the association of Rad51 with the LTR
sequence. Accordingly, stimulation of the viral promoter
by Rad51 relies, in part, on its interplay with p65 and the
NF-kB pathway. Treatment of the cells with PMA that
promotes nuclear entry of Rda51 or inactivation of the
NF-kB pathway by a dominant negative mutant of
IkBalpha modulates the ability of Rad51 to stimulate
LTR transcription. Infection of primary peripheral blood
mononuclear cells with HIV-1 indices Rad51 expression
and treatment of the infected cells with Rad51 inhibitor
suppressed lentiviral replication in this cells, suggesting
the operation of positive feedback pathway between
HIV-1 and Rad51. These observations ascribe a new role
for Rad51 in transcription of the HIV-1 genome and
offer a new avenue for the development of anti-HIV-1
therapeutics.
Supported by grant to Kamel Khalili. This study utilized
services offered by core facility of the comprehensive
neuroAIDS center, CNAC - (NIH P30 MH092177)
12th ISNV, Washington, DC, USA S41
P87
Neuroprotective Maraviroc Monotherapy in SIV-infected
Macaques: Reduced Replicating and Latent SIV
in the Brain
Kathleen Kelly1, Sarah Beck1, Kelly Metcalf Pate1, Suzanne
Queen4, Jamie Dorsey5, Robert Adams6, Patrick Tarwater2,
Joseph Mankowski1
(presenting author: jmankows@jhmi.edu)
1Dept of Molecular and Comparative Pathobiology, Johns
Hopkins University;
2Dept of Biostatistics, Texas Tech University School of
Medicine;
Given the association between HIV-induced CNS disease and
replication of HIV in macrophages in the brain, CCR5 antago-
nists could attenuate CNS disease both by limiting HIV repli-
cation in macrophages and by downmodulating inflammatory
signaling mediated by chemokine-CCR5 interactions. To deter-
minewhether CCR5 inhibition altered CNS disease progression
independent of treatment with other classes of anti-retroviral
drugs, CNS outcomes were compared between SIV-infected
animals treated with maraviroc monotherapy versus untreated
SIV-infected animals. SIV RNA and SIV DNA levels in brain
were markedly lower in maraviroc treated, SIV-infected ma-
caques versus untreated SIV-infected macaques, demonstrating
that maraviroc monotherapy limits replication of SIV in the
CNS andmay reduce the CNS latent viral reservoir. In addition,
maraviroc treatment lowered monocyte and macrophage acti-
vation, represented by CNS CD68 immunostaining and plasma
sCD163 levels, and reduced both TNFalpha and CCL2 RNA
expression in brain. Maraviroc treatment also reduced axonal
amyloid precursor protein (APP) immunostaining to levels
present in uninfected animals, demonstrating protection from
development of neuronal dysfunction. Although maraviroc
therapy reduced plasma viral load and SIV RNA levels in
spleen, relative decreases were less substantial than CNS de-
clines, underscoring the importance of assessing CNS-specific
outcomes in evaluating efficacy of CCR5 inhibition. The addi-
tion of CCR5 inhibitors to combined anti-retroviral regimens
may effectively prevent neurologic disorders in HIV-infected
individuals and also may reduce CNS viral reservoirs.
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In the absence of an effective microbicide that reduces or
eliminates the risk of human immunodeficiency type 1 (HIV-
1) transmission, the development of new anti-HIV-1 drugs
remains a priority. Cell penetrating peptides (CPP), which
are short peptides that are capable of crossing the plasma
membrane of a living cell, are under development as delivery
vehicles for therapeutic agents that cannot themselves enter
the cell. One well-studied CPP is the 10-amino acid peptide
derived from the human immunodeficiency virus type 1 (HIV-
1) Tat protein. In experiments to test the hypothesis that
multiple cationic amino acids within Tat peptide confer
antiviral activity against HIV-1, introduction of Tat peptide
resulted in concentration-dependent inhibition of HIV-1
IIIB (X4) infection yet minimal antiviral activity against
BaL (R5). In contrast, Tat peptide variants containing argi-
nine substitutions for two non-ionic residues and two lysine
residues, demonstrated a direct relationship between cat-
ionic charge and antiviral potency in HIV-1 inhibition
experiments. These studies of Tat peptide as an antiviral
agent raise new questions about the role of Tat in HIV-1
replication and provide a starting point for the development
of CPPs as novel HIV-1 inhibitors.
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Patients infected with human immunodeficiency virus type 1
(HIV-1) often display neurological complications in late stage
disease and increased viral loads directly correlated with
higher concentrations of extracellular HIV-1 protein r (Vpr)
in the blood serum and cerebrospinal fluid. Additionally, HIV-
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1-infected patients with a low CD4+ T-lymphocyte count
displayed lower concentrations of reduced glutathione
(GSH), the main intracellular antioxidant molecule, and lower
level of survival. Conditioned media obtained from the human
endothelial kidney (HEK) 293T cell line transfected either in
the absence or presence of HIV-1 Vpr contained free Vpr.
Exposure of U-87 MG cells to this conditioned media de-
creased intracellular levels of both adenosine triphosphate
(ATP) and GSH. These observations were recapitulated using
purified recombinant HIV-1 Vpr both in U-87 MG and pri-
mary human fetal astrocytes in a dose- and time-dependent
manner. Vpr-induced oxidative stress could be partly re-
stored by co-treatment with the antioxidant molecule N-
acetyl-cysteine (NAC). In addition, free Vpr augmented
production of reactive oxygen species due to an increase
in the level of oxidized glutathione (GSSG). This event
was almost entirely suppressed by treatment with an anti-
Vpr antibody or co-treatment with NAC. These studies
confirmed a role for extracellular Vpr in decreasing the
levels of intracellular ATP and GSH in astrocytes. Studies
are underway to better understand the intricate correlation
between reductions in ATP and GSH metabolites and the
impact they exert on neuronal survival in end-stage disease.
This work is supported by NIH/NINDS R01 NS32092,
NIDA R01 DA19807, NIMH P30 MH092177, and NIMH
T32 MH079785.
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Objective: To determine the frequency of hyperintense
cortical T1 signal (HCTS) on MRI in progressive multifocal
leukoencephalopathy (PML) patients, its association with sei-
zure risk and immune reconstitution inflammatory syndrome
(IRIS), and its pathologic correlate.
Background: PML, caused by JC virus (JCV) affects pre-
dominately white matter. Seizures point to a cortical origin
and add to increasing evidence of gray matter involvement
in PML. HCTS is a radiologic marker of cortical laminar
necrosis and is described in hypoxia, hypoglycemia and
status epilepticus.
Methods: We reviewed clinical data including seizure history,
presence of IRIS, and MRI scans from PML patients evaluat-
ed at our institution between 2003 and 2012. Cases that were
diagnosed either by CSF JCV PCR, brain biopsy or autopsy,
and who had MRI images available were included in the
analysis (n=49).We compared pathologic findings in areas of
the brain of two patients displaying HCTS with isointense
cortex in the same individuals.
Results: Of 49 patients, 17 (34.7%) had seizures and 30
(61.2%) had HCTS adjacent to subcortical PML lesions on
MRI. Of the 17 PML patients with seizures, 15 (88.2%) had
HCTS compared to 15/32 (46.9%) patients without seizures
(p= 0.006). Of the 20 patients with IRIS, 16 (80.0%) had
HCTS compared to 14/29 (49.3%) of those without IRIS,
(p=0.04). HCTS predicted seizures with an odds ratio (OR)
of 8.5 (95% confidence interval (CI) of 1.66 - 43.41). Togeth-
er, HCTS and IRIS predicted seizures with an OR of 9.9 (95%
CI of 2.5 - 39.3; p=0.001). On histological examination,
HCTS areas showed no evidence of ischemia but were asso-
ciated with striking demyelination of sub-cortical U-fibers,
significant macrophage infiltration and a pronounced reactive
gliosis in the deep cortical layers.
Conclusions: Seizures are a frequent complication in PML.
HCTS is associated with seizures as well as IRIS, and corre-
lates histologically with cortical segmental astrogliosis.
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Objective: We sought to characterize perfusion patterns of
progressive multifocal leukoencephalopathy (PML) lesions
by arterial spin labeling (ASL) perfusion magnetic resonance
imaging and to analyze their association with immune recon-
stitution inflammatory syndrome, and survival.
Background: ASL uses magnetic fields to alter the magneti-
zation of water in the inflowing arterial blood and then mea-
sures the effect of the inflow of altered magnetization on the
tissue signal. Because the "tracer" used is the endogenous
blood water, ASL does not require any injections or other
contrast agent.
Methods: A total of 22 patients with PML underwent a clinical
evaluation as well as magnetic resonance imaging of the brain
within 190 days of symptom onset. The presence of immune
reconstitution inflammatory syndrome was determined based
on clinical and laboratory criteria. Perfusion within PML
lesions was determined by arterial spin labeling magnetic
resonance imaging.
Results: We observed intense hyperperfusion within and at
the edge of PML lesions in a subset of subjects. This
hyperperfusion was quantified by measuring the fraction of
lesion volume showing perfusion in excess of twice normal
appearing gray matter. Hyperperfused lesion fraction was
significantly greater in PML progressors than in survivors
(12.8% vs 3.4% p=0.02) corresponding to a relative risk of
progression for individuals with a hyperperfused lesion frac-
tion ≤ 4.0% of 9.1 (95% CI of 1.4- 59.5). The presence of
hyperperfusion was inversely related to the occurrence of
immune reconstitution inflammatory syndrome at the time
of scan (p=0.03). Indeed, within three months after symptom
onset, hyperperfusion had a positive predictive value of
88% for absence of immune reconstitution inflammatory
syndrome.
Conclusions: Arterial spin labeling magnetic resonance imag-
ing recognized regions of elevated perfusion within lesions of
PML. These regions might represent virologically active areas
operating in the absence of an effective adaptive immune
response and correspond with a worse prognosis.
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While long term combined antiretroviral therapy (cART) has
greatly improved survival rates among AIDS patients, a sub-
stantial proportion of HIV-1 infected individuals continue to
develop comorbidities including heart failure (HF) secondary
to left ventricular dysfunction at higher rates than non-HIV-1
individuals. The underlying mechanisms whereby HIV-1 in-
creases susceptibility to HF remain poorly understood. In this
respect, HIV-1 Tat, which is produced and released by the
latent viral reservoir and upon its circulation can be taken up
by uninfected cells, has received special attention due to its
ability to induce an array of dysregulatory events that perturb
cell and organ function. We demonstrate that HIV-1 Tat phys-
ically associates with BAG3, a stress induced protein which is
involved in protein quality control, and modulates autophagy
and apoptosis. BAG3 is critical for normal cardiac develop-
ment and maintenance as BAG3 knockout mice develop left
ventricular (LV) dysfunction and have a shortened lifespan.
Furthermore, recent studies have identified a potential role for
BAG3 in patients with HF as heterozygous mutations that
decrease the level of BAG3 and lead to development of a
heritable form of dilated cardiomyopathy. Moreover, ventric-
ular myocardium isolated from failing human hearts examined
at the time of heart transplantation exhibit nearly 50%
reduction in BAG3 levels in cardiac tissue, all of which
supports the importance of BAG3 for healthy heart func-
tion. BAG3 is an important regulator of filamin and
myopodin and regulates protein turnover by autophagy
in cardiomyocytes. We provide evidence suggesting that
the interplay between BAG3 and HIV-1 Tat impacts the
ability of BAG3 to regulate several pathways involved in
the structural and functional integrity of cardiomyocytes.
Thus, one can envision a model in which the inactivation
of BAG3, upon its association with HIV-1 Tat, recapitu-
lates the clinical manifestations seen in patients with heart
failure associated with low/dysfunctional BAG3.
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HSV-1 is a ubiquitous, neurotropic human pathogen that
causes diseases ranging from mild orofacial lesions to poten-
tially fatal encephalitis. Cells present at the infection site
express pattern recognition receptors including Toll-like re-
ceptors that detect infection, produce antiviral cytokines, and
limit viral invasion of the nervous system. We assessed the
role of TLR2 in resistance to HSV-1 encephalitis in a natural
lip infection model. Multiple cell types express TLR2, which
recognizes HSV-1 glycoproteins. We show here that TLR2-
knockout (Tlr2-/-) mice were highly susceptible to HSV-1-
induced mortality. Their natural killer cells responded normal-
ly, but the mice exhibited impaired dendritic cell and CD8+ T-
cell activation. While virus replication within the lips was not
different, HSV-1 spread to the trigeminal ganglia more effi-
ciently in the Tlr2-/- group. Additionally, CNS entry was
exacerbated in the knockouts and viral loads there positively
correlated with disease severity. The elevated CNS viral load
precipitated the up-regulation of inducible nitric oxide syn-
thase. Nitric oxide is neurotoxic at high concentrations and
presumably contributed to the mortality in the knockout ani-
mals. We then assessed the infiltration of leukocytes to the
infected CNS to study their impact on disease. Neutrophils,
which contribute to irreparable inflammation during viral
encephalitis, were observed in the cerebral cortex of the mice
exhibiting the most significant signs of disease, irrespective of
their TLR2 status. Lastly, we utilized an intracranial infection
model to specifically assess the role of TLR2 within the CNS,
but the virus strain utilized proved too virulent to reveal a
phenotypic difference. In summary, TLR2 is critically impor-
tant for controlling the level of HSV-1 that spreads to the CNS,
and once the virus accesses the brain, TLR2-independent
responses contribute to the heightened inflammation observed
in the knockout animals. In future studies, we will focus on the
identification of the responsible TLR2+ cell type.
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Despite the widespread use of antiretroviral therapy, HIV-
associated neurocognitive disorders (HAND) continue to
persist, signifying a need for the development of adjunct ther-
apeutic strategies. We have identified the anti-oxidant and anti-
inflammatory enzyme heme oxygenase-1 (HO-1) as a potential
therapeutic target for HAND. Recently we characterized HO-1
within the prefrontal cortex of HIV+ individuals and found that
HO-1 protein was deficient in HIV+ individuals and correlated
with neurocognitive impairment; however, HO-1 RNA was
increased compared to HIV- controls. We have previously
shown that HO-1 protein is also deficient in HIV-infected
monocyte derived macrophages (HIV-MDM) and this defi-
ciency is associated with enhanced glutamate release and neu-
rotoxicity. To explain the HO-1 protein deficiency observed in
HAND patients and to probe mechanisms by which this defi-
ciency may contribute to neurotoxicity, we examined HO-1
regulation within astrocytes, which are the predominant source
of HO-1within the brain and are critical mediators of glutamate
handling. Primary rat and human astrocytes were treated with
immune activators relevant to HIV pathogenesis (IFN-gamma,
lipopolysachharide (LPS), TNF-alpha) and HO-1 expression
was assessed after acute (1, 6, 24 hours) and chronic (15 days)
exposure. Chronic, but not acute, treatment significantly re-
duced HO-1 protein expression in both rat and human astrocyte
cultures; HO-1 RNA was not altered throughout treatment.
Furthermore, chronic treatment did not alter the expression of
other antioxidant proteins (NQO1 and GPX1), suggesting that
the reduction of HO-1 protein driven by immune activators is
specific and not due to global suppression of the antioxidant
response. These results demonstrate that chronic immune acti-
vation suppresses HO-1 protein within astrocytes, and suggest
a mechanism by which chronic HIV infection leads to a global
deficiency of HO-1 within the frontal cortex. Reduced HO-1
within astrocytes may have important functional consequences
for glutamate regulation and subsequent neurodegeneration,
which will be addressed in future studies.
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TNF-alpha Dependent Degradation of RXR-gamma:
Implications for Substance Abuse Disorder in HIV
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Since the beginning of the AIDS epidemic, HIV infection and
substance abuse have been linked. The risk of contracting HIV
and transmitting HIV increases significantly with cocaine use.
Neurocognitive disorders associated with cocaine abuse or
with HIV infection are exacerbated in patients who are
HIV+ and use cocaine. Both cocaine and HIVinfection induce
pro-inflammatory cytokines, such as tumor necrosis factor
alpha (TNF-alpha) and ultimately lead to the disruption of
numerous neuronal signaling pathways. The retinoic acid
(RA) signaling pathway is important in a number of cellular
processes and in HIV patients this pathway is disrupted. Our
data show for the first time that cocaine and the HIV protein,
Tat significantly disrupt this pathway in the CNS. Retinoid X
receptors (RXR) can homodimerize or serve as required
heterodimeric partners for a number of ligand-activated nu-
clear receptors, which recognize specific DNA sequences on
target genes to regulate transcriptional activation. Our data
show that cocaine significantly down-regulates RXR-gamma
in brains of cocaine treated-mice, Tat transgenic mice and in
neurons in vitro. Additionally, genes regulated by RXR sig-
naling such as neurogranin, which encodes a protein required
for adult neuroplasticity, are significantly down regulated. The
cocaine-induced degradation of RXR-gamma is proteasome
dependent and involves nuclear export of the protein. Addi-
tionally, our data show that inhibiting TNF-alpha signaling, or
blocking downstream TNF-alpha effectors such as c-jun-
NH2-terminal kinase (JNK), can attenuate the cocaine-
mediated decreases in RXR-gamma levels. Data from our
studies provide the first evidence that exposure to co-
caine or to Tat disrupts RXR-gamma signaling in the CNS,
and that TNF-alpha activation likely plays a role. As RXR
dysfunction is implicated in a number of neurodegenerative
diseases and psychiatric disorders, our findings may extend to
other neuropathological conditions characterized by a
neuroinflammatory component.
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Extracellular human immunodeficiency virus type type 1
(HIV-1) viral protein R (Vpr) is a pleiotropic protein
accomplishing several functions within the viral life cycle.
While Vpr has been described extensively as an intracellular
protein, very little is known about its role as an extracellular
protein. In fact, HIV-1 Vpr has been detected in the blood,
serum, and cerebrospinal fluid of HIV-1-infected patients,
with concentrations increasingly higher in late-stage disease.
To determine the role exogenous Vpr plays in HIV-associated
central nervous system dysfunction, primary human fetal as-
trocytes were exposed to recombinant Vpr and a time- and
dose-dependent decrease was demonstrated in two fundamen-
tal intracellular metabolites (ATP and glutathione (GSH)).
Additionally, exposure to exogenous Vpr led to increased
caspase activity and secretion of proinflammatory cytokines
IL-6 and IL-8 and chemoattractants, monocyte chemotactic
protein-1 and migration inhibition factor. Extracellular Vpr
also dampened the glycolytic pathway through impairment of
GAPDH activity, causing a decline in the levels of ATP. The
reduction in intracellular ATP increased reactive oxygen spe-
cies buildup, decreasing GSH concentrations, which affected
several genes in the oxidative stress pathway. In addition,
exposure of the SK-N-SH neuroblastoma cell line to condi-
tioned medium from exogenous Vpr-treated astrocytes de-
creased synthesis of GSH, leading to their apoptosis. These
observations point to a role that Vpr plays in altering astro-
cytic metabolism and indirectly affecting neuronal survival.
We propose a model that may explain some of the neurolog-
ical damage and therefore neurocognitive impairment ob-
served during the course of HIV-1 disease. This work is
supported by NIH/NINDS R01 NS32092, NIDA R01
DA19807, NIMH P30 MH092177, and NIMH T32
MH079785.
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Behavioral phenotyping of mice lacking Pur-alpha,
an important regulator of HIV-1 mediated
neurodegeneration
Jessica Krueger, Jessica Otte, Mary Barbe, Jennifer Gordon
(presenting author: jennifer.gordon@temple.edu)
Department of Neuroscience and Center for Neurovirology,
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Pur-alpha is a highly conserved sequence specific DNA and
RNA binding protein with established roles in DNA replica-
tion, RNA translation, cell cycle regulation, and maintenance
of neuronal differentiation. Pur-alpha is also an important
mediator of HIV-1 gene expression through its strong interac-
tion with the regulatory Tat protein and neurotoxicity associ-
ated with Tat is mediated, at least in part, by Pur-alpha. Post-
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natal expression of Pur-alpha in the brain is essential to the
normal development of neurons and synaptic formation in the
hippocampus and cerebellum as homozygous deletion of Pur-
alpha causes premature death before adolescence. Animals
heterozygous for Pur-alpha demonstrate haploinsufficiency
with significantly reduced levels of Pur-alpha in the brain
and expire before one year of age suggesting that chronic
reduction in Pur-alpha leads to neuropathogenic effects. Here
we present for the first time an assessment of the behavioral
phenotype of mice heterozygous for the Pur-alpha knockout
allele. Due to the observed motor dis-coordination and cere-
bellar changes in the model, the less physically demanding
Barnes maze was used to assess spatial learning and locomo-
tor activity. A reversal protocol on the maze was used to
investigate the animals' retention of spatial memory long-
term as well as their capacity for new memory formation. A
second spatial learning paradigm with low but different motor
demands, the novel object location test, was used to further
characterize spatial memory function. A third test probed
sensory alterations using a free-two-choice thermal gradient
to assess peripheral nerve changes. Taken together, our find-
ings from our behavioral and histochemical assays implicated
Pur-alpha in the mediation of neurodegeneration in the context
of HIV-1 infection. Thus, the Pur-alpha knockout mice may
provide a well-defined animal model in which to study mech-
anisms of HIV-1 associated neurological disorders, including
cognitive deficiencies and peripheral neuropathies. Core fa-
cility services supported by CNAC at Temple (NIMH P30
MH092177).
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Background: HIV-1 associated neurodegeneration, and dys-
functional neurobiological systems in the CNS in pre- and
post-cARTera have been investigated in multitudes of studies,
including ours. However, studies are scarce on the impact of
HIV-1 on the CNS serotonin system, the major neurotrans-
mitter system that regulates behaviors. In an earlier study
carried out in the CSF of HIV-1+ individuals in pre-cART
era, we reported a dramatic decrease in 5-hydroxytryptamine
(5-HT) concentration without any change in 5-HIAA. In the
post-cART era, however, the impact of HIV-1 in the CNS
serotonin system has remained elusive, although, 30-50% of
HIV-1 infected individuals continue to experience spectrum of
neuropsychiatric disorders, including depression, affecting
quality of life, medication adherence and disease progression.
Objectives: To investigate the impact of HIV-1 on CNS sero-
tonin (5-HT) and 5-HIAA status as well as HIV-1 RNA load
in different regions (frontal cortex, basal ganglia, hippocam-
pus, hypothalamus, raphe nuclei, amygdale, and substantria
nigra) of postmortem brains of HIV-1+ individuals who dur-
ing life received cART and were evaluated for neuropsychiat-
ric disorders, compared to 5-HT status in the brain regions of
non-infected individuals.
Results: We found variable changes (%) in 5-HTand 5-HIAA
concentrations in different brain regions of HIV-1+ individ-
uals (5-HT, -13.7%, +4.5%, -9.6%, -8.9%, -0.244%, -9.27%,
+8.2%; 5-HIAA, +3.84%, -2.1%, -4.91%, -1.7%, +4.6%,
-4.3%, - 30% respectively), compared to that in non-infected
persons. The variable changes found in 5-HT and 5-HIAA
concentrations in different brain regions of HIV-1+ individ-
uals in this study are contrary to the dramatic decrease in CSF
5-HT in HIV-1+ individuals in the pre-cART era. Does cART
influence CNS 5-HT turnover?
Conclusion: Our data suggest that serotonin system in the
CNS is vulnerable to HIV-1 infection in the post-cART era.
Further studies are warranted on the effect of HIV-1 and cART
on multiple indices of CNS serotonergic systems.
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Growing evidence points to significant mechanistic overlap
between HIV-associated neurocognitive disorders (HAND)
and age-related neurodegeneration. HIV infected individuals
diagnosed decades ago are beginning to face age-related neu-
rodegeneration and combined with viral infection and long-
term exposure to cART, neurodegeneration is exacerbated.
Cellular dysfunction involving accumulation of aberrant pro-
teins, and loss of protein quality control are among the most
important causes for disease and age-related neurologic
decline. Accumulation of hyperphosphorylated Tau (hpTau)
is a neuropathological feature of aging in HIV encephalitis
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(HIVE) and other neurodegenerative disorders like
Alzheimer’s disease. We have discovered that an adaptor
protein called PINCH is important in the signaling cascade
of HIV-related Tauopathy at multiple levels including cell
signaling and as a clinical correlate of CNS disease severity.
PINCH is nearly undetectable in the healthy CNS, but during
HIV infection, it is robustly expressed by neurons. Our
in vitro, in vivo and human data show that PINCH binds
directly to hpTau and is associated with loss of Tau solubility
in disease. Unique isoforms of PINCH are detectable in the
CSF of HIV patients and pilot data suggest that CSF levels of
PINCH may correspond in part to immune recovery, rather
than viral burden. PINCH inhibits the PP1alpha phosphatase
and competes with Tat for binding. Tat induces Tau translo-
cation to the somatodendritic compartment of human primary
neurons, and decreasing PINCH expression results in the
detection of less hpTau. Understanding the contribution of
increased PINCH to HIV-associated Tauopathy may provide
a new therapeutic avenue for reducing levels of hpTau in the
brain. Moreover, characterizing the clinical significance of
PINCH in the CSF may warrant including PINCH as a mem-
ber of biomarker panel to assess severity or progression of
HIV-associated neurocognitive alterations.
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CD16+ monocytes are expanded in SIV infection
by mechanisms involving increased production of CD14+
monocytes in bonemarrow as well as increased peripheral
maturation (CD14+/CD16+)





We previously demonstrated the expansion of CD16+ mono-
cytes in HIV and SIV infection. Since the percentage of this
monocyte subset correlated with viral load and CD4+ T cell
count, we had suggested a role in AIDS and CNS pathogen-
esis. These cells likely also promote the persistent macrophage
reservoir of viral infection in the CNS as well as the periphery.
Here, we investigated the dynamics of production and clear-
ance of total (CD14+) and CD16+ monocytes using in vivo
BrdU and CFSE labeling in rhesus macaques infected with
SIVMac251. Three groups of animals included SIV+ (N=6),
SIV+/CD8 depleted (N=5), and SIV- [N=5(BrdU), 3(CFSE)] .
BrdU and CFSE were injected intravenously 3 months post-
infection in all groups in order to label proliferating (i.e. in
bone marrow), and peripheral circulating leukocytes, respec-
tively. Blood specimens were drawn at 30 minutes, 1, 2, 3, 4,
5, and 7 days post-BrdU/CFSE administration and analyzed
by flow cytometry. An increase in the production of BrdU+
monocytes was observed at day 1 in the SIV+/CD8 depleted
macaques. CD14+ monocytes, emerging as BrdU+, were
virtually all CD16- at 24 hours post BrdU administration,
despite the increased production of total CD14+ monocytes
in SIV+/CD8 depleted animals at this time point. At subse-
quent time points, however, the percentage of CD16+/BrdU+
monocytes increased, peaking at day 3 in all groups. These
results likely suggest an altered distribution of proliferating
monocyte precursors within the bone marrow. Monocyte
clearance was similar in all groups as determined by
CFSE labeling. Taken together, our results suggest the
importance of both altered monocyte production (in
bone marrow) as well as maturation in peripheral compart-
ments, leading to the overall expansion of CD16+ monocytes
in AIDS. Analysis of T cell turnover also provided novel
insights regarding CD4+ and CD8+ T-cell dynamics in
AIDS.
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The human herpesviruses HHV-6A and HHV-6B are widely
distributed in the adult population, though specifically associ-
ated with several disorders of the central nervous system
(CNS) including multiple sclerosis (MS). The association of
these viruses with neurologic diseases has been partly
established by the detection of elevated viral DNA levels in
patients compared to controls. Despite their high nucleotide
homology, HHV-6A and HHV-6B were recently reclassified
as separate species, owing to mounting evidence of their
biological differences. As it is now especially relevant to
investigate each virus separately, we investigated coinfection
of HHV-6A and HHV-6B in human biological material using
a novel quantitative PCR technology called digital droplet
PCR (ddPCR). DdPCR enables the absolute quantification
of target DNA molecules and is highly sensitive for low-
level targets. To investigate coinfection, we designed an assay
to PCR amplify both viruses with comparable kinetics, such
that small amounts of one could be distinguished in the
presence of large amounts of the other. Using this approach,
we observed a heretofore-underappreciated frequency of
HHV-6A and HHV-6B coinfection in the serum, PBMC and
saliva of healthy donors. Interestingly, upon comparing adult
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MS patients with healthy donors, we detected a significantly
elevated frequency of coinfection in MS saliva. We are
currently exploring whether there are clinical correlates
to coinfection, and assessing saliva samples from pediatric
MS patients and controls. Identifying and quantifying both
species of HHV-6 may provide clinically relevant information
and as we learn more about each virus in health and
disease, the observation of coinfection may have profound
implications.
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Immunologic dysfunction, mediated via monocyte activity,
has been implicated in the development of HIVassociated
neurocognitive disorder (HAND). We hypothesized that
transcriptome changes in peripheral blood monocytes relate
to neurocognitive functioning in HIV+ individuals, and that
such alterations could be useful as biomarkers of worsening
HAND. METHODS: mRNA was isolated from the mono-
cytes of 86HIV+ adults and analyzed with the Illumina HT-12
v4 Expression BeadChip. Neurocognitive functioning,
HAND diagnosis, and other clinical and virologic variables
were determined. Data were analyzed using standard expres-
sion analysis and weighted gene co-expression network anal-
ysis (WGCNA). RESULTS: Neurocognitive functioning was
correlated with multiple gene transcripts in the standard ex-
pression analysis. WGCNA identified two nominally
significant co-expression modules associated with
neurocognitive functioning, which were enriched with genes
involved in mitotic processes and translational elongation.
CONCLUSIONS: Multiple modified gene transcripts in-
volved in inflammation, cytoprotection, and neurodegenera-
tion were correlated with neurocognitive functioning. The
associations were not strong enough to justify their use as
biomarkers of HAND; however, the associations of two co-
expression modules with neurocognitive functioning warrants
further exploration.
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Amyotrophic Lateral Sclerosis (ALS) is a progressive neuro-
logical disease that affects both upper and lower motor neu-
rons. Patients develop gradual loss of voluntary muscle
strength and eventually most die of respiratory failure. Most
ALS cases are sporadic , while up to 10% may be inherited.
Although a number of gene mutations have been identified in
the familial form of ALS, the etiology of ALS is still largely
unclear. Our group and others have reported that human
endogenous retroviruses type K (HERV-K) is activated in
ALS patients, indicating the possible involvement of HERV-
K in the pathogenesis of ALS. HERVs are fossil sequences of
retrovirus infection that were integrated into human germline
chromosomes millions of years ago. Most HERVs are defec-
tive because of mutations. However, type K HERV has rela-
tively preserved genomic sequence. It may be activated and
produce viral particles under certain physiological and patho-
logical conditions. The reverse transcriptase activity of
HERVs in serum was detected in some ALS patients.
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Increased HERV-K pol gene was also found in the brain of
ALS patients. In this study, we further studied the expression
of HERV-K genes in autopsy brain tissue of ALS patients.
Using quantitative real time PCR, we determined the expres-
sion levels of HERV-K gag, pol, and env in frontal cortex. The
ALS patients had significantly higher expression levels of
HERV-K genes compared to controls. The expression of three
HERV-K genes correlated with each other. Our results
confirmed the activation of HERV-K in the brain of
ALS patients. This warrants further investigation of the
activation mechanism.
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Associated Myelopathy/Tropical Spastic Paraparesis
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Human T-cell lymphotropic virus-1 associated myelopathy/
tropical spastic paraparesis (HAM/TSP) and multiple sclerosis
(MS) can both lead to progressive inflammatory myelopathy.
Although spinal cord atrophy can be qualitatively detected on
routine clinical MRI, a robust and sensitive method to quan-
tify changes in spinal cord size might improve characteriza-
tion of disease severity and progression. Such a method could
help develop an imaging marker for disease, and serve as a
surrogate end point in clinical trials. MRI was performed on
18 HAM/TSP, 9 MS and 10 healthy volunteers on a Siemens
3T Skyra system equipped with head-neck and spine array
coils. Cross-sectional area of the spinal cord was measured
using a novel algorithm developed in-house that traces axial
contours perpendicular to the cord-edge at each point from C1
to T10 vertebral body segments. Average cross-sectional area
in both the T-spine and C-spine were significantly lower in
HAM/TSP patients (C-spine: 50.75 ± 10.02 mm2; T-spine:
24.76 ± 5.01 mm2) as compared to healthy controls (C-spine:
72.02 ± 5.792 mm2, p<0.0001; T-spine: 38.8 ± 6.048 mm2,
p<0.0001). However, cross-sectional area was only signifi-
cantly different in the T-spine when comparing HAM/TSP
with MS patients (C-spine: 61.84 ± 9.54 mm2; T-spine:
34.84 ± 5.72 mm2, p<0.001). In HAM/TSP, the cross-
sectional areas from multiple cord segments correlated
with disease duration (C1-C3, C6, T1-T2), Extended
Disability Status Scale (EDSS) (T2), and Hauser Ambu-
lation Index (T2, T6), but no correlation was observed
between HAM/TSP cross-sectional area and proviral
load. MS cross-sectional area correlated with EDSS
(C1-C3, T1-T6). These results suggest that patterns of
spinal cord tissue damage are specific to the underlying
disease, a finding that has direct implications for the use
of average cross-sectional spinal cord area as a surro-
gate end point for clinical trials. Longitudinal studies
are underway to help improve our understanding of the
disease process.
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Human immunodeficiency virus type 1 (HIV-1) subtype C,
which is the most predominant subtype in sub-Saharan
Africa as well as in Asia and India, is also the most
prevalent subtype worldwide. A large number of transcrip-
tion factor families have been shown to be involved in
regulating HIV-1 gene expression in T-lymphocytes and
cells of the monocyte-macrophage lineage. Among these,
proteins of the CCAAT/enhancer binding protein (C/EBP)
family are of particular importance in regulating HIV-1
gene expression within cells of the monocytic lineage
during the course of hematologic development and cellular
activation. Few studies have examined the role of C/EBPs
in long terminal repeat (LTR)-directed viral gene expres-
sion of HIV-1 subtypes other than subtype B. Within
subtype B viruses, two functional C/EBP sites located
upstream of the TATA box are required for efficient viral
replication in cells of the monocyte-macrophage lineage.
We report the identification of three putative subtype C C/
EBP sites, upstream site 1 and 2 (C-US1 and C-US2) and
downstream site 1 (C-DS1). C-US1 and C-DS1 were
shown to form specific DNA-protein complexes with
members of the C/EBP family (C/EBP alpha, beta, and gam-
ma). Functionally, within the U-937 monocytic cell line,
subtype B and C LTRs were shown to be equally responsive
to C/EBP beta-2, although the basal activity of subtype C
LTRs appeared to be higher. Furthermore, the synergistic
interaction between C/EBP beta-2 and Tat with the subtype
C LTR was also observed in U-937 cells as previously dem-
onstrated with the subtype B LTR. This work is supported by
NIH/NINDS R01 NS32092, NIDA R01 DA19807, NIMH
P30 MH092177, and NIMH T32 MH079785.
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Background: The HIV Dementia scale (HDS) has been
recommended as a cross-sectional screen to identify HIV-
associated neurocognitive disorder (HAND) but its longitudi-
nal usefulness has not been established.
Method: 55 HIV+ participants (aged 57.7±8.3, 96% males)
underwent baseline and follow-up HDS screening at 3.9±1.1
months, a standard neuropsychological (NP) evaluation, and
baseline clinical and laboratory examination. At baseline
49.1%met the gold standardHANDdiagnostic definition. Based
on longitudinal published normative standards, 12.7% showed
statistically significant decline (gold standard decline was based
on an 80% confidence interval; 1-tailed to include mild decline).
To systematically assess HDS criterion validity against the NP
gold standard, we determined HDS baseline impairment status
based on the three published HDS cut-offs (≤10, ≤14, and
demographically-corrected HDS T-scores<40). To determine
statistically significant decline on the HDS (80% confidence
interval; 1-tailed), we developed standard HDS regression-
based change scores after arcsine-root transformation to normal-
ize the data distribution. HDS longitudinal criterion validity was
determined by comparing HDS-based decline to gold standard
NP-based decline using indexes of sensitivity and specificity.
Results: Baseline HDS cut-off ≤14 yielded the highest sensi-
tivity and specificity (52% sensitivity, 81% specificity) com-
pared to the other cut-offs ≤10 (26% sensitivity, 96% speci-
ficity) and T-score <40 (41% sensitivity, 57% specificity). The
magnitude of the HDS reliability was very large r=.76
(p<.0001). We found that 21.8% declined by the HDS. In
cases congruently identified, median raw decline=2.75; medi-
an HDS-change score decline=1.98. The HDS showed 57%
sensitivity and 82% specificity in detecting clinically mean-
ingful decline, signifying that only cases that declined
moderately were congruently identified. Having a HAND
diagnosis at baseline (p=0.01) and more severe HAND diag-
nosis were associated with greater chance of decline (p<0.03).
No HIV biomarkers were associated with decline.
Conclusions: This is the first study to optimally demonstrate that
theHDS reliably detects at leastmoderate neurocognitive decline.
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Neurological disorders including HIV-associated neurocognitive
disorders (HAND) have been linked to abnormal excit-
atory neurotransmission. Perturbations in glutamate cy-
cling can have profound impacts on normal activity, lead
to excitotoxicity and create or exacerbate impairments in
these diseases. Astrocytes play a key role in excitatory
signaling as they both clear glutamate from the synaptic
cleft and house enzymes responsible for glutamate con-
version to glutamine. However, mechanisms responsible
for the regulation of glutamate cycling including the main
astrocytic glutamate transporter excitatory amino acid
transporter 2 (EAAT2) or GLT-1 in rodents and glutamine
synthetase (GS) which catalyzes the ATP-dependent reac-
tion of glutamate and ammonia into glutamine, remains
largely undefined. We previously demonstrated that beta-
catenin, a transcriptional co-activator and the central me-
diator of Wnt/beta-catenin signaling pathway, regulates
both EAAT2 and GS expression in astrocytes in vitro.
We assessed here whether beta-catenin regulates these
two proteins in vivo. Towards this end, we injected
vivo-morpholinos (500nM) to knockdown beta-catenin
expression or control morpholinos into the prefrontal cor-
tex (co-ordinates, AP+2.0, ML+/- 0.3, DV 1.0) of 4-6
week old C57 BL/6 male mice using stereotaxic microin-
jection technique. Morpholinos, which block the transla-
tion initiation of their gene target, were injected at day 0
and day 3. At day six post first injection, a small chunk of
brain tissue at the injection site was collected, processed
for protein isolation using RIPA buffer and analyzed by
western blotting. We demonstrate that knockdown of beta-
catenin resulted in a significant reduction in GLT-1 and
GS protein expression by 99 and 93 percent respectively.
These studies confirm that beta-catenin regulates key pro-
teins responsible for excitatory glutamate neurotransmis-
sion in vivo and reveal the therapeutic potential of Wnt/
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beta-catenin modulation in treating diseases with abnormal
glutamatergic neurotransmission and excitotoxicity. This
work is supported by R01NS060632 to LA.
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Co-morbidity of HIV-1 and illicit drugs modulate proper-
ties of neural precursor cells (NPCs). In an attempt to gain
insights into the pathways that may mediate such comor-
bidities, human fetal brain derived neural precursor cells
(hNPCs) were exposed to HIV Transactivating protein, Tat
and illicit opioid, morphine at various doses and time
points. Alterations in hNPC proliferation with Tat and
morphine exposure were assessed by Ki67 and BrdU
immunoreactivity of treated cells. Changes in proliferative
genes were analyzed at RNA and protein levels and sev-
eral molecular mediators were investigated. Using cell
biology and molecular approaches, we observed that
chronic treatment of HIV protein, Tat and morphine affect
hNPC proliferation. DNA content analysis by FACS and
decreased BrdU levels in Tat-morphine treated hNPCs
indicated perturbations in S-phase of the cell cycle. HIV-
Tat and morphine attenuated Sox2 and CyclinD1 and
increased the expression of p53 and CDK inhibitor, p21
thereby reducing the actively dividing population of
hNPCs. p21 was found to be governed by Extracellular
signal-regulated kinase-1/2 (ERK1/2) while p53 was found
to be essential for Tat and morphine induced decrease in
NPC proliferation. The synergy of Tat and morphine in-
duced changes in hNPC proliferation were mostly ob-
served after chronic exposure as opposed to the acute
exposure to these neurotoxic agents. Interferon-gamma
(IFN-g) levels were also elevated in NPCs with Tat and
morphine exposure, leading to altered Signal Transducer
and Activator of Transcription (Stat) levels and derange-
ment of Stat-Sox-2 pathway. Such growth arrest in hNPCs
may have far reaching clinical implications as it may lead
to impaired ability of these cells to maintain their own
pool as well as compromise replenishment of damaged
brain cells.
Authors acknowledge financial support from Department
of Biotechnology, ICMR and NBRC to PS and Univer-
sity Grants Commission, New Delhi for fellowship to
SM.
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The immuno-pathogenic phenomena leading to neurodegen-
eration of multiple sclerosis (MS) are thought to be triggered
by environmental factors operating on predisposing genetic
backgrounds. Among proposed co-factors are EBV, and the
potentially neuropathogenic HERV-W/MSRV/Syncytin-1 en-
dogenous retroviruses. The ascertained EBV-MS links are late
primary infection (possibly with infectious mononucleosis,
IM), and high titers of pre-onset anti-EBNA IgG. During
MS, there is no MS-specific EBV expression, while continu-
ous expression of HERV-Ws occurs, paralleling MS stages,
active/remission phases, and therapy outcome. (A) In vitro
data: the expression of HERV-W/MSRV/syncytin-1, with/
without exposure to EBV or to EBVgp350, was studied in
PBMC from healthy volunteers and MS patients, and in
astrocytes. Expression of HERV-W/MSRV/syncytin-1 is am-
plified in untreated MS patients, and dramatically reduced
during therapy. In EBVgp350-treated PBMC, MSRVenv and
syncytin-1 transcription is activated in B cells and monocytes,
but not in Tcells, nor in the highly expressing NK cells. (B) In
vivo data: hospitalized young adults with IM symptoms were
analyzed for expression of HERV-W/MSRV transcripts and
proteins. Healthy controls were either EBV-negative or latent-
ly EBV-infected with/without high titers of anti-EBNA-1 IgG.
HERV-W/MSRV is activated in PBMC of IM patients
(2Log10 increase with respect to EBV-negative controls).
When healthy controls are stratified for high, low, or no anti-
EBNA-1 IgG titers, a direct correlation occurs with MSRV
expression. Flow cytometry shows increased percentages of
cells exposing surface HERV-Wenv protein, that occur
differently in specific cell subsets, and in acute disease
and past infection. Conclusions: in vitro EBV activates
the potentially immunopathogenic and neuropathogenic
HERV-W/MSRV/syncytin-1, in cells deriving from blood and
brain. In vivo the two main links between EBV and MS (IM
and high anti-EBNA-1-IgG titers) are paralleled by HERV-W/
MSRV activation. These novel findings suggest HERV-W/
MSRV activation as the missing link between EBV and MS,
and may open new avenues of intervention.
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Human immunodeficiency virus-associated peripheral neu-
ropathy (HIV-PN) is currently the most frequent neurologic
complication of HIV infection, affecting most individuals
living with HIV. HIV-PN is a length-dependent small sensory
fiber neuropathy typified by bilateral numbness, tingling, and
burning sensations in the lower legs. Because electrophysiol-
ogy is insensitive to changes in small unmeylinated fibers,
microscopic evaluation of epidermal nerve fiber density in
skin biopsies has become the standard for diagnosis of HIV-
PN. However, longitudinal assessment is limited by the inva-
siveness of this technique. While noninvasive assessment of
corneal sensory nerves has proven clinically useful in
diagnosing and monitoring other peripheral neuropathic
conditions, such as diabetic neuropathy, corneal nerve
alterations in HIV have yet to be characterized. In this
study based in the SIV/macaque model, we first devel-
oped a beta-III tubulin immunostaining protocol for
detecting corneal nerves, and then developed both man-
ual and automated counting methods to measure corneal
nerve density. These counting methods each demonstrat-
ed significantly lower subbasal corneal nerve fiber
counts among SIV-infected animals that rapidly
progressed to AIDS as compared to slow progressors.
Concomitant with decreased corneal nerve fiber density,
rapid progressors had increased levels of SIV RNA,
CD68-positive macrophages, and GFAP expression by
glial satellite cells in the trigeminal ganglia. These find-
ings demonstrate that corneal nerve assessment has great
potential to diagnose and monitor HIV-induced periph-
eral neuropathy and set the stage for introducing nonin-
vasive techniques to evaluate PNS damage in the HIV
clinical setting.
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Inflammation in the nervous system is a necessary part of the
response to CNS infection, but also causes neuronal damage
in both infectious and autoimmune diseases of the CNS.
Sindbis virus is an enveloped, positive-strand RNA virus that
causes acute encephalomyelitis and fatal paralysis in mice.
Adult C56BL/6 mice inoculated with the neurovirulent strain
of Sindbis virus (NSV) succumb to fatal paralysis despite
clearing infectious virus from the central nervous system.
We show that low daily doses of the non-reversible glutamine
antagonist, DON (6-diazo-5-oxo-l-norleucine), rescues mice
from fatal paralysis by inhibiting the inflammatory immune
response. DON-treated mice fail to induce an adaptive im-
mune response to the virus in the deep cervical lymph-nodes
and show decreased CD45+ and CD3+ lymphocyte infiltra-
tion into the brain and delayed viral clearance compared to
vehicle-treated controls. DON-treated mice show significantly
reduced mRNA expression of neurotoxic and inflammatory
cytokines (TNF-alpha, IL-1b, IL-6, and IFN-gamma) during
the course of viral infection in the brain compared to vehicle
controls. Additionally, in vitro studies using purified CD3+ T-
cells show that DON inhibits the growth and proliferation, but
not the activation, of primary mouse CD3+ T-cells in response
to stimulation with anti-CD3/CD28. Following stimulation,
DON-treated lymphocytes show a defect in S6 phosphoryla-
tion, a downstream mTOR pathway target suggesting im-
paired protein translation in primary lymphocytes. Stim-
ulated DON-treated T-cells have lower IL-2 protein pro-
duction despite having similar levels of IL-2 mRNA
compared to vehicle controls. These studies suggest that
small molecules that antagonize glutamine metabolism are
immunomodulatory and could be beneficial in the treatment
of neuroinflammatory diseases.
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Drug abuse is common among HIV-seropositive persons but
questions arise if HIV’s neurocognitive effects can be
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distinguished from more nonspecific effects of drug depen-
dence and associated comorbidities. In a preliminary study, we
administered four cognitive neuropsychological tasks to a
sample of 77 HIV- and 25 HIV+ men and women with no
history of drug dependence that were well-matched on demo-
graphic characteristics; and 310 HIV- and 137 HIV+ individ-
uals with lifetime DSM-IV-diagnosed cocaine or opioid de-
pendence. The drug using groups were well matched on
demographic, substance use severity, and potentially con-
founding comorbid disorders including PTSD, depression,
ADHD and antisocial traits. Current and nadir CD4 counts
and viral suppression did not differ significantly between
HIV+ drug users and non-users. All subjects performed motor
and cognitive procedural learning tasks dependent on the
integrity of neostriatum and two measures of impulsive be-
havior typically performed poorly by drug users. HIV affects
neostriatal systems relatively more than drug dependence,
which typically engages ventral/limbic striatal processing;
we reasoned that HIV+ groups would perform procedural
learning tasks more poorly than HIV- groups, regardless of
drug history. In a series of HIV Serostatus x Drug History
analyses of variance, we found significant main effects
(poorer performance) for Drug Use but not HIV Serostatus
on both inhibitory tasks, p < .05 for each task; and significant
main effects for HIV Serostatus but not Drug History for each
procedural learning task, p = .01 for each test. This demon-
stration provides proof of concept that theory driven cognitive
neuropsychological tasks may have the capacity to detect
effects of HIV on neurocognition not attributable solely to
drug dependence; however, conclusions that are more defin-
itive will require more sophisticated statistical approaches.
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Clinical trial of a humanized monoclonal anti-IL15Rbeta
(CD122) antibody, in HTLV-1 associated myelopathy/
tropical spastic paraparesis (HAM/TSP)
Raya Massoud1, Yoshimi Enose-Akahata1, Joan Ohayon1,





CD122 is the common beta subunit shared by the receptors of
interleukins-2 and -15 (IL-2, IL-15), two cytokines implicated
in the immunopathogenesis of HTLV-1 associated
myelopathy/ tropical spastic paraparesis (HAM/TSP). Several
in vitro findings suggest that CD122 might be a therapeutic
target in this condition : HAM/TSP CD8+ T-cells show in-
creased CD122 expression at baseline and the addition of
Mik-Beta1, a monoclonal antibody against CD122, to cultures
of HAM/TSP peripheral blood mononuclear cells (PBMC)
decreases endogenous STAT-5 phosphorylation, spontaneous
CD8+T-cell degranulation, spontaneous lymphoproliferation
and reduces the frequency and cytotoxicity of Tax-specific
CD8+T-cells. Based on these findings, we are currently eval-
uating the safety, clinical and immunological effects of anti-
IL15RBeta monoclonal antibody therapy at 1mg/kg in
patients with HAM/TSP. As of today three subjects have
been treated at this dose and all showed saturation of
the CD122 receptor. The therapy seems to be well
tolerated and we have detected a reduction in multiple
ex vivo immune activation markers (CD8 spontaneous
degranulation, STAT5 phosphorylation and spontaneous
lymphocyte proliferation). Notably, one patient reported
resolution of neurogenic bladder symptoms and we ob-
served objective clinical improvement in two out of three
treated patients.
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HIV disrupts normal immune system functioning, and can
also induce a wide range of neurological deficits, collectively
known as HIV-associated neurocognitive disorder (HAND).
Our previous work has shown that neurotoxic effects induced
by the HIV-1 proteins Tat and gp120 are variably enhanced by
co-exposure to morphine, an opiate that preferentially acts
through mu-opioid receptors (MOR). This mimics co-
morbid neurological effects observed in opiate-abusing HIV
patients, which occur even in patients receiving HAART.
Previous studies have shown that HIV induces abnormal
activation of GSK3beta, leading to neurotoxicity, but little is
known about the role of GSK3beta in HIV-opiate interactive
effects. As tau-immunoreactive tangles have been found in
brains of young opiate abusers, we predict crosstalk between
MOR-mediated signaling pathway/s and GSK3beta. To mim-
ic the disease process more closely, the current studies use
supernatant from HIV-infected monocytes instead of single
HIV proteins. U937 human leukemic monocyte lymphoma
cells were infected with HIVSF162, an R5-tropic strain. Su-
pernatants were collected and p24 levels were measured by
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ELISA to assess infection. Adjusted titers were added to
cultured murine striatal neurons, in the presence or absence
of morphine; all treatments were carried out either in presence
or in absence of GSK3beta-inhibitors (VPA, SB415286 and
Calbiochem® GSK3beta Inhibitor XXVI) to determine role of
GSK3beta in these processes. Both lethal and sublethal
effects on neurons were assessed in populations, and
also by time-lapse imaging of individual cells over 72
h. Infective supernatants (p24 = 25 pg/ml) induced
neurotoxicity, affecting both survival and neuritic arbor-
ization; and for selective neurotoxic measures there
were significant interactions with morphine. Importantly,
GSK3beta-inhibitors significantly reduced HIV-mediated
neurotoxicity, and also negated the interactive effects of
morphine. Our results suggest that GSK3beta activation
is a point of convergence and therapeutic target for
opiate- and HIV-mediated neurocognitive deficits.
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Approximately one-third of human immunodeficiency virus
type 1 (HIV-1) cases resulting in acquired immunodeficiency
syndrome (AIDS) in the United States have been associated
with injection drug use within the HIV-1-positive population.
Specifically, opioid abuse within this population exacerbates
disease progression, including increased viral replication and
peripheral viral load, as well as incidence and severity of
neurocognitive impairment, as compared to non-users. The
blood-brain barrier (BBB) is altered as a component of the
pathology associated with the processes that ultimately result
in HIV-associated neurocognitive disorders (HAND). HIV-1
proteins, as well as selected drugs of abuse, have been impli-
cated in compromise of the BBB. Previous studies have
suggested that exposure to mu-opioids alters BBB permeabil-
ity, resulting in increased cellular transmigration, as well as
overall barrier leakiness. In this study, a human brain micro-
vascular endothelial cell (hBMEC) line, hCMEC/D3, was
utilized to establish an in vitro transwell model of the BBB
to investigate the effects of chronic (24, 48, or 72 h) morphine
exposure on the tight junction proteins (TJPs) of the BBB. We
observed that hCMEC/D3 cells form a confluent monolayer
with a basal rate of passage of a 70 kDa tracer molecule com-
parable to primary hBMECs. Although chronic morphine expo-
sure did not induce overall barrier leakiness, changes in mRNA
transcripts of tight junction proteins were observed throughout
the course of exposure. At the protein level, TJP localization was
analyzed following cell fractionation and western immunoblot
analysis. Overall, these studies demonstrated that prolonged
morphine exposure induced changes in TJP expression patterns
at both the mRNA and protein level. This work is supported by
NIH/NINDS R01 NS32092, NIDA R01 DA19807, NIMH P30
MH092177, and NIMH T32 MH079785.
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HIV-1 infection continues to cause associated neurocognitive
disorders (HAND) despite the success of combination anti-
retroviral therapy (cART). The cellular mechanisms underly-
ing the development of HAND are poorly understood. Virus-
associated or soluble viral envelope glycoprotein gp120 inter-
acts with CD4 in conjunction with CCR5 and CXCR4 leading
to infection and/or cellular signaling, and we study the role of
the viral co-receptors in HIV-associated brain injury. Mice
expressing a CXCR4-utilizing HIVgp120 as transgene in the
brain (gp120tg) share key neuropathological features with
AIDS patients, such as the loss of neurites and synapses,
pronounced astrocytosis and activated microglia. However,
the genetic knockout of CCR5 in gp120tg mice abrogates
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neuronal injury and microglial activation, but not astrocytosis.
In order to further characterize the protective effect of the
CCR5KO we performed a gene expression analysis for brains
of CCR5WT and CCR5KO HIVgp120tg mice and non-tg
controls. The microarray study revealed that brains of
HIVgp120tg mice and HIV patients with neurocognitive im-
pairment, with and without encephalitis (HIVE) share a sig-
nificant part of differential gene regulation. Furthermore,
brains of CCR5WT and CCR5KO HIVgp120tg mice express
markers of an innate immune response, and one of the most
significantly up-regulated factors is the acute phase protein
lipocalin-2 (LCN2). In follow-up in vitro experiments we
found that LCN2 is itself neurotoxic in a CCR5-dependent
fashion whereas, as expected, blockade of CCR5 alone failed
to block neurotoxicity of a CXCR4-utilizing gp120. However,
the combination of LCN2 and disruption of CCR5 signaling
caused a significant loss of microglial cells and at the same
time completely abrogated neurotoxicity induced by the
CXCR4-utilizing gp120. Altogether our studies identified
LCN2 as a potential novel player in HIV-associated brain
injury and provided a mechanism of how CCR5-deficiency
could protect against neurotoxicity of a CXCR4-utilizing
HIVgp120. Supported by NIH grants R01 MH087332,
DA026306 and DA029480 (to M.K.).
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HIV enters the brain early during infection and induces a
chronic inflammatory state that can result in neurological
abnormalities ranging from mild cognitive dysfunction to
severe encephalitis. To better understand the effects of HIV
on neural cells, we have used an in vitro model consisting of
human neuroepithelial progenitor (NEP) cells that undergo
directed differentiation into astrocytes and neurons.
In the presence of HIV-1-containing culture supernatants,
maturing neurons having the apolipoprotein E4 allele have
lower total neurite lengths per cell and moderately reduced
levels of neurofilament protein. To investigate whether apoli-
poprotein E genotype influences changes in gene expression
in HIV-exposed NEP cultures, gene expression was detected
usingmicroarrays with the IlluminaHT-12 V4_0_R1 platform
array. This was performed in 4 independent cultures of the
apoE3/E3 genotype and 3 independent cultures of the apoE3/
E4 genotype. Through this approach, we identified 32 genes
specifically upregulated with a fold change of ΓëÑ 1.5 during
exposure to virus, most related to interferon induced responses
and antigen presentation. Interestingly, this innate immune
response was more robust in the apolipoprotein E3/E3 geno-
type cultures than in the apolipoprotein E3/E4 counterparts.
Biological processes, as defined by the gene ontology (GO)
program, corroborated these observations, and processes relat-
ed to antigen presentation and the actions of interferons were
also different among the apoE cultures. Differences were
manifested both in the numbers of genes affected as well as
their significance in the GO processes in which they participate,
with apoE3/E3 higher and more significant than apoE3/E4.
These data suggest that maturing NEP cultures respond to
HIV by mounting an innate immune response with a vigor
that is influenced by the apolipoprotein E genotype of the
cells.
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CD39 and CD73 are ectonucleotidases that hydrolyze extra-
cellular ATP into ADP/AMP and adenosine, respectively.
Adenosine exerts suppressive effects on effector T cells via
interaction with A2A and A2B receptors and furthermore,
promotes M2 polarization of macrophages via A2B receptors.
Conversely ATP exerts immune stimulatory effects. The hy-
drolysis of ATP by extracellular CD39 and CD73 has been
investigated in the context of certain tumor microenviron-
ments and has been proposed to provide an important mech-
anism for evasion of immune surveillance in cancer. HIV,
which establishes chronic and persistent infection, resistant
to eradication via adaptive immune mechanisms, may also
promote immune suppression via the hydrolysis of extracel-
lular ATP. In our initial pilot studies, CD39 and CD73 levels
were evaluated qualitatively and quantitatively in the frontal
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white matter of rhesus macaques by immunohistochemistry.
CD39 and CD73 are primarily expressed within microglia,
perivascular macrophages, and microglial nodules, the latter
in brain tissue from animals with SIV encephalitis. Samples
from macaques with SIV infection with and without enceph-
alitis exhibited increased expression of CD39 and CD73 com-
pared to uninfected, control specimens. These results suggest
a role for ectonucleotidases in the pathogenesis of AIDS and
may provide a mechanism for the persistence of HIV/SIV
infected reservoirs within the CNS and potentially other
compartments.
Acknowledgements: This work was supported by grants from
NIH/NIMH 1R01MH090910 and R01MH101010 to JR. We
acknowledge the support from the Comprehensive
NeuroAIDS Center (Kamel Khalili, Ph.D. Program Director,
P30MH092177), Basic Science Core II, for providing Neuro-
pathology consultation services (Yuri Persidsky, M.D., Ph.D.).
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Background: HIV-associated neurocognitive disorders
(HAND) affect up to 50% of HIV-infected adults, indepen-
dently predict HIVmorbidity/mortality, and are pathologically
associated with neuronal damage and monocyte activation.
CSF neurofilaments (NFL, pNFH) are sensitive surrogate
markers of neuronal damage in other diseases. In HIV, CSF
NFL is elevated in untreated HAD. However, CSF NFL/
pNFH expression has not been characterized in milder forms
of HAND (MND, ANI). In addition, the relationship between
neurofilaments and CSF/plasma markers of monocyte activa-
tion has not been fully explored.
Objectives: 1. Determine CSF NFL/pNFH expression across
HAND stages and neurocognitively normal (NCN) HIV+
controls. 2. Determine the relationships between CSF NFL/
pNFH and CSF/plasma markers of monocyte activation
(sCD14/sCD163/HO-1).
Methods: This retrospective descriptive cross-sectional study
included 48 HIV-infected adults (15 each ANI/MND/NCN; 3
HAD) off ART, enrolled in CHARTER. Biomarkers were
measured by validated ELISAs of CSF (NFL/pNFH), paired
CSF/plasma (sCD14/sCD163), and plasma (HO-1).
Intergroup comparisons were performed using Kruskal-
Wallis and Wilcoxan rank-sum tests. Spearman’s correlation
coefficients compared different biomarker profiles.
Results: CSF NFL/pNFH were not significantly different
across the different sub-groups of HAND in this unadjusted
viremic cohort. However, among individuals with CD4 nadirs
≤200, CSF NFL levels were elevated in HAD compared with
NCN, ANI, and MND. Plasma sCD163 did not vary signifi-
cantly across different sub-groups of HAND, in contrast to
previous studies of virologically-suppressed individuals on
ART. CSF NFL was significantly positively correlated with
CSF pNFH/sCD163/sCD14.
Conclusion: This study is the first to correlate CSF NFL
expression with CSF sCD14/sCD163 in viremic HIV-
infected individuals off ART, eliminating unanticipated direct
effects of ART on inflammation and neurodegeneration. In
addition, this is the first study to examine NFL across different
sub-groups of HAND. Our results confirm that systemic HIV
replication is strongly correlated with CNS monocyte activa-
tion and neurodegeneration in individuals with a history of
severe CD4 depletion.
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Immunodeficiency lentiviruses, including FIV, readily pene-
trate the host central nervous system (CNS) and establish a
protected reservoir of infection in macrophages and microglia.
These reservoirs have been difficult to control with combined
antiretroviral therapy (CART) due, in part, to limited CNS
penetration of current antiretroviral compounds. Using the
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FIV model, we explored the therapeutic potential of the novel
antiretroviral compound, FX101, in an effort to reduce or
eliminate CNS infection while minimizing toxicity. FX101
is a proprietary compound that targets a strictly conserved
region of the nucleocapsid protein shared by FIV, SIV, and
HIV. Binding of the drug appears to disrupt virus particle
assembly allowing control of infectious virus production in
previously infected cells. FX101 distributes in tissues and has
an apparent long plasma and CSF half-life of 4.2 and 3.3 days,
respectively. At a dose of 2 mg/kg, plasma concentrations
peaked at 21.07 uM. CSF concentrations were variable with
peak values ranging from 0.052 to 1.18 uM. Clinical pathol-
ogy demonstrated no significant renal, liver, or red blood cell/
white blood cell abnormalities. In vitro, neurotoxicity was
relatively low with a median toxic concentration of 20.5 uM.
FX101 inhibited FIV replication in feline macrophages
in vitro to 8% of controls. To establish antiviral efficacy
in vivo, six cats, previously intracranially infected with FIV
plus 4 sham infected cats were treated with 2 mg/kg FX101 in
2% DMSO intravenously twice per week over a 4 week period.
Virus load in plasma and CSF and provirus loads were signifi-
cantly reduced to 6-23% of baseline and remained at 5-12.5% of
original virus burdens even 36 weeks after treatment was com-
pleted. These results show that FX101 has significant antiviral
activity which is sustained for long periods and may include
effects that progressively reduce the proviral burden in cells.
Supported by NIH Grant 5R43MH096663
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HIV-1 enters the CNS soon after peripheral infection and
causes chronic inflammation and CNS damage that leads to
cognitive impairment in greater than 50% of HIV infected
people even with successful cART treatment. PrPc (protease
resistant prion protein) is the non-pathogenic cellular isoform
of human prion protein that is constitutively expressed in the
CNS and is involved in several physiological processes that
are disrupted during HIV neuropathogenesis. PrPc is also
expressed on monocytes and brain microvascular endothelial
cells (BMVEC) and is essential for the transmigration of
monocytes across the blood brain barrier (BBB). The surface
expression of PrPc is increased in HIV infected monocytes as
detected by flow cytometry analysis. Previously, our labora-
tory showed that soluble PrPc (sPrPc) levels are increased in
the CSF of people specifically with HIV associated
neurocognitive disorder (HAND). Our in vitro studies also
showed that HIV infection as well as treatment of CNS cells
with the chemokine CCL2 caused increased PrPc shedding. All
of these data suggest that sPrPc participates in the mechanisms
that mediate NeuroAIDS. To determine the effect of this shed
PrPc on the transmigration of monocyte across the BBB, we
used our in vitro BBB model which consists of astrocytes and
endothelial cells co-cultured on opposite sides of 0.3um pore
tissue culture insert. In these studies we demonstrated that sPrPc
treatment blocked the transmigration of monocytes across the
BBB, suggesting that it could be an initial mechanism of
protection against the influx of monocytes across the barrier
during early stages of HIV infection. Thus, PrPc may be both
protective and neuroinflammatory depending upon its temporal
and spatial expression during HIV neuropathogenesis.
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Background: HIV-associated neurocognitive disorder
(HAND) has been associated with abnormal glucose metabo-
lism. In our cohort, we showed that high soluble insulin
receptor (sIR) levels positively associated with HAND. Re-
cently, we observed that sIR secretion from human neuronal
cells is influenced by CSF components fromHIV-seropositive
women. Our objective was to investigate CSF cytokine levels
from HIV-seropositive women and their influence on sIR
secretion from human neuronal cells. Methods: CSF cytokine
levels were determined in 24 HIV-seropositive women
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stratified by HAND into normal cognition (NC, n=8), asymp-
tomatic impairment (AI, n=7), and symptomatic impairment
(SI, n=9) and 5 controls. Cytokine levels (TNF-alpha, IFN-
gamma, IL-2, IL-4, IL-6, and IL-10) were quantified by CBA
immunoassay kit and flow cytometry. Neuronal cells (SH-
SY5Y cells) were cultured in the presence of cytokines for
24 hours using concentrations similar to those quantified from
the CSF of the HIV-seropositive women. Secreted sIR levels
were assayed by ELISA. Results: CSF levels of TNF-alpha,
IFN-gamma, IL-10, and IL-2 were increased in SI and AI
when compared to NC (p<0.05). IL-6 levels were significantly
increased in SI when compared to NC (p<0.05). No significant
differences were observed in IL-4 CSF levels among groups.
sIR levels secreted by neurons increased significantly (p=0.02)
after 24hrs exposure to TNF-alpha. Although exposure to IL-
10 had slight decrease in sIR secretion this was not significant
(p= 0.08). IFN-gamma and IL-6 did not induce any change in
sIR secretion as compared to control. Conclusion: This study
suggests that CSF cytokine levels in HIV-seropositive women
alter neuronal sIR secretion, and may contribute to insulin
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Autophagy is an evolutionary conserved and selective degra-
dation pathway of cellular components that is important for the
maintenance of cell homeostasis under healthy and pathologic
conditions. Here we demonstrate that an increase in the level of
BAG3 results in stimulation of autophagy in glioblastoma cells.
BAG3 is a member of a co-chaperone family of proteins that
associate with Hsp70 through a conserved BAG domain posi-
tioned at the C-terminus of the protein. Expression of BAG3 is
induced by a variety of environmental changes causing stress to
cells. Our results show that BAG3 interacts with Beclin-1, a key
regulator of autophagy, through its unique WW domain posi-
tioned at the N-terminus of the protein. In addition, similar to
Beclin-1, BAG3 associates with Bcl2, which plays an impor-
tant role in proliferation and apoptosis. Induction of BAG3 and
its association with Beclin-1 diminish interaction of Bcl2 and
Beclin-1. Interestingly, an elevated level of BAG3 also pro-
motes cleavage of caspase 3 suggesting a dual role for BAG3 in
modulating autophagy and apoptosis. These observations place
BAG3 in a unique position suggesting that its interplay with
Beclin-1 and Bcl2 has a functional consequence on coordinat-
ing the stage of autophagy and apoptosis in glioma cells.
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(presenting author: moranl@email.sc.edu)
Department of Psychology, University of South Carolina
Approximately 50% of HIV-1-positive individuals are
afflicted with HIV-1-associated neurocognitive disorders
(HAND), despite the effectiveness of combination antiretro-
viral therapy (CART) in reducing the prevalence of more
severe neurocognitive impairment (i.e., dementia). Deficits
in executive function are a distinguishing feature of HAND
in the CART era, decaying more rapidly during HIV disease
progression than other cognitive domains. In the present
study, ovariectomized female Fischer HIV-1 Tg (n=41) and
control rats (n=43) were tested with a sustained attention task,
a component of executive function. Rats were trained to
discriminate signals (illumination for 100, 500, or 1000 msec
duration) from non-signals (no illumination) and were
reinforced with sucrose pellets for pressing the lever corre-
sponding to each event (hits and correct rejections vs. misses
and false alarms). A decrease in hits and an increase in misses
as a function of decreased signal duration were observed for
both groups; however, theHIV-1 Tg groupwasmore adversely
affected by the shorter signal durations. In contrast to the
performance of controls, the HIV-1 Tg rats did not display
differential target detection (hits vs. misses) at the 500 or
100 msec durations. Subsequently, a daily oral dose of S-
equol (0.05, 0.1, or 0.2 mg, or vehicle), a metabolite
produced via the gut microbiome following ingestion of
soy isoflavone daidzein, was administered to determine its
potential therapeutic effects. After 45 days of treatment,
the HIV-1 Tg animals that received the 0.2 mg dose of S-
equol missed significantly fewer signals across all stimu-
lus durations compared to their pre-dosing performance.
Their improvement was twofold that of the control group.
The phytoestrogen metabolite S-equol may be useful as a
therapeutic for attentional deficits in HAND. Funded by
NIH grants DA013137 and HD043680.
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Understanding the mechanism and environmental influences
which shape the development of neurodegenerative diseases
such as Alzheimer’s is of importance given the trend for an
aging population. The majority of neurodegenerative dis-
eases involve abnormal protein deposits within the CNS,
degeneration of synapses and neurons and the activation of
astrocytes and microglia. It has been suggested that microg-
lia in a brain with ongoing chronic neurodegenerative dis-
ease are susceptible to systemic inflammatory signals that
switch cells from an atypical anti-inflammatory phenotype to
one in which they cause neuronal damage. Defining the
impact of environmental factors such as infections on the
diseased brain will have profound implications for protecting
neurones. We are using a well characterised TSE agent,
ME7, as a model for neurodegenerative disease. The locus
and timing of the initiation of neurodegeneration by ME7 is
under precise experimental control and rodent models of
these diseases display all the features of a chronic neurode-
generative process. We challenged mice in vivo with a
transient neuroinvasive viral infection, Semliki Forest virus,
pre- and post- inoculation with ME7 to ask if "priming" of
the immune system by a viral infection which is cleared by
the host prior to the onset of a neurodegenerative disease
would alter the pattern of progression of the neurodegener-
ative disease. We observe that co-infection with SFV during
the early phase of neurodegeneration does not change dis-
ease incubation time but does result in a subtle change in
clinical disease onset. Interestingly, we see a significant
alteration of early stage disease pathology with a change in
the pattern of PrPSc deposition and gliosis. In addition, we
address if viral infection prior to the onset of chronic neu-
rodegeneration can switch the innate immune response of
microglia from a neuroprotective to a tissue damaging
phenotype and exacerbate neurodegenerative disease
progression.
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In vivo and in vitro experiments were undertaken to elucidate
the role of regulatory B lymphocytes in controlling neuroinflam-
mation following brain infection with murine cytomegalovirus
(MCMV). This unique subset of CD19(+)CD1d(hi)CD5(+) B-
cells was found to infiltrate the brains of chronically infected
animals, reaching highest levels at the latest time point tested (35
d p.i.). B-cell-deficient Jh-/- mice (BKO) displayed exacerbated
neuroimmune responses when compared to infected, wild-type
(Wt) animals as measured by enhanced accumulation and/or
retention of CD8+ T lymphocytes within the brain, as well as
increased levels of microglial cell activation (MHC class II).
Conversely, levels of regulatory T-cells (Tregs) were found to be
significantly lower in infected BKOmice when compared toWt
animals. Further experiments showed that in vitro generated
interleukin (IL)-10-secreting Breg cells were able to inhibit
cytokine and chemokine responses from microglia following
stimulation with viral antigens. In addition, these in vitro gener-
ated Bregs were also found to promote conversion of CD4+ T-
cells into a regulatory T-cell (Foxp3+) phenotype. Finally, gain-
of-function experiments demonstrated that reconstitution of B-
cells into BKO mice restored these neuroimmune responses to
levels exhibited by infected Wt animals. Taken together, these
results demonstrate that regulatory B-cells modulate T lympho-
cyte as well as microglial cell responses within the brain, and
promote CD4+ T-cell transition into a Treg phenotype.
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HIV anti-retroviral therapy nucleoside reverse
transcriptase inhibitors induce mitochondrial
dysfunction, oxidative stress, and premature senescence
in primary human fibroblasts
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HIV patients are currently treated with highly active anti-
retroviral therapy (HAART) that employs nucleoside reverse
S60 12th ISNV, Washington, DC, USA
transcriptase inhibitors (NRTIs). Although successful in decreas-
ing the HIV viral-load and rate of infection, NRTIs predispose
patients to an increased risk of developing pathologies associat-
ed with aging. These age-related pathologies are thought to arise
frommitochondrial toxicity that is attributed by NRTI-mediated
inhibition of mitochondrial DNA polymerase gamma. The
newer generation of NRTIs currently used in HAART, tenofovir
and emtricitabine (TDF/FTC), contain a decreased inhibitory
affinity for DNA polymerase gamma, but mitochondrial toxicity
remains eminent. We postulate that TDF/FTC impair mitochon-
dria in primary human fibroblasts. Primary human fibroblasts
are a relevant model to study aging in vitro, as they contain a
finite proliferative capacity before entering cellular senescence,
an irreversible growth arrest that recapitulates aging at the
cellular level. Cellular senescence is activated by oxidative
stress, which could be contributed by reactive oxygen species
(ROS) produced from impaired mitochondria. Therefore, we
also examined whether TDF/FTC increased mitochondrial and
cellular ROS and induce premature senescence. Previous studies
in the laboratory shown that treatment with rapamycin, an
mTORC1 inhibitor, promotes mitochondrial homeostasis, de-
creases oxidative stress, and delays senescence in aging primary
human fibroblasts. We further examined whether rapamycin
could alleviate NRTI-induced effects. After treatment with
TDF/FTC, we found that mitochondrial integrity is impaired,
ROS is increased, and premature senescence is induced. How-
ever, these alterations were ameliorated in the presence of
rapamycin. Our results demonstrate that the latest generation
of NRTIs impair mitochondria and induce senescence in vitro.
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Varicella zoster virus (VZV) vasculopathy is caused by pro-
ductive infection of cerebral arteries leading to pathological
vascular remodeling and stroke. Purinergic signaling, mediat-
ed by ATP and its metabolites, has emerged as important in
vascular remodeling. In addition, purinergic signaling is in-
volved in RNA virus infection, but its role in DNA virus
infection is unknown. Thus, we hypothesize that specific
purinoreceptors are involved in VZV infection of cerebral
arteries and vascular remodeling. Because the arterial adven-
titia is the initial vascular site infected by VZV after virus
reactivation, we treated VZV-infected primary human brain
vascular adventitial fibroblasts (BRAFs) with antagonists of
purinoreceptors P2X1, P2X4, P2X7, P2Y2, P2Y6, P2Y11 and
P2Y12. Three days later, viral DNAwas quantified by qPCR.
Compared to untreated infected controls, the P2Y11 antago-
nist significantly down-regulated VZV DNA by 37% and the
P2Y12 antagonist by 69%. Significant differences were not
found with other purinoreceptor antagonists. Because the
P2Y12 antagonist (clopidogrel) produced the greatest reduc-
tion of VZV DNA, we also studied its effect on HSV-1 and
HSV-2-infected BRAFs. Clopidogrel significantly down-
regulated HSV-1 and HSV-2 by >99% compared to untreated
infected controls. Furthermore, clopidogrel reduced the titer of
infectious virus for all three alphaherpesviruses. Overall, we
demonstrated that the P2Y12 purinoreceptor antagonist de-
creases VZV, HSV-1 and HSV-2 DNA and infectivity in
BRAFs. The clinical effectiveness of the P2Y12 antagonist
clopidogrel remains to be determined.
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Recently, much interest has developed regarding mechanisms
of extracellular delivery of nucleic acids and proteins among
virally infected and recipient cells.While the role of exosomes
in viral pathogenesis and disease states remains largely un-
known, it is now widely accepted that exosomes play
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important roles in intercellular communication, cellular in-
flammation, antigen presentation, programmed cell death,
and pathogenesis. HIV-1 encodes its own miRNAs that regu-
late viral and host gene expression. Themost abundant HIV-1-
derived miRNA, first reported by us and later by others using
deep sequencing, is the TAR (Trans-Activation Response
element) miRNA. We have recently found the presence of
TARRNA in exosomes from cell culture supernatants of HIV-
1 infected cells and patient sera. We report that transport of
TAR RNA from the nucleus into exosomes is a CRM1-
dependent active process. Prior exposure of naive cells to
exosomes from infected cells increased susceptibility of the
recipient cells to HIV-1 infection. Exosomal TAR RNA down
regulated apoptosis by lowering Bim and Cdk9 proteins in
recipient cells. We found 10^4 -10^6 copies/ml of TAR RNA
in exosomes derived from infected culture supernatants and
10^3 copies/ml of TAR RNA in the serum exosomes of
Highly active antiretroviral therapy (HAART)-treated patients
or Long term nonprogressors (LTNPs). Very recently, we have
found that TAR is able to activate cytokines in the recipient
cells by increasing the nuclear accumulation of both p65 and
p50 (component of NFkB complex). This increase may
be related to a newly formed IKKb in the TAR treated
cells which may be the result of TLR activation by
TAR. We will discuss the effect of these biochemical
steps in the recipient macrophage cells that result in alteration
of cytokines which in part may explain the neuroinflam-
mation observed in AIDS patients who are under HAART
treatment.
P130
Morphine induced expression and subcellular localization
of Ferritin Heavy Chain in rat brain cells
Bradley Nash, Juhi Motiani, Olimpia Meucci
(presenting author: bsn25@drexel.edu)
Drexel University College of Medicine, Department of
Pharmacology and Physiology
Ferritin Heavy Chain (FHC), a subunit of the ubiquitously
expressed iron storage complex Ferritin, has recently been
shown to be upregulated in the central nervous system
(CNS) in response to HIV/SIV infection and illicit drug abuse.
Previous research has suggested that an unexpected conse-
quence of increased CNS FHC lies in its ability to inhibit
homeostatic signaling of the chemokine receptor CXCR4,
resulting in decreased dendritic spine density in cortical neu-
rons. Interestingly, initial studies indicate that these changes
correlate with disease progression and behavioral symptoms
observed in HIV associated neurocognitive disorders
(HAND). Opiates, including morphine and DAMGO, are able
to upregulate FHC in a mu opioid receptor dependent manner,
suggesting a novel avenue of CXCR4 regulation via opioid
signaling. Previous experiments have shown that chronic
morphine treatment (both in vitro and in vivo) caused a
general upregulation of FHC in cortical neurons, which
corresponded with decreased levels of phosphorylated, or
activated CXCR4, and decreases in the activation of down-
stream signals (i.e. ERK1/2 and Akt). However, this interac-
tion has yet to be studied in other CNS cell types such as
astrocytes, which express both CXCR4 and MOR and are
critically involved in neuronal function. Additionally, charac-
terization of morphine-induced changes in the subcellular
distribution of FHC, in neurons or other CNS cells, may
provide clues about the nature of the CXCR4/FHC interac-
tion, and additional roles of FHC in HAND, and other neuro-
degenerative diseases.
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Tetherin or bone marrow stromal antigen 2 (BST-2) is an
interferon-inducible plasmamembrane protein that has recent-
ly emerged as a key innatemammalian restriction factor which
impedes release of enveloped viruses by physically tethering
nascent budding virions to the plasma membrane. Several
in vitro studies have demonstrated that BST-2 is a potent
antiviral that acts upon many virulent enveloped viruses, such
as retroviruses (HIV), arenaviruses (Lassa), filoviruses
(Ebola), paramyxoviruses (Sendai), orthomyxoviruses (Influ-
enza A), rhabdoviruses (VSV), etc. However, it remains
unclear how this important innate immune protein participates
in sequestering a persistent viral infection in vivo. In this
study, we used the lymphocytic choriomeningitis virus
(LCMV) clone 13 (CL13) model of persistent viral infection
to evaluate the role of BST-2 in facilitating the transition from
an innate to a virus-controlling adaptive immune response.
Importantly, BST-2 knockout mice had an impaired ability to
control LCMV CL13 in peripheral tissues as well as the
central nervous system (CNS). Viral clearance was delayed
by one month in the sera and never purged from the CNS.
Anatomically, BST-2 expression mapped to plasmacytoid
dendritic cells (DCs), myeloid DCs, and brain resident mi-
croglia, consistent with the impaired ability of BST-2-/- mice
to sequester LCMV antigen in the splenic marginal zone and
brain after infection. Analysis of the adaptive immune re-
sponse to CL13 revealed that BST-2-/- mice generated less
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polyfunctional virus-specific CD8+ and CD4+ T cells and
showed reduced expansion when compared to wild type con-
trol mice, demonstrating that BST-2 is an important partici-
pant in the bridge between innate and adaptive immunity.
Collectively, our data indicate that BST-2 plays an essential
role in controlling a persistent viral infection, which explains
why so many viruses have developed strategies to thwart the
activity of this potent antiviral protein
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HIV-1 Infection leads to a wide spectrum of neurodegenerative
diseases. Among central nervous system cells, astrocytes have
been shown to be susceptible to HIV-1 infection. Vpr is an HIV-
1 accessory protein that negatively affects the highly controlled
CNS compartment, inducing astrocytic apoptosis and secretion
of neurotoxins that causes neuronal loss. Telomerase is a cellular
ribonucleoprotein complex key in controlling cellular senes-
cence, and involved in inhibition of apoptosis and improvement
of DNA repair. Considering that HIV-1 has been shown to
modify the cellular aging process by interfering with telomerase
activity (TA), the aim of our study was to evaluate the impact of
Vpr protein expression on TA in astrocytes. Vpr coding se-
quence fromHIV-1NL4-3 strainwas PCR-amplified and cloned
into the pEGFP-C3 expression vector. U373 astrocytic cells
were transfected with the pEGFP-Vpr vector, and TAwas eval-
uated by real-time PCR (expressed as Relative Telomerase
Activity, RTA), 48 h post-transfection. Transfection efficiency,
expressed as percentage of GFP-positive cells, was measured by
FACS. Statistical differences were calculated by t-student test.
Telomerase activity (RTA) was found to be significantly reduced
in U373 astrocytic cells transfected with the HIV-1 Vpr-
expression vector (25.7% RTA, p<0.05), when compared to
untransfected (considered as 100% RTA) and pEGFP-C3-
transfected cells (44.3% RTA). Mean transfection efficiency for
pEGFP-C3 and pEGFP-Vpr transfected cells, was 41% and
39.1%, respectively, as determined by the percentage of GFP-
positive cells evaluated by FACS. Data presented here indicates
that expression of HIV-1 Vpr has a negative impact on astrocityc
TA.Given the critical roles this cell type plays in creating a three-
dimensional framework for the CNS, in maintaining the
bloodΓÇôbrain barrier, and in neural metabolism and activity,
the observed phenomenon is relevant in the context of under-
standing the astrocyte biology changes that could be involved
neurodegenerative process observed during HIV-1 infection.
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Apoptosis plays a critical role in HIV-1-associated neuropatho-
genesis. HIV-1 has developed multiple strategies to modulate
apoptosis related-pathways on infected cells thus promoting its
survival and favoring its role as viral reservoirs. HIV-1 establishes
infection in astrocytes of theCNS causingminimal cytopathology
in these long-lived cells. This study aimed to evaluate the HIV
infection impact on apoptosis cascade in infected astrocytes and
their neighboring uninfected cells. An HIV infectious molecular
clone pNL43-derived and tagged with the GFP (named HIV-
GFP) was constructed. It was also pseudotyped with the VSV-
G glycoprotein by co-transfection of 293T cells. U373 human
astrocytic cells were used as in vitro models for astrocyte infec-
tion. To detect apoptotic events at 1 to 6 days post infection (dpi),
co-staining with 7AAD and annexin-V was performed. Single-
cell analysis aimed at simultaneously identifying apoptotic-
infected (Ann+/GFP+) and apoptotic-uninfected (Ann+/GFP-)
neighbor cells by FACS. The values were expressed as mean
±SD. Statistic analysis was performed by Student T test and
p values <0.001 were considered significant. Initially the level
of apoptosis (annexin V+) at 1 and 2 dpi depicted no differences
(p>0.005) between productively infected astrocytes (13±7.7 and
7.3±9.7 GFP+, respectively) and neighbor uninfected cells (16.5
±9.5 and 7.65±6.5 GFP-, respectively). In contrast, when com-
paring the level of apoptosis (annexin-V+) at 3, 4, 5 and 6 dpi
between infected vs. neighbor uninfected astrocytes (GFP+/
GFP-) a significant decreased (p<0.0001) (12±4/18±6, 14±3.8/
26±12.8, 8±2.8/22±10, and 6±3.6/20±10, respectively) was ob-
served. Such differences were independent of the level of viral
replication (GFP+ cells). HIV infection of astrocytes results in
survival of infected astrocytes and apoptosis of neighbor
uninfected cells. Such anti-apoptotic effect was independent of
the viral replicationmagnitude and its kinetic exhibited a biphasic
pattern according the infection progress. In advances stages of
infection the resistance to apoptosis wasmore pronounced, which
could support the generation of HIV reservoirs.
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This study evaluated the relationship between illicit drug use and
HIV-1 disease severity in HIV-1-infected patients enrolled in the
DrexelMed HIV/AIDS Genetic Analysis Cohort. Since cocaine
is known to have immunomodulatory effects, the cytokine pro-
files of preferential non-users (PN), cocaine users (PCo) or multi-
drug users (MDU) were analyzed to understand the effects of
cocaine on cytokine modulation and HIV-1 disease severity.
Patients within the cohort are assessed approximately every 6
months for HIV-1 clinical parameters and history of illicit drug,
alcohol, and tobacco use. The Luminex human cytokine 30-plex
panel was used for cytokine quantification. Analysis was
performed using a newly developed biostatistical model. Sub-
stance abuse was found to be common within the cohort. Utiliz-
ing the drug screens at the time of each visit, it was determined
that the cohort could be categorized as PN, PCo, and MDU. The
overall health of the PN population was better than that of the
PCo population, with peak and current viral loads in PN sub-
stantially lower than those in PCo andMDUpatients. Among the
30 cytokines investigated, differential cytokine profiles were
established within the three populations. The Th2 cytokines,
IL-4 and IL-10, known to play a critical role during HIV-1
infection, were positively associated with increasing cocaine
use. Clinical parameters such as latest viral load, CD4+ and
CD8+ T-cell counts, and CD4:CD8 ratio were also significantly
associatedwith cocaine use. Based on these assessments, cocaine
use appears to associate with more severe HIV-1 disease. This
work is supported by NIH/NINDS R01 NS32092, NIDA R01
DA19807, NIMHP30MH092177, andNIMHT32MH079785.
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DC-SIGN (dendritic cell specific ICAM-3-grabbing non-
integrin), a membrane protein of the C-type lectin family, is
found in high levels on monocyte-derived DCs, some macro-
phages, and activated B cells. In vivo, DC-SIGN-positive cells
have been found in lymph nodes, tonsils, skin, and the
subepithelial regions of the cervix. With respect to HIV-1 trans-
mission, DC-SIGN has been shown to serve as ligand that
efficiently binds, concentrates, and mediates transfer of virus
from the mucosal surface to CD4+ T cells. Subepithelial DCs
expressing DC-SIGN have been demonstrated to play an im-
portant role in cervicovaginal transmission of HIV-1. Additional
studies have examined the process of DC-SIGN-mediated trans-
mission of various pathogens, suggesting that targeting this cell
surface molecule may serve as a potential therapeutic strategy.
DC-SIGN binds to mannose and fucose moieties present on the
HIV envelope glycoprotein gp120 with high affinity. Blocking
this interaction at the site of primary infection could potentially
be prophylactic and/or serve as a potential microbicidal target.
We have developed a novel high throughput screening assay
(HTS) to identify inhibitors of DC-SIGN:gp120 interaction and
validated this assay by using quinoxazoline small molecules that
block mannose dimer binding to DC-SIGN demonstrating that
HTS of non-carbohydrate libraries can produce micromolar (or
lower) non-carbohydrate hits. Further, we completed virtual
screen of diverse libraries of small molecule inhibitors by
docking into the calcium-binding domain of DC-SIGN crystal
structure and subjected virtual hits into the HTS assay. In
addition, we began a novel approach of “binding-site directed
lipophilic mining” for hypothesis-driven drug discovery.
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Interplay between macrophage senescence, microRNA
expression, and HIV-1 infection
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In the context of HIV-1 infection, senescence is accelerated,
facilitating opportunistic infections and increased viral repli-
cation. Cellular senescence is irreversible growth arrest in the
lifetime of a cell. Although increased macrophage tropism and
HIV-1 replication has been shown, the contribution of macro-
phages to this process has not been clearly established.
Changes in microRNA (miRNA) expression during cellular
senescence and/or aging have also been described. MiRNAs
seem to contribute to the aging process at the level of cellular
senescence, tissue aging, and lifespan of whole organism.
However, the specific role of miRNAs in macrophages during
aging has not yet been established. Alterations in miRNA
profiles during cellular senescence may affect HIV-1 infec-
tion, and potentially HIV-1 infection could as well affect
cellular senescence through miRNA modulation. We have
induced senescence in primary human macrophages and
THP-1-derived macrophages by oxidative damage (H202
treatment). To confirm the presence of a senescent phenotype,
we used a senescence-associated beta-galactosidase (SA beta-
gal) assay, and western blot analysis of the levels of p16, p21,
and p53, which have been shown to increase in senescent
cells. We determined that aged and senescence-induced mac-
rophages display a senescent-like phenotype that consists of
increased expression of p53, p21, and an enlarged flattened
morphology with positive staining for SA beta-gal. Further
studies will include the analysis of the cytokine and chemo-
kine secretion profile to determine whether or not they exhibit
a senescence-associated secretory phenotype, and the investi-
gation of changes in miRNA profiles due to infection and
senescence.
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Despite combined antiretroviral therapy achieving efficient
HIVreplication control, neurocognitive complications defined
as HAND continue to be highly prevalent in HIV infection.
One of explanations could be constant compromise of blood
brain barrier (BBB) function driven by chronic inflammatory
responses documented in HIV infected individuals even with
well-controlled virus replication yet with HAND progression.
Brain endothelial cell injury and its underlying mechanisms
have been explored during last years. However, changes in
other cells constituting BBB (like pericytes) have not been
studied in detail in context of HIV-1 infection.We found
partial pericyte loss and down regulation of key receptors on
these cells in brain tissue of HIV-1 infected patients (even
without detectable HIV-1 in CNS) and HIV-1 infected huNSG
mice that paralleled BBB compromise and neuroinflamma-
tion. Primary human brain pericytes treated with IL-1 beta or
TNF-alpha demonstrated decreased secretion of angiopoetin-
1/ transforming growth factor-beta 1, diminished expression
of PDGF-R beta 1 (controlling pericyte survival and recruit-
ment to BBB) and connexin 43 (critical for establishing gap
junctions between pericytes and brain microvascular endothe-
lial cells, BMVEC). Pericytes exposed to IL-1 beta/TNF alpha
showed enhanced expression of numerous pro-inflammatory
factors (relevant to HIV-1 neuropathogenesis) and adhesion
molecules (ICAM-1, VCAM-1) paralleling increased adhe-
sion of monocytes to pericyte monolayers. Using BBB
models (composed of BMVEC-pericytes) we showed in-
creased monocyte migration across BBB constructs in re-
sponse to relevant chemokine, CCL2. IL-1 beta/TNF alpha
treatment of pericytes diminished their ability to migrate pro-
viding potential mechanism of their decrease in brain tissue of
HIV-1 infected patients. Taken together, these data point to a
major decrease in barrier supporting function and enhanced
inflammatory responses in brain pericytes after exposure to
relevant cytokines and in brain tissues of HIV-1 infected
patients.
P138
Cocaine mediated downregulation of SAMHD1 facilitates
HIV-1 infection in CNS cells
Sudheesh Pilakka-Kanthikeel, Andrea Raymond, Venkata
Subba Rao Atluri, Vidya Sagar, Upal Roy, Madhavan Nair
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Human immunodeficiency virus 1 (HIV-1) remains one of the
leading causes of death worldwide. HIV penetrates CNS
during early infection, establishing a viral reservoir. Even
though astrocytes are infected by HIV, unlike microglia
and brain macrophages, they are not productively
infected. Non-productive infection could be significant
to neuropathogenesis. Although the potent antiretroviral ther-
apies have significantly improved the morbidity in HIV pa-
tients, the biggest challenge is inability of HAART to eradi-
cate the virus from the reservoirs. The mechanisms governing
the establishment of HIV reservoir in vivo are still not fully
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understood. The brain is also a target organ for cocaine.
Cocaine enhances HIV-1 expression in susceptible cells, serv-
ing as a co-factor in the susceptibility and progression of
infections. Recently identified restriction factor, SAMHD1,
which hydrolyses dNTPs has been shown to restrict HIV
infection in resting CD4+ T cells. Based on the previous
reports from literature, we hypothesized that increased
SAMHD1 expression in astrocytes results in suppression of
cellular dNTPs subsequently hampering retrovirus reverse
transcription, which in turn leads to non-productive infection.
We examined constitutive expression of SAMHD1 in astro-
cytes and microglia at the gene and protein level and its
modulation by cocaine. Astrocytes displayed higher expres-
sion level of SAMHD1 compared to microglia, suggesting
that SAMHD1 plays a role in astrocytes facilitating them to
maintain non-productive infection. Cocaine degraded
SAMHD1, which in turn increased viral replication in astro-
cytes. Suppressing the level of SAMHD1 in astrocytes by
cocaine reactivates the latent virus from astrocyte.
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The long terminal repeat (LTR) regulates HIV-1 gene expres-
sion by interacting with multiple host and viral factors. Cross-
sectional studies in the pre-HAART era demonstrated that
SNPs in C/EBP site I and Sp site III from peripheral blood-
derived LTRs increased in frequency as disease severity in-
creased and correlated with HIV-1-associated dementia. Cur-
rent studies focus on the identification of LTR signatures
derived from peripheral blood virus that can be used as mo-
lecular markers to identify HIV-1-infected individuals more
prone to developing advanced stage disease and/or neurologic
disease. A prospective, longitudinal study was conducted on
504 HIV-1 seropositive patients currently enrolled in the
DREXELMED HIV/AIDS Genetic Analysis Cohort in Phil-
adelphia, PA. History of clinical parameters and comorbities
were obtained approximately every 6 months. The collection
of extensive clinical parameters on these patients have
allowed for cross-sectional and longitudinal analyses of the
impact of these parameters on the development of SNPs
during the course of disease. To date, SNPs have been iden-
tified that associated with CD4 T-cell count and viral load. Of
the SNPs identified, SNPs at position 108 were the most
significant and correlated with a gain in transcription factor
binding. These results suggest that the HIV-1 genomic swarm
may evolve during the course of disease in response to selective
pressures that lead to changes in prevalence of LTR SNPs that
may be predictive of more advanced stage HIV disease and that
may result in alterations in viral function. This work is support-
ed by NIH/NINDS R01 NS32092, NIDA R01 DA19807,
NIMH P30 MH092177, and NIMH T32 MH079785.
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HIV-Tat protein enhances amyloid beta aggregation
Alina Popescu Hategan1, Joseph Steiner1, Emilios
Dimitriadis2, Avindra Nath1
(presenting author: alina.popescu@nih.gov)
1NIH/NINDS, Section of Infections of the Nervous System,
Bethesda MD;
3NIH/NIBIB, Scanning Probe Microscopy Unit, Bethesda
MD
We show that amyloid beta 1-40 aggregation under physio-
logical conditions in the presence of HIV-Tat protein presents
significant structural changes. Atomic force microscopy im-
aging shows that the predominant typical singular uniform
amyloid fibrils formed at a 200 micromolar amyloid concen-
tration turn into a population with more double twisted fibers
when 0.08 micromolar HIV-Tat is present and at higher Tat
concentrations (0.4 to 1.8 micromolar) turns into thick un-
structured filaments and nonspecifically aggregated large
patches. At a 1:10 molar ratio of HIV-Tat per amyloid beta
at incubation, fibrils are much larger and irregular along the
length compared to amyloid fibrils, their dimensions being
similar with those of amyloid fibrils formed at extreme con-
centrations (>1 mM), but without the uniformly striated struc-
ture. Importantly, the presence of Tat in the amyloid fibrils
significantly increases the neurotoxicity of amyloid fibrils, as
shown in neuronal cell culture experiments. Future studies
will involve localization of Tat molecules throughout the
amyloid filaments and aggregates, for a better understanding
of the interaction between HIV-Tat protein and amyloid beta
peptide.
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cells: Relevance to NeuroHIV
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Victoria Lutgen, Lena Al-Harthi
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HIV invades the CNS shortly after infection and despite anti-
retroviral therapy leads to a spectrum of neurologic complica-
tions termed HIV-Associated Neurocognitive Disorders
(HAND). While extensive studies have probed the cellular
and molecular mechanisms driving HIV-mediated neuro-
pathogenesis, little is known about the complex interaction
between infiltrating immune cells and resident brain cells,
especially astrocytes. We evaluated the interaction between
peripheral blood mononuclear cells (PBMCs) and astrocytes.
We show that conditioned media from primary human
progenitor-derived astrocytes (PDAs) induced Beta-catenin ex-
pression in PBMCs by 50%, inhibited HIVreplication in Tcells
by 75% and induced CD4 expression on CD8 T cells to
generate a double positive (DP) T cell phenotype. Depleting
PDAs conditioned media of Wnt ligands (Wnt 1, 2b, 3, 5b and
10b) abrogated these responses, indicating that Wnt ligands
secreted from astrocytes mediate these changes in T cells.
Conversely, conditioned PBMCs media activated PDAs as
indicated by elevated expression of IFNgamma and HLA-
DR, reduced Beta-catenin expression in PDAs, and enhanced
HIV replication in PDAs. These data indicate a feedback loop
whereby activated PBMCs can alter astrocyte phenotype and
susceptibility to HIV infection and astrocytes can alter the
phenotype and function of Tcell. We propose a model in which
crosstalk occurs between astrocytes and infiltrating immune
cells; shaping the microenvironment of the brain, and
perturbing the functional potential of each cell type. This work
is supported by R01NS060632-LA and F32NS08065701-MR.
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PURPOSE: In the era of combined antiretroviral treatment,
HIV-seropositive patients are living longer. With the increase
survival, we observe a high prevalence of neurocognitive
impairments. Memory Island (MI) is a computer based test
useful in identifying susceptibility to cognitive impairments
especially in spatial learning and memory with the advantage
of being a non-invasive test that can be easily administered.
Since MI is not affected by culture, its validation and charac-
terization in neurocognitive disorders could represent a good
screening test for HAND. The MAIN OBJECTIVE of this
study is to determine the validity and use of MI as a reliable
instrument in the characterization of spatial learning and
memory in HIV-seropositive women. DESIGN METHODS:
60 women were evaluated, 44 HIV-seropositive and 16 con-
trols HIV-seronegative, with viral-immune profiles, MI, and
neuropsychological tests. Parametrics and non-Parametrics
statistics were performed. RESULTS: There were no group
differences in speed of navigation in the visible or hidden
target trials. During the visible target trials, there were no
differences in ability of the two groups to locate the target
location. However, during the “hidden" trials, HIV-
seropositive women required more time and moved longer
distance than controls. Thus, HIV-seropositive women had
less efficient acquisition (learning) and worse performance
when compared with HIV-seronegative women. When spatial
memory retention was assessed in the probe trial (no target
present), HIV-seropositive women spent less time in the part
of the island (quadrant) that contained the target previously
than the controls. CONCLUSION: The use of MI test is valid
in detecting spatial learning and memory deficits in HIV-
seropositive women. While MI resembles the findings of the
Morris Water Maze, serves as a new translational technology
and useful valid instrument to spatial and memory screening.
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TLR3 activation on dendritic cells suppresses HIV-1
infection by inducing miR-155 and APOBEC-3G
Fiorella Rossi, Gokul Swaminathan, Julio Martin-Garcia3
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Human Immunodeficiency Virus type-1 (HIV-1) is transmit-
ted predominantly through the vaginal or rectal mucosa where
dendritic cells (DCs) are among the first cells to interact with
the virus. In addition to support viral replication, DCs facili-
tate viral dissemination and contribute to HIV-1 pathogenesis
by migrating to the lymph nodes and assisting the infection of
CD4+T cells. DCs show less susceptibility to HIV-1 infection
depending on the type of stimuli and maturation stage. Upon
DCs maturation, various cellular host factors such as
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microRNA-155 (miR-155) and Apolipoprotein B mRNA
editing enzyme 3G (APOBEC-3G) are highly up-regulated.
However, these upregulation in the context of HIV-1-infection
has not been elucidated in DCs. Our goal is to determine the
mechanism that explains how maturation of DCs causes sup-
pression of HIV-1 infection in vitro. Immature DCs were
activated with different Toll-like receptor ligands (TLR-L) to
obtain a mature phenotype and determined the expression
levels of miR-155, APOBEC-3G, and the susceptibility of
DCs to a HIV-1 recombinant virus (ADA-Fluc). We observed
an upregulation on the expression of both factors upon TLR3
stimulation in comparison to non-stimulated cells (p=0.003)
and other TLR-L. This up-regulation in TLR3-stimulated DC
correlates with increased expression of the maturationmarkers
CD80, CD86, HLA-DR and CD83 (p=0.03), and a complete
suppression of HIV-1 infection (p=0.031). By using a miR-
155 inhibitor and silencing APOBEC-3G, the phenotype re-
verses to 60% of wild type infectivity. This suggests that other
factors are also involved in suppressing infection upon TLR3
stimulation. Future studies will address other mechanism(s)
involved in these processes.
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Activation of macrophages and microglia is a critical compo-
nent of the host response following brain damage. Previous
studies in our laboratory demonstrated that HSV-1 brain in-
fection stimulates neural stem/progenitor cell (NSC) prolifer-
ation between 3 and 6 d p.i., concurrent with macrophage
infiltration. In the present study, we examined the role of
macrophage activation phenotypes on NSC proliferation.
Evaluation of infiltrating macrophages [CD45(hi)CD11b(+)]
revealed that 68.6±3.3% of the cells were Ly6C(hi) at 5 d p.i.
Expression of an M2 marker, CD206, was five-fold higher
than CD86, an M1 phenotype marker, in Ly6C(hi) macro-
phages at 5 d p.i, indicative of an alternative activation phe-
notype. To determine if macrophage polarization modulated
neurogenesis, NSCs were cultured with supernatants fromM1
or M2 polarized bone-marrow derived macrophages. NSC
cultures treated with M2 conditioned media (M2CM) had 4-
fold more proliferating cells compared to those cultured in
control media. Cells in all treatment groups maintained their
stem cell phenotype [≥95% nestin(+)] at collection. M2CM
treated NSCs continued to increase in number at 96 h post-
treatment with significantly higher numbers of cells in the G2/
M phase of cell division. Transplantation of M2 macrophages
into the lateral ventricles of uninfected mice resulted in a 15%
increase in Sox2(+) NSC proliferation and the total number of
Sox2(+) NSCs doubled compared to saline or heat-killed cell
controls, at 5 d post-treatment. Interestingly, Wnt5a expres-
sion was significantly increased in M2 polarized macrophages
and treatment with either dickkopf-1, a Wnt5a inhibitor, or
Wnt5a neutralizing antibody suppressed NSC proliferation to
control levels. Finally, Wnt5a gene expression in HSV-1
infected brains increased at 3 d p.i., coinciding with the
increase in neurogenesis and M2 macrophage infiltration into
the brain. Results from these studies suggest that M2 macro-
phages promote neurogenesis following herpes virus-induced
brain damage and may provide an avenue for therapeutic
intervention.
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Herpes Simplex encephalitis and render neural
stem/progenitor cells refractory to growth stimuli
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Herpes Simplex encephalitis (HSE) is characterized by chron-
ic inflammation, dominated by the presence of CD8 T-cells.
Previous studies in the laboratory showed that neural stem/
progenitor cell (NSC) proliferation was significantly impaired
during the chronic phase of HSE (15 - 30 dp.i.). The current
study evaluated the role of CD8(+) T-cells in modulating this
anti-proliferative milieu. At 15 dp.i, approximately 50% of
CD8 T-cells in HSV-1-infected brains produced interferon-
gamma following virus stimulation. CD8 T-cells were deplet-
ed from mice brains at 15 d p.i, using a neutralizing antibody
to CD8a. CD8 T-cell depletion resulted in a 5-fold increase in
CD45(-) nestin(+) NSCs compared to isotype antibody-
treated controls. While CD4(+) T-cell numbers or phenotype
did not change significantly following depletion, an increase
in the total number of infi l t rat ing macrophages
(CD45(hi)CD11b(+)) as well as a down-regulation of MHC-
II on microglia was observed. Interestingly, a 3-fold increase
in number of CD206(+)infiltrating macrophages, an M2 mac-
rophage phenotype marker, was seen compared to appropriate
controls. Further analysis of macrophage phenotypes showed
that, in the absence of CD8 T-cells, the ratio of CD206 to
CD86 expressing macrophages shifted from 2:1 to
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approximately 4:1, suggesting that CD8 T-cell depletion pro-
motes an M2 macrophage activation phenotype. Moreover,
gene transcription analysis demonstrated a significant reduc-
tion of IFN-gamma expression in depleted animals, compared
to isotype-treated mice. Previous studies in our laboratory
have shown that M2 polarized macrophages enhance NSC
proliferation. However, transplantation of M2 polarized mac-
rophages into the lateral ventricles of chronically infected
mice showed no significant change in neurogenesis. In addi-
tion, cultured NSCs treated with IFN-gamma were refractory
to M2 macrophage induced increase in proliferation. Taken
together, these data suggest that CD8 T-cells impair endoge-
nous NSC proliferation subsequent to HSE in an IFN-gamma
dependent manner. These studies may help identify therapeu-
tic interventions to enhance neurogenesis during viral
encephalitis.
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and Oxidative Stress Marker Gene Expression in HIV
Transgenic Rat Brains
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Objective: Cigarette smoking has been linked to an increased
risk of disease progression in HIV infection, including an
increased risk of cognitive impairment. In these preliminary
studies were examined effects of cigarette smoke exposure on
the induction of gene expression of mediators of inflammation
and oxidative stress in brains of HIV-1 transgenic rats.
Methods: 3-6 month old wild-type (WT) and transgenic (TG)
Fisher 344/NHsd rats were exposed to cigarette smoke (CS)
from 3R4F research grade cigarettes, which contain a regular
amount of nicotine, in a specially constructed smoking cham-
ber for 5 days per week for 4 weeks. Frontal cortex and
subcortical white matter from the CS-exposed and non-
exposed animals (n=4 rats group) were examined by real-
time PCR for IFN-gamma, TNF-alpha, IL-6, CCL2/MCP-1,
CCL-3/MIP-1-alpha, iNOS, the NADPH oxidase isoform
dual oxidase 1 (DUOX1), thioredoxin (TXN) and superoxide
dismutase (SOD) gene expression.
Results: INF-gamma gene expression was higher for WT than
for TG rats and increased by CS exposure. TNF-alpha gene
expression was increased only in CS+ WT vs CS- WT rats,
and there was no difference in IL-6 expression for either TG or
WT rats +/- CS exposure. In the absence of CS exposure,
MCP-1/CCL2 expression was higher for TG thanWT rats and
was higher for TG CS+ rats than for all other groups. There
was no elevation of MIP-1-alpha/CCL3 expression with CS
exposure. Levels of iNOS and TXN expression were similar
for all groups. However, SODwas decreased by CS inWT rats
but was unchanged in TG rats. Also, CS increased DUOX1
expression in WT rats but did not affect expression in TG rats.
Conclusions: Increased pro-inflammatory and decreased oxi-
dative stress marker gene expression resulted from CS expo-
sure in the TG rats. CS effects on oxidative stress responses in
the TG rat may reflect altered sensitivity to nicotine.
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Objective: Neurocognitive impairment (NCI) in HIV infection
has been linked to nervous system involvement by virus-
infected and activated mononuclear phagocytes. In this study,
associations between levels of markers of monocyte/
macrophage activation, levels of circulating monocytes and
the presence of NCI were examined in individuals in Nigeria.
Methods: 160 antiretroviral-naïve seropositive (SP; 97 wom-
en and 63 men) and 56 seronegative (SN; 38 men and 18
women) subjects received a medical assessment and neuro-
psychological testing in 7 ability domains. An average global
deficit score (GDS), with impairment indicated by GDS > 0.5,
was derived from demographically adjusted test scores. Per-
centages of circulating monocytes and HIV RNA measures
were performed in a clinical laboratory. Levels of plasma
soluble CD163 and soluble CD14 (which are markers of
monocyte/macrophage activation) were determined by
ELISA. Measures were compared for SP and SN and by
gender using t-tests and analysis of variance. Associations
between test results were examined using regression analysis,
and analyses of categorical data employed chi-square tests.
Results: 81.7% of SP had asymptomatic HIV infection. GDS
> 0.05 were noted for 9 (16.07%) SN and 34 (21.25%) SP
patients (p=0.4). Among impaired SP, measures were higher for
sCD163 (p=0.03), sCD14 (p=0.0002) and HIV RNA (p=0.02)
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than for non-impaired subjects. Higher measures of GDS
(p=0.017), sCD163 (p<0.0001), sCD14 (p=0.008) and percent
monocytes (p<0.0001) were noted for SP than for SN subjects.
GDS correlated with levels of sCD163 (p=0.02) and sCD14
(p<0.0001). HIV RNAmeasures were higher for women than
men (p<0.0001). Among women, sCD163 (p<0.05) and
sCD14 (p<0.001) levels were higher for SP than for
SN. Among men, sCD14 (p<0.0001) and percent mono-
cytes (p<0.05) were higher for SP than SN.
Conclusion: Measures of circulating monocytes and mono-
cyte activation can be useful for detecting evidence of disease
activity among clinically stable individuals, particularly
women, with HIV infection.
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Despite the development of combination antiretroviral therapy,
HIV-associated neurocognitive disorders remain prevalent. Tra-
ditional neuropsychological (NP) approaches commonly use
paper and pencil-based psychometric tests for impairment as-
sessment. Although these approaches provide highly standard-
ized control and delivery of performance challenges, the extent
to which these tasks predict everyday functioning is not always
clear, as these tasks do not simulate real world activities, such as
managing finances or remembering appointments. The assess-
ment of neurocognitive ability using tasks to simulate everyday
activities may confer an estimate of the patient’s functioning
more accurate than the onewithin laboratory conditions. Virtual
reality (VR) allows (1) the user to interact in real time with a
pseudo immersing 3D environment by a behavioral interface;
(2) the presentation of close to real life testing environments.
The aim of this study was to design a measure that will detect
NP impairment of HIV-infected subjects in a simulated envi-
ronment and to analyze how the number of errors detected in
this environment will correlate with NP dysfunction on tradi-
tional tests. To this end, we developed the NP function of an
interactive VR supermarket. The facets of NP functions we
expect to correlate with the VR test will be episodic memory
and executive functions tests. This study was supported by a
developmental grant from the Comprehensive NeuroAIDS
Center (CNACNIMHGrant Number P30MH092177) at Tem-
ple University School of Medicine.
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Viral oncoprotein Tax plays key roles in transformation of
human T-cell leukemia virus type 1 (HTLV-1)-infected T cells
leading to adult T-cell leukemia (ATL), and is the key antigen
recognized during HTLV-associated myelopathy (HAM).
In HLA-A2+ asymptomatic carriers as well as ATL and
HAM patients, the Tax(11-19) epitope has exhibited
immunodominance. In this regard, the immunotherapeutic po-
tential of this epitope has been evaluated in HLA-A2 transgenic
mice in the absence and presence of dendritic cells (DCs) given
the recent encouraging observations made with Phase 1 DC-
based vaccine trial for ATL. To facilitate these studies, an HLA-
A2/DTR hybrid mouse strain carrying the HLA-A2.1 and
CD11c-DTR genes was generated. The CD8+ T-cell immune
response was generated against the Tax(11-19) epitope deliv-
ered in the absence or presence of Freund’s adjuvant and/or
DCs. Overall, the results demonstrate that naturally presented
Tax epitope could initiate an antigen-specific CD8+ T-cell
response in vivo but failed to do so upon DC depletion. In
addition, the presence of adjuvant potentiated the Tax(11-19)-
specific response. Elevated serum IL-6 levels coincided with
depletion of DCs whereas decreased TGF-beta was associated
with adjuvant use. Thus, the Tax(11-19) epitope is a potential
candidate for the DC-based anti-HTLV-1 vaccine and the newly
hybrid mouse strain could be used for investigating DC in-
volvement in human class-I-restricted immune responses.
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Dendritic cell trafficking into the central nervous system:
involvement of lectin adhesion receptors and actin
polymerization
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In the healthy individual, infiltration of dendritic cells (DCs)
into the central nervous system (CNS) is tightly controlled by
the highly specialized blood-brain barrier (BBB). However, in
an inflammatory disease likemultiple sclerosis (MS), DCs have
potential to transmigrate across the BBB into the CNS due to
the presence of chemoattractants, particularly CCL2 orMCP-1.
Hence, studying the interaction of circulating DCs with the
BBB represents a critical step in cellular trafficking during
neuroinflammation. Near-infrared imaging of DC accumula-
tion into CNS correlated with the severity of inflammation in
EAE (experimental autoimmune encephalomyelitis) model of
MS. Ex vivo histology confirmed the presence of CCL2 in
lesions, with DCs emerging from perivascular spaces. Confocal
imaging revealed that CCL2 exposure leads to polymerization
of actin on DCs suggesting a migratory phenotype. During
mechanistic studies in BBB model, DCs exhibited more effi-
cient transmigration than T cells in the presence of CCL2.
Additionally, a paracellular versus transcellular pattern of mi-
gration by DCs and Tcells was seen. The unique enrichment of
lectin receptors on DCs led to differential profile for each
specific subset of DCs includingmyeloid (mDC), plasmacytoid
(pDC) and monocyte-derived (MDDC). Subsequently, in the
presence of CCL2, each DC subset was found to utilize a
different lectin receptor in order to adhere and transmigrate
across the BBB. At the subcelleular level a cross-talk be-
tween actin and lectin pathways was also established. The
prospect of selectively regulating DC entry into the CNS
will open up new possibilities for disease pathogenesis and
propagation in MS.
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NMR structure-based mutagenesis studies of JC virus
agnoprotein revealed the importance of Leu29, Leu32
and Leu36 in protein stability, dimer/oligomer formation
and in viral DNA replication
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Agnoprotein is a small and multifunctional regulatory protein
of JC virus (JCV) and plays essential regulatory roles in the
viral replication cycle. In the absence of its expression, JCV is
unable to sustain its productive life cycle. We have recently
demonstrated that agnoprotein forms highly stable dimers and
oligomers in vivo and in vitro and the Leu/Ile/Phe-rich hydro-
phobic domain of the protein plays a key role in formation of
such multimeric structures. Previous mutagenesis analysis of
the region resulted in phenotypes that show defects in viral life
cycle. In addition, previous attempts to determine the 3D
structure of agnoprotein have been unsuccessful. Here, we
report the NMR structure of a synthetic agnoprotein peptide
encompassing amino acids Thr17-Glu55 demonstrating that
amino acids spanning from Lys22 to Phe39 form an amphi-
pathic alpha-helix. We have also performed NMR
structure-based mutagenesis studies to identify amino
acids critical for agnoprotein multimeric structures and
function. Alanine substitution of three leucine residues;
Leu29, Leu32 and Leu36 located within alpha-helix
region resulted in a mutant that exhibits a substantially
reduced level of agnoprotein expression and viral DNA
replication. Consistent with these in vivo findings,
in vitro studies with this mutant demonstrated consider-
ably low level of protein expression in a bacterial ex-
pression system and showed defects in monomer, dimer
and oligomer formation. Collectively, these findings
suggest that Leu29, Leu32 and Leu36 residues found
in the dimer interface of agnoprotein play critical roles
in protein stability, dimer/oligomer formation and in
viral DNA replication. Thus, the dimerization domain
of agnoprotein represents a potential target site for de-
veloping novel therapeutics against JCV infections in
affected PML patients.
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JC virus (JCV) agnoprotein harbors a putative nuclear
export signal (NES) and interacts with a host RNA export
factor, CRM1: Evidence for its involvement
in nucleo-cytoplasmic export of JCV transcripts
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Temple University School of Medicine, Department of
Neuroscience, Laboratory of Molecular Neurovirology,
Philadelphia, PA, 19140, USA
12th ISNV, Washington, DC, USA S71
Viruses have evolved highly sophisticated mechanisms
to exploit the host machinery for their own benefit to
produce infectious virions. They achieve this in part by
encoding and utilizing multifunctional proteins in multi-
ple steps of the viral infection cycle including RNA
export. These types of viral proteins have distinct func-
tional domains used by viruses in such processes. JCV
agnoprotein is one of those multifunctional proteins
with multiple properties. For example, it localizes main-
ly to the perinuclear area of the infected cells but a
considerable amount of it is also found in the nucleus.
This protein is consists of several functional domains,
including a bipartite nuclear localization signal (NLS)
and a Leu/Ile/Phe-rich multimerization domain and ex-
hibits a highly basic nature containing multiple Arg, and
Lys residues found at the N- and C-terminus of the
protein. In addition, it specifically interacts with JCV
RNA and harbors a putative NES similar to that of
HIV-1 Rev; and treatment of the JCV-infected cells with
a selective CRM1 inhibitor (Leptomycin B) leads to the
accumulation of agnoprotein inside the nucleus, suggest-
ing that it may be involved regulation of the export of
the JCV transcripts in a CRM1-dependent manner. To
provide evidence for such a possibility, a protein-protein
interact ion study has been performed between
agnoprotein and CRM1 using whole cell extracts from
SVG-A cells infected with JCV and purified CRM1.
Results showed that agnoprotein strongly interacts with
GST-CRM1, but not with GST alone, suggesting that
the observed interaction between these two proteins is
specific. Collectively, results from these studies support
a hypothesis that agnoprotein may play a regulatory role
in nucleo-cytoplasmic export of JCV transcripts in a
CRM1-dependent manner. Our future studies are aimed
at investigating the molecular mechanisms regulated by
agnoprotein in export of JCV transcripts.
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The majority of the human population is latently
infected with JC virus, which causes the fatal demye-
linating disease of the brain, progressive multifocal
leukoencephalopathy, in immunocompromised individ-
uals. The mechanism of viral reactivation and the
molecular switch to activate productive replication is
not well understood. Previous studies have identified
Pur-alpha and SF2/ASF, also known as SRSF1, as pos-
itive and negative regulators of JCV gene expression,
respectively. Here we studied the functional interplay
between Pur-alpha and SRSF1 in regulation of JCV
gene expression at the transcriptional and splicing
levels. Western blot analysis of brain lysates and em-
bryonic fibroblasts from mice lacking Pur-alpha showed
a dramatic increase in SRSF1 levels compared to wild
type mice, pointing to a negative correlation in cellular
expression of both proteins. In addition, overexpression
of Pur-alpha in glial cell lines caused a significant
reduction in SRSF1 levels. Next, we tested the effects
of Pur-alpha and SRSF1 on JCV transcription by lucif-
erase assay. As expected, while SRSF1 caused a strong
inhibition, Pur-alpha showed a moderate increase in
transcription levels driven by the JCV-early promoter.
Interestingly, we observed that SRSF1 mediated sup-
pression of JCV transcription was significantly restored
by expression of Pur-alpha. These data have revealed a
novel interaction between SRSF1 and Pur-alpha in the
regulation of JCV reactivation.
This work was made possible by grants awarded by NIH to
IKS and JG.
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The JC virus (JCV) is one of the abundant polyomaviruses
which infects the majority of human population during child-
hood, and establishes a persistent life-long infection. JCV
replicates in glial cells in the brain, and causes the fatal demy-
elinating disease, progressive multifocal leukoencephalopathy
(PML). PML is usually seen in patients with underlying
immunocompromised conditions, notably among AIDS
patients and those on chronic immunosuppressive regimens.
JCV genome is composed of three functional regions, includ-
ing the viral early and late coding regions and viral noncoding
regulatory region. The late leader sequence contains an open
reading frame encoding a small regulatory protein called
agnoprotein. Previous studies from mutational analysis
suggested that agnoprotein is required for the sufficient
progression of the infection cycle in glial cells with an
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unknown mechanism. Here, we have discovered that
agnoprotein can be detected in cell-free fractions of glial
cultures infected with JCV, transfected with expression plas-
mids or transduced with adenovirus expression system. More-
over, treatment of cells with Brefeldin A but not Monensin
suppressed the secretion of agnoprotein suggesting that con-
ventional secretion pathway was mainly involved in
agnoprotein secretion. We further demonstrated that the se-
creted agnoprotein was uptaken by glial cells. These studies
have revealed a novel phenomenon of agnoprotein during the
viral life cycle with a potential of developing diagnostic and
therapeutic interventions.
This work was made possible by grants awarded by NIH to
IKS and KK.
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Opiate drug use by HIV-1 positive individuals is report-
ed to exacerbate HIV encephalitis (HIVE) and HIV-
associated neurodegenerative disorders (HAND). It has
recently been suggested that, besides mu-opioid recep-
tors, opiate drugs can also activate Toll-like receptor 4
(TLR4). Likewise, this receptor is a plausible target for
HIV-1 proteins such as transactivator of transcription
(Tat). Therefore, we aimed to clarify the role of mor-
phine and Tat directly at TLR4 using HEK cell lines
that express human TLR4, MD2 and CD14 [TLR4(+)
cells] or only MD2 and CD14 genes [TLR4(-) cells], as well
as an NF-kappaB-inducible reporter which quantifies TLR4
activation. We found that a 16-h exposure to HIV-1 Tat1-86
(100 nM) increased TLR4 reporter activity, but under our
current conditions at this time point, exposure to (-)-morphine
or (+)-morphine enantiomers (500 nM-5 uM) did not appear
to activate the TLR4 reporter; however, higher doses still need
to be tested. Additionally, activity of Tat at TLR4 seems to be
specific, as co-application of the TLR4-selective antagonist,
LPS-RS, significantly decreased Tat- or LPS-EK (TLR4-
specific agonist)-induced activity similarly. No significant
activation by Tat or morphine was noted in TLR4(-) cells.
Finally, using an ELISA, we noted that a 24-h exposure to Tat
increased MCP-1 production in TLR4(+) cells, though (-)-
morphine did not. We validated the model by confirming the
presence of TLR4 and absence of mu-opioid receptors in the
appropriate cell lines using qRT-PCR. Overall, our current
results suggest that, in a TLR4 over-expressing HEK cell
model designed to purely test TLR4 activity, Tat, but not
morphine, activated TLR4 and its signaling pathway. Sup-
ported by NIH T32 DA007027, K02 DA027374, and R01
DA034231.
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A novel model for proviral HIV-1 latency in neural cells
reveals similarities between HIV-1 latency in the brain
and in the immune system
Martha Schneider, Christoph Ziegenhain, Bianca Tigges,
Markus Helfer, Ruth Brack-Werner
(presenting author: brack@helmholtz-muenchen.de)
Helmholtz Center Munich, Institute of Virology
Potential carriers of transcriptionally latent HIV-1 proviruses
in the immune system and the central nervous system (CNS)
include CD4+ memory T-cells and astrocytes and possibly
also neural progenitor cells. While powerful cell culture
models exist for proviral HIV-1 latency in CD4-positive T-
cell reservoirs, comparable models have been lacking for
neural cells. To establish a cell culture model for proviral
transcriptional HIV-1 latency in neural cells, we subjected
cells of the human neural stem cell line HNSC.100 to single-
round infections with various Env-defective HIV-1 genomes,
including reporter viruses with GFP-encoding sequences.
HIV-1 infection and viral expression were monitored by quan-
titative PCR analysis of proviral DNA and viral transcript
levels and by flow cytometry analysis of GFP-expression.
Long-term culture led to establishment of cell populations that
had ceased HIV-1 expression but retained HIV-1 proviral
DNA. HIV-1 expression was reactivated by treatment with
the proinflammatory cytokine TNF-alpha and SAHA
(suberoylanilide hydroxamic acid), which are potent HIV-1
activators in latently infected T-cells. Inducible re-activation
of HIV-1 expression was maintained over numerous passages
and in differentiated cells and was retained by single-cell
clones. Side-by-side assays with latently infected neural and
T-cells (J-Lat) revealed that reactivation of HIV-1 expression
could be blocked in both HIV-1 reservoir cell types by
pretreatment with various small molecules that inhibit
activation of NF-kappaB or the positive transcriptional
elongation factor pTEFb. In summary, we report estab-
lishment of a potent cell culture model for persisting
latent HIV-1 proviruses in neural cells and use this
model to compare modulation of proviral HIV-1 latency
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in brain cells and T-cells. Our results raise the possibility that
agents that influence HIV-1 proviral latency in the immune
system may also affect proviral latency in the CNS and
provide proof-of-concept for blocking of reactivation of pro-
viral HIV-1 latency in different HIV-1 reservoirs by small
molecules.
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Myocyte enhancer factor-2 (MEF-2) plays critical role
in HTLV-1 infection and transformation of CD4+ T cells
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The transactivator protein of human T-cell leukemia virus type
1 (HTLV-1), Tax, is capable of regulating both virus (via
transcriptional activation of the viral long terminal repeat,
LTR) and the host transcriptional machinery, however there
is no clear understanding about the involvement of host tran-
scription factors. Herein, we describe the role of myocyte
enhancer factor-2 (MEF-2) in Tax-mediated activation of
HTLV-1 LTR in infected primary CD4+ T cells and the
virus-producing cell line, MT-2. MEF-2 was confirmed by
ChIP assay to be recruited to LTR inMT-2 and primary CD4+
as well as CD4+CD25+ T cells in association with Tax.
Furthermore, an increase in MEF-2 expression was observed
upon infection and correlated with Tax and HAT complex
formation, while MEF2 knockdown through shRNA and
inhibition of MEF-2 activity by overexpression of a known
repressor, HDAC9, reduced viral mRNA and protein expres-
sion in both primary cells and cell lines. Confocal microscopy
also confirmed that MEF-2 colocalizes with Tax in virus
producing cell lines. Next, in order to understand the regula-
tion ofMEF-2, we performed comparative protein-DNA array
analyses and observed a global upregulation of many MEF-2
associated transcriptional factors in infected cells. Additional
studies demonstrated the expression of key signaling media-
tors and clearly indicated that MEF-2-integrated signaling
pathways are activated during HTLV-1 infection, including
PI3K/Akt, NF-kappaB, MAPK, TGF-beta and JAK/STAT
signaling. Overall, these studies are the first to describe the
involvement and regulation of a novel transcription factor,
MEF-2, during the course of HTLV-1 infection and
pathogenesis.
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HIV-1/HCV co-infection represents a significant burden on
global economy and public health. Up to 30% of HIV-infected
patients and 60-90% of HIV-infected injection drug users are
infected with HCV. It is now widely accepted that HIVaccel-
erates the course of HCV-related chronic liver disease. The
current standard treatment for treating HCV infection in HIV-
1/HCV co-infected patients is administration of PEGylated
interferon alpha-2a/2b (PEG-IFNalpha-2a/2b) and an anti-
viral drug ribavirin (RBV). Recent breakthroughs in direct-
acting antivirals (DAAs) such as Telaprevir and Boceprevir
against HCV genotype 1/2 have provided hope for HCV cure.
However, development of viral resistance during DAA treat-
ment, and drug-drug interaction among protease inhibitors are
two key concerns in the clinical management of infection.
Furthermore, Telaprevir or Boceprevir yield optimal results
upon combination with IFN and/or RBV, suggesting IFN/
RBV will still be the backbone of anti-HCV treatment.
Plasmacytoid dendritic cells (pDCs) are the natural producers
of type 1 IFN in response to many viral infections including
HIV-1. However, HCV is known to be a weak inducer of IFN-
alpha in pDCs and it is not known how this scenario changes
in the presence of HIV. Therefore, we investigated the quality
of DC responses in co-infected patients during the course of
IFN/RBV therapy. Further, to understand the molecular basis
of these responses, we analyzed differential expressed
miRNAs and their target mRNAs in sustained virological
responders (SVRs) and non-responders (NRs), pre- and
post-treatment. Collectively, results of these studies led to
key immune and molecular correlates of IFN/RBV treatment
in HIV-1/HCV co-infected patients.
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Identification of cellular proteins in addition to already known
transcription factors such as NF-kappaB, SP1, and CEBP that
interact with the HIV-1 LTR is critical in understanding the
mechanism of HIV-1 replication in monocytes/macrophages.
Our studies demonstrate upregulation of pyruvate kinase iso-
form M2 (PKM2) expression in HIV-1JRFL infected PBMCs
and during reactivation of HIV-1 in chronically infected U1
cells. Furthermore, we observed that infection of PBMCs with
HIV-1 and reactivation of HIV-1 in U1 cells results in in-
creased levels of nuclear PKM2. Hence we focused on under-
standing the potential role of PKM2 on HIV-1 LTR
transactivation. Our studies demonstrate that over expression
of PKM2 in U937 and in TZM-bl cells lead to transactivation
of the HIV-1 LTR reporter construct. Using various deletions
constructs of HIV-1 LTR, we mapped the region spanning
between -203 bp to -80 bp to be essential for PKM2 mediated
transactivation. This region contains the NF-kappaB DNA
binding site and mutation of NF-kappaB binding site attenu-
ated PKM2 mediated transactivation of HIV-LTR. Chromatin
immune-precipitation (ChIP) analysis in PMA activated
TZM-bl cells demonstrated interaction of PKM2 with HIV-1
LTR. Our studies suggest that PKM2 is a transcriptional co-
activator of HIV-1 LTR. Hence it opens up another possible
target to curb HIV-1 replication at transcriptional level. This
work was supported by the NIH grants to SA and PKD. The
study also utilized services offered by core facilities of the
Comprehensive NeuroAIDS center (CNAC) NIMH Grant #
P30MH092177 to KK.
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Viruses have evolved various strategies to protect infected
cells from apoptosis. Glycolysis is linked closely to the cell
fate and it is known that HIV-1 infected macrophages are long
lived and considered to be viral reservoirs. We provide evi-
dence that HIV-1 protects infected macrophages from apopto-
sis by modulating the host glycolytic pathway. Glycolytic
enzyme Hexokinase (HK) and product of its enzymatic
activity Glucose 6 phosphate (G-6-P) are known to play a
non-metabolic role in resisting and supporting apoptosis, re-
spectively. Increased association of HK with voltage depen-
dent anion channel of mitochondrial outer membrane can
resist apoptosis by maintaining mitochondrial membrane in-
tegrity. On the other hand increased G-6-P pool in cytoplasm
can force HK to dissociate frommitochondrial membrane and
induce apoptosis by cytochrome c leakage. In this study, we
analyzed regulation of HK that converts glucose to G-6-P and
Glucose-6-phosphate-dehydrogenase (G6PD) that converts
G-6-P in to fructose 6 phosphate, in response to HIV-1 acti-
vation in chronically infected U1 cell line. We found that HIV-
1 replication in U1 cell induces HK expression followed by
translocation of HK from cytoplasm to mitochondria of cell.
We also observed that viral replication increases the enzymatic
activity of G6PD. As a consequence, HK can associate strong-
ly with mitochondrial membrane and this association is kept
under tight control by rapidly turning over G-6-P through
increased activity of G6PD enzyme. We also found that treat-
ment with pentose phosphate pathway blocker Dehydroepi-
androsterone (DHEA) which also inhibits HK and VDAC
interaction; reduced viral replication. Hence our work sug-
gests Hexokinase as a new therapeutic target for intervention
to curtail viral persistence in the macrophage. This work was
supported by the NIH grants to SA and PKD. The study
also utilized services offered by core facilities of the Compre-
hensive NeuroAIDS center (CNAC) NIMH Grant #
P30MH092177 to KK.
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Selective pressures and the low efficiency of reverse
transcriptase lead to genetic alterations within the hu-
man immunodeficiency virus type 1 (HIV-1) genome
resulting in quasispecies that can be differentially regu-
lated and can potentially form niches within specific
cell types and tissues. Previous studies identified a
single nucleotide polymorphism (SNP) within C/EBP
site I (3T, C-to-T change at position 3 of the consensus
B site) that correlated with HIV-1-associated dementia.
In addition, our current cohort shows a SNP within Sp
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site III (5T, C-to-T change at position 5 of the consen-
sus B site) that occurs as frequently as the consensus
subtype B sequence. Stably transfected cell lines were
developed using bone marrow progenitor, T, and mono-
cytic cell lines to explore the promoter (LTR) phenotype
associated with these genotypic changes from an inte-
grated microenvironment. The LAI LTR was coupled to
green fluorescent protein (GFP), and polyclonal HIV-1
LTR-GFP stable cell lines were developed. To examine
the mechanism of LTR-driven gene expression as well
as epigenetic modifications that may control it, clones
were derived from each population of cells. The clones
were examined with respect to basal transcription, cyto-
kine response, and Tat transactivation. Results have
suggested that non-expressing clones containing the
3T5T LTR within TF-1 cell lines can be induced to
express. Additionally, the non-expressing LAI 3T and
LAI 5T Jurkat clone genotypes could be induced into
expression. Results demonstrate that genetic signature,
epigenetic modifications to viral and host DNA, and
cellular phenotype may determine the overall level of
LTR activity. This work is supported by NIH/NINDS
R01 NS32092, NIDA R01 DA19807, NIMH P30
MH092177, and NIMH T32 MH079785.
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Background: The National NeuroAIDS Tissue Consortium
(NNTC) has served the research community since 1998 as
an NIH-sponsored multi-site repository that distributes ante-
mortem and postmortem tissue with clinical and serological
data from HIV-infected individuals. The NNTC has recently
evolved its tissue bank processes, clinical data, and web
resources to meet the changing needs of the research commu-
nity it serves.
Methods: The NNTC collects and distributes CNS and
systemic samples from HIV sero-positive and sero-
negative individuals. Tissues are provided as embedded,
fixed sections or frozen blocks. Plasma, serum, and
PBMCs are also available. Tissue and/or associated data
are available to qualified investigators at no charge
beyond shipping expenses.
New web resources available for users include:
& Public use data set with documentation
& Query tool with download utility
& Experimental results from previous NNTC studies






39% have antemortem plasma
28% serum
17% CSF







530 are deceased with autopsy
254 are deceased without autopsy
730 are inactive
1874 have a baseline neurocognitive diagnosis:
20% normal
21% MCMD
12% HIV associated dementia
NNTC Impact:
12,774 specimens of various tissue types have been distribut-
ed between 1999 and 2013.
Scientific contributions resulting from the NNTC resources
are significant, with close to 400 publications resulting
from the use of the NNTC resources. The resource was
important in 16 investigators securing 25 funded research
applications.
Conclusions: The NNTC has become an invaluable re-
source, expanding the field of NeuroAIDS research by
making available a unique neurologically focused tissue
linked to antemortem clinical data. The website for the
NNTC, including user information and cohort descrip-
tion: www.nntc.org.
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Millions of HIV-1/AIDS patients develop severe chronic pain that
drastically deteriorates their life quality, but the pathogenic mech-
anism is unclear and effective therapies are not available. We are
interested in elucidating the host mechanisms in CNS that interact
with HIV toxins and contribute to this devastating neurological
complication in HIV patients. We are undertaking an interdisci-
plinary approach in this line of research. In the first approach, we
focus on analyzing the postmortem nervous tissues from HIV-1/
AIDSpatients. The goal is to identify clinically relevantmolecular
and cellular abnormalities in the pain-processing pathway. The
analyses reveal the critical HIV-1 protein that may cause this pain
syndrome. In the second approach, we are interested in generating
a rodent model for the HIV-1-associated chronic pain, based on
the findings from human specimen analysis. The goal is to
establish a clinically relevant animal model. We have created a
mouse model that develops extensive similarities to the patholo-
gies seen in the HIV-1 patients with chronic pain. In the third
approach, we focus on elucidating the molecular and cellular
processes that are critical for the pathogenesis of HIV-1-
associated chronic pain, using the mouse model that we have
generated and characterized. We are currently determining the
contribution of synaptic degeneration, glial activation and Wnt
signaling dysregulation to the pathogenesis.
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HIV-1 enters the CNS early after systemic infection, leading to
a variety of neurocognitive and motor impairments referred to
as HIV-1 associated neurocognitive disorders (HAND). Mac-
rophages and microglia support productive viral infection in
the brain and the virus subsequently adapt to the CNS envi-
ronment. Our goal is to elucidate the role of the HIV-1 enve-
lope glycoprotein (Env) during HIV-1 infection in the CNS.
We obtained viruses derived from the cerebrospinal fluid
(CSF) of two HIV-1-infected individuals with HIV-1-
associated dementia, the most severe form of HAND. These
isolates are macrophage tropic (i.e. efficiently infect macro-
phages, whereas most blood-derived isolates do not) and
highly neurotoxic. We amplified by PCR multiple env genes
from these isolates and have performed extensive genotypic
and phenotypic characterization. Interestingly, a mixture of
genotypes and phenotypes has been found. From both viruses,
we obtained a mixture of macrophage-tropic and non-
macrophage tropic Env, as well as Env with various degrees
of fusogenicity, ability to use low levels of CD4 for infection,
sensitivity to entry and fusion inhibitors, and sensitivity to
neutralizing antibodies directed against the conserved CD4
binding site. Importantly, some of these Env, in the context of
isogenic recombinant viruses, are able to mediate infection of
macrophages and lead to the production of conditioned medi-
um which causes neurotoxicity in primary pure neuronal
cultures, whereas others do not. Correlations between genetic
determinants and the above reported phenotypes are being
further investigated.
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Imaging lentiviral reservoirs in vivo based on molecular
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Jiasheng Song, Won-Bin Young
(presenting author: songj2@upmc.edu)
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HIV-1 infections persist in spite of exposure to highly active
antiretroviral therapies (HAART) due to the latent stage of the
virus. The latently infected cells present a major barrier for
curing HIV-1 infections. The identification of viral reservoirs
is essential in monitoring the therapeutic response to HAART
including during the latent stage. Bioluminance imaging
(BLI), positron emission tomography (PET), and magnetic
resonance imaging (MRI) are non-invasion imaging tech-
niques that can be employed to identify viral reservoirs elim-
inating the need for repeat biopsies in vital organs, such as the
brain. However, during the latency stage there are no detect-
able viral proteins for targeted imaging. Our lab has developed
a “Trojan Horse” type strategy where we’ve engineered hu-
man, simian, and feline immunodeficiency viruses (HIV, SIV,
FIV) to carry a reporter gene for non-invasive imaging
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modalities, including BLI, PET or MRI. The engineered vi-
ruses remain replication competent after infecting target cells
for reporter gene expression. The reporter was engineered into
the virus either with or without its own promoter to allow
detection of the infected cells during the latency stage, while
the long terminal repeat (LTR) promoter is inactive. We have
demonstrated that the imaging reporter genes are incorporat-
ed, expressed and functional in infected cells and the replica-
tion kinetics of engineered lentivirus is comparable to that of
the wild type virus. Currently, we are working towards the
evaluation of the engineered viruses in the individual species:
humanized mice (HIV), macaque monkeys (SIV) or felines
(FIV) to further evaluate the use of non-invasive imaging to
visualize the spatial and temporal nature of viral reservoirs and
their response to HAART. The further analyze of these
engineered viruses will provide the ability to image viral
reservoirs providing a much needed tool for monitoring and
evaluating therapeutic efficacy.
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The benefit of highly active antiretroviral therapy for
preventing and treating HIV-associated neurocognitive disor-
ders (HAND), especially HIV-associated dementia, is well
documented. Nonetheless, the milder forms of HAND remain
prevalent and hence are suspected to be associated with var-
ious co-morbid factors including cumulative exposure to an-
tiretroviral (ARV) medications. We propose that chronic toxic
effects of ARV drugs on the cell components of blood vessel
walls can contribute to brain vascular pathology, particularly
cerebral small vessel disease (CSVD, including
arteriosclerosis and arteriolosclerosis). Even at its early stages
when a decrease in the cerebral blood flow is not severe
enough to cause infarcts or white matter lesions, CSVD can
lead to disturbance of cerebrovascular autoregulation and
deficiency in functional hyperemia. We used multinomial
logistic regression to determine associations between the use
of ARV drugs and the occurrence of CSVD in 144 autopsy
HIV-infected cases in the California NeuroAIDS Tissue Net-
work. Using univariable analysis we found that mild CSVD
(vs. absent) was associated with nucleoside reverse transcrip-
tase inhibitors (NRTIs) or protease inhibitors (PIs) [odds ratio
(OR) 19.23 and 2.84, P=0.003 and =0.06, respectively], but
not with any of the vascular risk factors (i.e., older age [≥50
years], diabetes mellitus, hypertension, hyperlipidemia, ciga-
rette smoking, and lifetime psychostimulant dependence). On
the other hand, moderate/severe CSVD (vs. absent) was asso-
ciated with older age and diabetes (OR 2.56 and 6.55, P=0.035
and =0.01, respectively), but not with any of the ARV-related
predictors. Our findings suggest that the use of NRTIs or PIs
may increase the risk of mild CSVD and consequently
neurocognitive impairment. Of particular interest are further
studies of the molecular mechanisms of ARV toxicity to the
cell components of brain vessel walls and identifying potential
biomarkers for CSVD in HIV-infected persons.
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The receptor for haptoglobin-hemoglobin complexes, CD163,
is expressed on cells of monocytes-macrophage origin. The
membrane-bound molecule is cleaved by proteases and re-
leased in biological fluids in a stable soluble form (sCD163).
Plasma levels of sCD163 are elevated in HIV infected indi-
viduals; however, the direct involvement of membrane-bound
or soluble CD163 in HIV pathogenesis is unknown. In this
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study we demonstrate that relatively high concentrations of SP
(10 microM) trigger intracellular calcium increase in mono-
cytes, most likely due to the activation of the truncated iso-
form of neurokinin 1 receptor (NK1R). SP also enhances
CD163 expression on monocytes in a dose- and time-
dependent manner, albeit to a lower extent than IL-10, a
cytokine well known to induce the alternative pathway of
monocyte differentiation. The SP-induced expression of
membrane-bound CD163 is accompanied by increased shed-
ding of sCD163 from human monocyte-derived macrophages
(MDM) and this effect is inhibited by the NK1R antagonist,
aprepitant. Decreasing the expression of membrane-bound
CD163 in MDM using siRNA resulted in a significant de-
crease of HIV infection. In order to further demonstrate that
the level of expression of membrane-bound CD163 is impor-
tant for HIV infection, we used cell sorting to separate human
monocytes expressing high and low levels of CD163. The
productivity of HIV infection was higher in cells expressing
high levels, vs. cells expressing low levels of CD163. Our
study indicates that high levels of membrane-bound CD163
facilitate HIV infection in macrophages.
This work was supported by National Institutes of Health
Grants U01-MH 090325, R01-MH 049981, R21-AI 108298
(to SDD)
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Opioid abuse by human immunodeficiency virus type 1
(HIV-1)-infected individuals leads to more rapid disease pro-
gression, increased viral replication and peripheral viral load,
and increased incidence and severity of neurocognitive abnor-
malities compared to non-drug abusers. The blood-brain bar-
rier (BBB) is an obstacle that must be overcome during
neuroinvasion with subsequent development of HIV-
associated neurocognitive disorders (HAND). Previous stud-
ies addressing the role of mu-opioids in altering BBB perme-
ability have suggested that exposure increases cellular trans-
migration through an uncharacterized mechanism. In this
study, a human brain microvascular endothelial cell
(hBMEC) line, hCMEC/D3, was used to establish an
in vitro transwell model of the BBB to investigate the effects
of chronic (24, 48, or 72 h) morphine treatment on barrier
structure and function. We observed that hCMEC/D3 cells
form a confluent monolayer with a basal rate of passage of a
70 kDa tracer molecule comparable to primary hBMECs. It
has also been shown that these cells express mu opioid recep-
tor, and that prolonged morphine treatment induces changes in
mRNA levels of cellular adhesion molecules. Functionally, an
increase in PBMC transmigration and firm adhesion was
observed following prolonged morphine exposure, in the ab-
sence of an increase in overall barrier leakiness. These results
have suggested that morphine activates hCMEC/D3 cells
leading to a cellular environment permissive to transmigra-
tion. These studies may uncover a mechanism through which
morphine disrupts periphery-CNS homeostasis leading to ac-
celeratedHAND. This work is supported byNIH/NINDSR01
NS32092, NIDA R01 DA19807, NIMH P30MH092177, and
NIMH T32 MH079785.
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immune activation and HIV-1 associated
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Viral particles of HIV-1, the causative agent of AIDS, contain
two copies of a ssRNA genome. Toll-Like Receptors (TLRs)
such as endosomal TLRs 7 and 8 have been reported to sense
HIV-1 RNA sequences. The endosomal TLR3 primarily
senses dsRNA, a common viral replication intermediate that
is absent during retroviral replication. However, since HIV-1
ssRNAs contain multiple hairpin-like secondary structures
that could potentially mimic a dsRNA entity, we hypothesized
that TLR3 could sense and respond to HIV-1 infection. No
difference in susceptibility to infection with HIV-1 virions
pseudotyped with murine leukemia virus envelope glycopro-
tein or vesicular stomatitis virus glycoprotein (VSV-g) was
observed between bone marrow-derived macrophages isolat-
ed from wild-type and TLR3 knock-out (TLR3KO) mice.
However, production of pro-inflammatory cytokines and
chemokines, including type-I IFNs was significantly reduced
in BMDMs from TLR3KOmice. Similarly, in the presence of
a TLR3-specific inhibitor, HIV-1 BAL pseudotype infection
of human monocyte-derived macrophages and THP1-derived
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macrophages resulted in significantly reduced production of
pro-inflammatory cytokines and chemokines. Phosphoryla-
tion of the transcription factor IRF-3 (p-IRF3), is an essential
step for TLR3 dependent upregulation of type-I IFNs. HIV-1
BAL infection upregulated p-IRF3 3-6hrs post infection, how-
ever, inhibition of TLR3, significantly reduced HIV-1 induced
p-IRF3 levels. Surprisingly, HIV-1 BAL infection of human
macrophages resulted in significant upregulation of TLR3
mRNA levels and moderate increase in TLR3 protein levels.
Finally, infection of 293T cells stably expressing the murine
TLR3, with VSV-g pseudotyped virions, resulted in signifi-
cant induction of TNF-alpha and IL-6. Current and future
experiments are aimed at investigating the potential for direct
interaction between HIV-1 ssRNA and TLR3. Overall, this
study provides the first known evidence that TLR3 senses and
responds to HIV-1 infection in macrophages. Since TLR3 is a
crucial innate immune sensor in the brain, these results have
important implications in HIV-1 neuropathogenesis, inflam-
mation and other co-morbidities.
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Recent studies show that proinflammatory cytokines includ-
ing osteopontin (OPN, SPP1) remain elevated in the plasma
and cerebrospinal fluid (CSF) in individuals suffering from
HIV-associated neurocognitive disorders (HAND). Beyond
its ability to enhance HIV replication, OPN promotes in-
creased numbers of activated monocytes in the CNS by facil-
itating chemotaxis and cell survival. However, the molecular
mechanisms by which OPN mediates its function in the con-
text of HAND remain unexplored. We used next-generation
high-throughput sequencing and transcriptome analyses to
identify the genes and pathways that are differentially regu-
lated in primary human macrophages knocked down with
siRNA against SPP1 (SPP1 KoD) compared to wildtype
macrophages. As predicted by a disruption of SPP1 expres-
sion, OPN receptors, the integrins ITGAVand ITGB3, which
signal through NF-kappaB were markedly downregulated.
Chemokines CXCL10, CXCL9, CCL2, CXCL1, CCL13,
and CCL7 were up- or downregulated 3-6 fold. TNF-
responsive genes including TRAF1, TANK, TIFAB,
TNFSF9, TIFAB, TNFAIP6 and TNFAIP3 and toll-like re-
ceptors -1, -4, -5, -6, and -8 were differentially expressed in
SPP1 KoD macrophages. Key genes involved in cytokine
signaling including STAT1, STAT2, NFKBIZ, NFKBID, were
either up- or down modulated in OPN KoD macs. A promi-
nent feature in SPP1 KoDmacs was the differential regulation
of 13 members of the mitogen-activated protein kinase cas-
cade. Interestingly, several members of the host restriction
factors that target HIV including the TRIM and APOBEC
proteins were downregulated in SPP1 KoD macrophages.
Unexpectedly, CD163, a biomarker strongly associated with
HAND was significantly decreased in SPP1 KoD macs sug-
gesting a link between proinflammatory gene regulation by
OPN and CD163 expression. Several other host genes impli-
cated in the HIV life cycle were also differentially regulated.
Together, these data suggest that OPN is a potent regulator of
proinflammatory gene expression impacting macrophage ac-
tivation and host cell resistance and susceptibility to HIV
infection and replication.
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Background: JCV causes progressive mult ifocal
leukoencephalopathy(PML) in immunocompromised pa-
tients. Up to 80% of the general population is seropositive
for JCV and JCV-specific cellular immune response is neces-
sary for containment of viral proliferation. The mechanism of
JCV reactivation and immunity in a transplanted immune
system remains unclear.
Methods: We prospectively enrolled 30 patients undergoing
allogeneic HSCT, and collected blood and urine samples
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before and 3, 6, and 12 months after HSCT. We detected JCV
DNA by PCR in blood and urine samples, performed ELISA
for detection of JCV IgM and IgG, as well as Elispot
and ICS for measurement of T-cells responses to JCV.
Multivariate analysis accounted for conditioning regimens,
cancer diagnosis, concurrent viremia, age, and transplant type.
Results: Pre HSCT, JCV DNAwas detected in 7/30 urine, 5/
30 PBMC and 6/30 plasma samples. While viruria remained
stable after HSCT, viremia was detected in only 1/22 plasma
and none of 22 PBMC samples 12 months after HSCT.
Prevalence of anti-JCV IgG was 83% pre HSCTand remained
stable at 72% at 12 months. Anti-JCV IgM was rarely detect-
ed. A significant increase in JCV-specific T cell responses 12
months after HSCTwasmediated by both CD4+ and CD8+ T-
cells. While JC viruria correlated directly with detection of
anti-JCV IgG, the cellular immune response to JCV measured
by ELISPOT was inversely correlated with anti-JCV IgG
response. Age of the patients and the diagnosis of leukemia
both significantly reduced cellular immune responses to JCV.
Conclusions: JC viruria triggers an antibody response in
HSCT. However, an increase in JCV-specific cellular
immune response 12 months after HSCT leads to sup-
pression of JC viremia, and decrease in JCV humoral
immune response. This prospective study in HSCT pa-
tients provides a model of interactions between the host
immune response and viral activation in multiple com-
partments over time.
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Mosquito-borne La Crosse virus (LACV) infections are a
leading cause of infectious encephalitis in children, but adults
are generally resistant to neuroinvasive disease. Age-
dependent susceptibility to LACV is also observed in mouse
models. Mice younger than 30 days are susceptible to neuro-
logical disease while mice older than 30 days are resistant. In
the current study, we demonstrate that the resistance of adult
animals is dependent on type I IFN responses generated
through TLR3 and RIG-I like receptor (RLR) signaling path-
ways. These pathways are essential for peripheral virus con-
trol and prevention of spread to the CNS. In particular, TLR3
and RIG-I receptor signaling in myeloid dendritic cell
populations is implicated in virus control. Young mice have
significantly lower numbers of myeloid dendritic cells and
generate weaker type I IFN responses in peripheral tissues
following either LACV infection or direct stimulation with
TLR3/RLR ligands compared to older mice. The inability of
young mice to generate strong peripheral type I IFN responses
in myeloid dendritic cells following TLR3/RLR stimulation
may explain their increased susceptibility to viral infec-
tion, spread and encephalitis.
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Neuronal cell death is a hallmark of various neurological
diseases including virus infections. The innate immune
response in the CNS contributes to neuronal damage
through cytokine and neurotoxin production as well as
the recruitment of inflammatory cells. However, the direct
role of the innate immune response in mediating cell death
during virus infection of neurons is not known. In the
current studies, we identified sterile alpha and HEAT/
Armadillo motif containing 1 (SARM1), a negative regu-
lator of TLR signaling, as a mediator of bunyavirus-
induced neuronal apoptosis. SARM1 was induced in neu-
rons following La Crosse virus (LACV) infection and
inhibition of SARM1 suppressed virus-mediated neuronal
apoptosis. Mechanistic studies demonstrated that SARM1
upregulation was due to stimulation through MAVS (IPS-
1) and that SARM interacted with MAVS on the mito-
chondria and induced oxidative damage leading to neuro-
nal apoptosis. This data provides a novel mechanism for
immune mediated neuronal death during virus infection by
activation of pattern-recognition receptors (PRRs) leading
to MAVS activation, SARM1 induction and oxidative
stress. Since stimulation of neurons through endosomal
TLRs can inhibit neuronal growth and induce apoptosis,
we also analyzed the role of SARM in TLR-mediated
neuronal death. SARM1 was induced by TLR7/TLR9
agonist stimulation of cortical neurons and TLR-induced
neuronal apoptosis was SARM1 dependent. These data
indicate that activation of pattern-recognition receptors
on neurons, in the presence or absence of active virus
infection, can lead to neuronal death and that the mecha-
nism of death is through production of SARM which leads
to mitochondrial damage.
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Purpose: HIV-associated neurocognitive disorder (HAND) is
a complication of HIV, in which HIV-infected individuals
suffer a varying degree of neurocognitive impairment. HAND
can occur in both treated and untreated HIV patients, making
it a large public health problem. The etiology of HAND is
generally thought to be at least partly neuroinflammatory, as
infected cells in both the periphery and CNS cause immune
activation leading to synaptodendritic damage and neuronal
apoptosis. Recently, several labs, including ours, have found
that peripheral inflammation is correlated with the progress of
neurocognitive disease, raising the possibility that peripheral
inflammatory mediators may promote neuroinflammation by
crossing into the CNS. Since protein expression, lipid synthe-
sis, and small molecule metabolism may all be involved in
inflammatory cascades, in this study we determine levels of all
three species in the spleen.
Methods: In this study, 6 pig-tailed macaques were dual
inoculated with a neurovirulent molecular clone and an im-
munosuppressive viral swarm, in which we have shown pig-
tailed macaques to develop AIDS and encephalitis within 84
days. Macaques were sacrificed at 7 days post-infection and
spleen tissue was harvested, then extracted for protein, lipid
and metabolite species. Protein, lipid and metabolite species
were then profiled by mass spectrometry.
Results: Lipidomic profiling by anMS/MS-ALLmethod found
changes in triacylglycerides. Metabolomic profiling by high-
flow LC/MS alignment and then targeted MS/MS found
changes in the nucleotides guanosine and inosine, the small lipid
adipic acid, and the small molecule diethyl oxalopropionate.
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Background: The question whether HIV+ individuals experi-
ence aging-related deficits earlier than healthy individuals or
simply experience increased age-associated deficits across the
age-range is unresolved. We present graph theory models of
brain functional connectivity (FC) that add important evi-
dence that HIVmay lead to an advanced brain-age phenotype.
Methods: BOLD resting-state FC scans were collected in
HIV+ (N=46) and HIV- (N=59) participants on a Siemens
3T scanner. These groups had similar demographics, though
the HIV+ group had a higher viral load and lower CD4+ white
blood cell count. FC time-series were sampled in 160 ROIs for
each subject and graphs were constructed from cross-
correlation matrices. Clustering coefficient (a measure of local
efficiency), path length (a measure of global efficiency), and
modularity (a measure of sub-network structure) were com-
puted across a range of correlation thresholds for each subject
in order to assess the stability of group differences. Effects of
HIV and linear and quadratic effects of age as well as age by
HIV interactions on graph theory topology were assessed
using ANCOVA.
Results:Higher clustering coefficient and lower path length
were observed for HIV+ (p<.05, FDR).Modularity decreased,
suggesting that graph structural changes may explain changes
in efficiency measures. Modularity began to decline earlier in
HIV+ individuals than HIV- individuals and declined as a
quadratic effect of age (p<.01). Immune system strength mod-
ulated modularity changes in HIV+ (p<.01).
Conclusions: By investigating graph structure (particularly
modularity), we showed the first fMRI evidence that age-
related changes may occur earlier in HIV+ individuals. Im-
portantly, we showed that modularity decreases were
explained by strength of immune system response (stronger
immune activation led to greater decreases). Because immune
activation may be an important underlying cause of brain
deficits in both HIV and aging, our result suggests HIV &
aging may both impair brain function through immune system
mechanisms.
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Due to the success of combination antiretroviral therapy
(cART), which changed the clinical picture of HIV infection
from acute to chronic disorder, there is a sharp increase in
infected patients 50 years old and older. This increase in age of
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the HIV infected population constitutes a new challenge in the
HIVepidemic in the affluent countries. Importantly, older HIV
infected patients are more susceptible to neurocognitive im-
pairments associated with the disease. HIV infected brains are
characterized by increased deposition of amyloid beta (Abeta)
in perivascular space, indicating the importance of brain
microvessels in amyloid accumulation. Our research focused
on the mechanisms of HIV-1 interaction with Abeta at the
blood-brain barrier level. Exposure to HIV resulted in accu-
mulation of Abeta in brain endothelial cells, with the promi-
nent nuclear predisposition. We demonstrated that these effects
are dependent on functional caveolae and can be prevented by
inhibition of Ras and the receptor for advanced glycation end
products (RAGE). In additon, HIV-induced nuclear entry of
Abeta involves activation of the dynamin-dependent the EEA1
and TGF-beta/Smad signaling. Using transgenic mice that
express a chimeric mouse/human amyloid precursor protein
and a mutant human presenilin 1, we next demonstrated that
cerebrovascular toxicity of HIV specific protein Tat is en-
hanced in mice with amyloid deposits in the brain. Indeed,
exposure to Tat increased permeability across cerebral capil-
laries, enhanced disruption of ZO-1 tight junction protein, and
elevated brain expression of MMP-9 in transgenic mice as
compared to age-matched littermate controls. These changes
were associated with increased leukocyte attachment and their
transcapillary migration. Supported by MH098891,
MH63022, MH072567, DA027569, and NS39254.
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The mechanism by which brain inflammation drives the sys-
temic immune response is currently unknown. In this study
we provide evidence that this neuroimmune axis involves
microvesicles released from brain that enter into peripheral
circulation. IL-1beta, TNFalpha and ATP evoked a rapid and
robust efflux of microvesicles from astrocytes. The stimulated
release of these microvesicles from astrocytes involved a
stabilization of nSmase2 into ceramide-rich membrane caps
that were primarily located to filopodia. Microvesicle release
was blocked by inhibition of IL-1beta receptor binding, or
inhibition of nSMase2. Microvesicles were 65.6 ± 22.2 nm in
size, and contained a complex lipid and protein content that
was consistent with exosomes. Using an in vitro BBB-model
prepared with BmuEC with GFAP-GFP expressing astrocytes
we determined that microvesicles carrying GFP as cargo
readily crossed endothelial cells with intact tight junctions.
Electron microscopy demonstrated that a small fraction of
these exosomes were endocytosed into endothelial cells
through caveolae, with the majority appearing to readily cross
as intact particles, possibly involving local phase transitions in
the membrane. We next determined if the release of these
exosomes from the injured brain regulated leukocyte trafficking.
Intrastriatal injections of IL-1beta induced rapid focal genera-
tions of ceramide, and a transmigration of neutrophils to the
lesion site within 24h. Genetic mutation of nSMase2, or simul-
taneous injections of nSMase2 antagonists (GW4869 or
altenusin) blocked IL-1beta from inducing ceramide, and
blocked neutrophil influx. Purified exosomes isolated from plas-
ma 2h following intrastriatal injections of IL-1beta, but not
exosomes isolated from mice receiving intrastriatal injections
of saline, re-activated neutrophil influxwhen infused into the tail
vein of acceptor mice who received intrastriatal injections of IL-
1beta + altenusin. These data demonstrate that microvesicles
released from astrocytes readily cross the BBB and regulate the
peripheral immune response to CNS inflammation.
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Clinical, pathological, immunological and virological features
of simian varicella virus (SVV) infection of primates parallel
human varicella zoster virus (VZV) infection. Primary SVV
infection of primates causes varicella, after which virus be-
comes latent in ganglionic neurons and reactivates. Earlier, we
demonstrated experimental reactivation of SVV after X-
irradiation and treatment with tacrolimus and prednisone of
latently infected monkeys. Herein, 5 rhesus macaques were
inoculated intrabronchially with 10000 pfu of SVV or SVV-
EGFP (SVV expressing green fluorescent protein) and 5
months later, after the establishment of latency, all monkeys
were transported to an irradiation facility and 4 of them were
exposed to a single dose (200 cGy) of X-irradiation and
treated with tacrolimus (80 ug/kg/day) and prednisone (1
mg/kg/day) for the duration of the experiment; one monkey
was not immunosuppressed, but was subjected to the stress of
transportation. Zoster rash developed 7-12 weeks after
immunosuppression in all 5 monkeys which were eutha-
nized 24-48 hrs later, and multiple tissues (skin, lungs,
ganglia and lymph nodes) were harvested. In all 5 mon-
keys, immunohistochemistry revealed SVV antigens in
these tissues. Immunofluorescence and confocal analysis
of multiple lymph nodes corresponding to the area of
rash, showed colocalization of SVV proteins in macro-
phages and dendritic cells, but not in lymph nodes from
a SVV-seronegative monkey. Detection of SVV proteins
was confirmed by Western blot in 2 of 2 lymph nodes
from one monkey and by qPCR detection of SVV DNA
in 3 of 3 lymph nodes from another monkey. These
findings suggest that SVV antigens may be transported
into draining lymph nodes where macrophages and den-
dritic cells present them to activate T cells directed against
SVV.
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Amyotrophic lateral sclerosis (ALS) is a fatal neurodegener-
ative disease, characterized by the progressive loss of motor
neurons. Its pathogenesis is unclear, although several
mechanisms have been suggested. We previously study
showed that Human Endogenous Retrovirus type K (HERV-
K) was activated in the brain of ALS patients, indicating that
HERV-K may be involved in the pathogenesis of ALS.
HERVs are genomic sequences of retroviral originwhich were
believed to be integrated into germline chromosomes millions
of years ago. Although mostly defective and inactive, some of
the HERVs may be activated under certain physiological and
pathological conditions. While no drugs are designed specif-
ically targeting HERVs, there are a panel of FDA approved
HIVantiretroviral drugs. We hypothesized that HIVantiretro-
viral drugs may also be effective in inhibiting the infection and
replication of HERVs and may be used for the treatment of
HERV-K activation in ALS. We constructed a plasmid with
consensus HERV-K sequence and produced HERV-K virus
for testing the effect of antiretroviral drugs on HERV-K replica-
tion. We first determined the effects of nucleoside and non-
nucleotide reverse transcriptase inhibitors on HERV-K by prod-
uct enhanced reverse transcription assay (PERT). We found that
Abacavir and Zidovudine could significantly inhibit HERV-K
reverse transcriptase activity at similar effective dosages for
HIV-1. To determine the effects of Abacavir and an integrase
inhibitor, Raltegravir on HERV-K viral replication, we
pseudotyped HERV-K with VSV-G and used the pseudotyped
HERV-K virus to infect HeLa cells. Replication of HERV-Kwas
measured by quantitative real time polymerase chain reaction
(qRT-PCR). We found that both Abacavir and Raltegravir
blocked the replication of HERV-K at very low concentration.
In summary, we identified several FDA approved antiretroviral
drugs that can effectively inhibit HERV-K virus. These
antiretrovirals may open new prospects for treatment of
HERV-K activation in ALS and other neuropsychiatric diseases.
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Reactivation of the JCV polyomavirus (by not fully
explained mechanisms) causes progressive multifocal
leukoencephalopathy in patients severely immunosuppressed
or treated with immunosuppressive antibodies. In most of
these diseases, upregulation of HERV-W/MSRV/syncytin-1
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endogenous retroviruses was reported. HERV-Ws are poten-
tially neuropathogenic, being gliotoxic, superantigenic,
fusogenic, immuno-disregolatory, etc. We wondered about
JCV/HERV-W interactions, that could contribute to neurode-
generation. To this end human primary fetal astrocytes and
U87MG and SVG cell lines were either infected by JCV-
Mad1 strain or transfected with expression plasmids carrying
early or late JCV genes, to monitor the expression of HERV-
W/MSRV/syncytin-1 env, or that of constructs carrying the
ERVWE-1/syncytin-1 promoter. Data showed that JCV infec-
tion upregulates bothMSRV-like and syncytin env transcripts.
Transient transfection experiments showed that both JCV-
early and late proteins stimulate the transcription and the
expression of HERV-W/MSRV/syncytin-1 env genes up to the
glycosylated form. These data were obtained by RT-Real time
PCR or western blotting analysis. As for the HERV-W promoter
activity in presence of JCV proteins, gene reporter experiments
with constructs carrying the full-length syncytin-1 promoter, or
promoter deletion mutants, co-transfected with JCVearly or late
plasmids were carried out. Data indicate that the full-length
promoter is upregulated by both JCV early and late proteins.
Deletion of the upstream (cellular) regulatory region indicate
that the stimulatory effect lies on the 5’LTR (viral) moiety. Due
to the identities between the 5’LTR of MSRVand syncytin-1, it
is likely that up-regulation by JCVantigens of both MSRVand
syncytin-1 requires mainly the promoter’s viral moiety. Given
the neuropathogenic properties of HERV-W/env proteins, we
wonder whether their upregulation by JCV in astrocytes could
contribute to neurodegeneration. This novel interaction among
JCVand HERV-Wmay open new avenues in the understanding
of neurodegenerative diseases.
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Brain white matter hyperintensities (WMH) by magnetic res-
onance imaging (MRI) are known to occur with HIV, typically
with late disease and linked to dementia. WMH can also occur
with cerebrovascular disease (CVD) in the absence of HIV.
Since CVD risk increases with age and as patients living with
HIV age, the underlying mechanisms and clinical importance
of WMH become less clear. Using a customized WMH quan-
tification pipeline, we measured lesion volume, number of
lesions (count) and lobar distribution of WMH in 65 HIV+
compared to 29 age and gendermatched healthy HIV-negative
controls. HIV+ subjects were all over age 60 years (median,
range of 63, 60-76) with median (range) CD4 count of 531
(203-1098) and duration of HIV of 22 (3-31) years. Eighty-
eight percent had suppression of plasma HIV RNA < 400
copies. WMH volume was tightly linked to WMH count
(Spearman's rho=0.89 and 0.75 for HIV+ and HIV-negative,
respectively, p<0.005). The highest WMH volumes, adjusted
for intracranial volume (ICV), were seen in HIV+ subjects
(Wilcoxon test of medians, p=0.006). In HIV+ subjects,
higher WMH volume correlated to poorer performance on
executive functioning tests (Spearman's rho=-0.35, p=0.006).
WMH volume did not correlate to CD4 count, nadir CD4
count, duration of HIV, or plasma HIV RNA. In the HIV+
group, subjects who smoke or have hypertension had higher
burden of WMH volume (Wilcoxon test of medians p=0.03
and p=0.04, respectively). Smoking and HIV status have in-
teractive effect on WMH volume adjusted for age (p=0.04).
Similarly, hypertension and HIV status tend to have an inter-
active effect (p=0.09). We conclude that WMH in older HIV+
subjects is more closely related to CVD rather than HIV risk
parameters, and that HIVappears to modulate this effect. These
lesions are linked to cognitive performance. Lifestyle factors
remain important targets for improving cognitive morbidity.
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HIV enters the CNS in infected monocytes within two weeks
of peripheral infection. Once within the CNS, these cells
mediate an inflammatory environment that leads to HIVasso-
ciated neurocognitive disorders in >50% of infected individ-
uals despite successful antiretroviral therapy. Increased
amounts of CCL2 and CXCL12 are present in the CNS of
individuals with neurocognitive disorders. CCL2 increases the
transmigration of HIV-infected CD14+CD16+ monocytes
across the blood-brain-barrier (BBB), but the effect of
CXCL12 on the transmigration of these cells is largely un-
known. CXCL12 engages the HIV co-receptor CXCR4. The
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finding that CXCL12 also interacts with CXCR7 contributes
to a different understanding of CXCL12 mediated processes.
To characterize CXCL12 directed transmigration of CD14+
CD16+ monocytes across the BBB, we studied this process in
an in vitro BBB model. To examine mature CD14+CD16+
monocytes, we enrich for this population in culture. We now
demonstrate that these cultured CD14+CD16+ monocytes
transmigrate preferentially across the BBB as effectively to
CXCL12 as to CCL2. Moreover, the expression of CXCR4
and CXCR7 on our cultured monocytes is similar as that on
monocytes from HIV-positive individuals, validating our cul-
ture model. CD14+CD16- and CD14+CD16+ monocytes from
HIV-positive individuals express comparable amounts of
CXCR4, but CXCR7 expression is specifically increased on
the CD14+CD16+monocyte population. These CD14+CD16+
monocytes transmigrate across the BBB to very low concen-
trations of CXCL12. CXCL12 is also a potent T cell
chemoattractant, yet T cells require higher CXCL12 concentra-
tions for BBB transmigration. Surface CXCR4 on these mono-
cytes is decreased after transmigration, but is greatly increased
on T cells, suggesting that CXCR7 may specifically mediate
CD14+CD16+ monocyte transmigration across the BBB. We
propose that the significant response of CD14+CD16+ mono-
cytes to CXCL12 when transmigrating across the BBB is likely
mediated by both CXCR4 and, at least in part, CXCR7, having
implications for HIV neuropathogenesis and therapeutics.
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In the last few years the role that pannexin hemichannels play
in immune cells has received extensive attention. Our previous
work showed that HIV infection induced a biphasic opening of
these channels, an early opening between 5-30 min and a late
opening between 48-120 h after HIV exposure. Our data indi-
cates that opening of panx-1 hemichannels is essential for viral
entry and replication, however there function in physiological
conditions is unknown. Thus, we proposed that activation of
specific chemokine receptors results in the physiological open-
ing of pannexin-1 hemichannels (Panx-1) in T lymphocytes.
We determined that treatment of T lymphocytes with SDF-1/
CXCL12, a key chemokine in lymphocyte migration and HIV
infection, induces a transient opening of Panx-1 when com-
pared to HIV, but not connnexin43 hemichannels. Blocking
Panx-1 blocked the lymphocyte migration induced by SDF-1/
CXCL12, suggesting that opening of Panx-1 is essential for
lymphocyte migration by a mechanism that involves local
release of ATP. Alterations in migration occur in HIV infected
cells but also in other PNS and CNS diseases such as multiple
sclerosis (MS). Using a KOmouse model and EAE (an animal
model of MS) we demonstrated that Panx-1 hemichannels are
essential for migration of immune cells into the CNS and PNS.
In conclusion our findings demonstrate that Panx-1 hemichan-
nels play an essential role in HIV infection and in leukocyte
migration into the CNS opening potential new therapeutic
targets to block the pathogenesis of NeuroAIDS and MS.
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Virus-induced cellular targets for intrathecal
autoimmunity in multiple sclerosis
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Viral infections have been associated with autoimmune dis-
eases such as multiple sclerosis (MS), but the exact mecha-
nisms how viral infection could induce autoimmunity are
poorly characterized. Although molecular mimicry have been
suggested as a mechanism, convincing viral and autoantigen
targets have not been identified in MS. Another possibility is
that viral infection could induce and/or modify cellular proteins
that are recognized by the immune system. Human herpesvirus
6 (HHV-6) antigen and nucleic acids have been found in MS
brain lesions suggesting that HHV-6 might participate to the
lesion development. To identify possible intrathecal humoral
immune response targets in human HHV-6 infected cells we
used immunoprecipitation basedmass spectrometry analysis to
identify possible cellular targets present only in HHV-6
infected cells. Furthermore, we identified MS brain endoge-
nous IgG protein targets using similar approach. Cerebrospinal
fluid (CSF) IgG pulled 26 unique proteins from infected cells
that did not came up with serum or from non-infected cells.
Three of these proteins were identified as MS brain lesion
associated endogenous IgG targets as well. We are in the
process of validating these results with other immunoassays.
Our results suggest that HHV-6 infection can induce cellular
proteins that are recognized by MS CSF IgG, and thus, might
provide targets for the autoimmunity in MS.
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Intrathecal immune response to HTLV-1 antigens
in HAM/TSP




Human T-lymphotropic retrovirus (HTLV-1) is the causative
agent of the central nervous system disease HTLV-1 associated
myelopathy/tropical spastic paraparesis (HAM/TSP). Like pa-
tients with multiple sclerosis (MS), a related disease of the
central nervous system, HAM/TSP patients have increased
IgG index and oligoclonal bands (OCBs) as a marker of intra-
thecal antibody production. In this study, we investigated the
specificity of the cerebrospinal fluid (CSF) and serum antibod-
ies to HTLV-1 antigens by luciferase immunoprecipitation
system (LIPS) assay and the specificity of the oligoclonal bands
to HTLV-1 antigens in HAM/TSP. All of the 22 patients had
HTLV-1 gag, env and tax antibodies in CSF and all but one had
OCBs specific to at least one HTLV-1 antigen studied. Gag-
and env-specific OCBswere foundmore often than tax-specific
OCBs in HAM. Our data shows that in HAM/TSP HTLV-1
antibodies are produced intrathecally and most of the OCBs are
specific for HTLV-1 antigens. Detection of intrathecal antibody
production by LIPS and HTLV-1 antigen specific OCBs by
isoelectric focusing and immunoblot might provide tools to
differentiate HAM/TSP patients from HTLV-1 seropositive
MS cases and might suggest the involvement of humoral
immune response in the pathogenesis of HAM/TSP.
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Background: Natalizumab, a monoclonal antibody directed
against alpha4 integrins, has to date been associated with
395 cases of progressive multifocal leukoencephalopathy
(PML) worldwide in patients receiving treatment for multiple
sclerosis (MS). Due to the limited number of histological
studies, the interplay between MS and PML lesions has not
been investigated.
Objective: We report the clinical, radiological and histological
findings of a MS patient who developed PML after 32 months
of natalizumab monotherapy. Following withdrawal of
natalizumab, she received plasma exchange, mefloquine and
mirtazapine, but passed away soon thereafter. Post mortem
studies were restricted to examination of the brain and spinal
cord.
Results: Extensive PML lesions, characterized by the presence
of JCV DNA were found in the cerebral white matter and
neocortex. Sharply demarcated areas of active PML lesions
contained prominent inflammatory infiltrates composed of
approximately equal numbers of CD4+ and CD8+ T cells,
consistent with an immune reconstitution inflammatory syn-
drome (IRIS). Conversely, all MS lesions identified were
hypocellular, long-standing inactive plaques characterized by
myelin loss, relative axonal preservation, and gliosis, and im-
portantly, were devoid of JCV-DNA and active inflammation.
Conclusions: This case demonstrates the coexistence of
chronic inactive MS and PML lesions harboring active JCV
infection.Chronic inactive MS lesions were separate and dis-
tinct from nearby PML lesions. Furthermore, IRIS greatly
affected the shape and appearance of PML lesions but did
not involve MS lesions. Whether PML may alter the nature of
active MS lesions remains to be determined.
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Human immunodeficiency virus type 1 (HIV-1) infection
causes activation of innate immune pathways in the brain,
often with ensuing neurovirulence that is evident as neuronal
injury and death with accompanying neurobehavioral disor-
ders. The specific innate immune genes that drive early in-
flammatory responses to HIV-1 remain uncertain in brain cells
but activation of inflammasomes in myeloid cells with subse-
quent cleavage and release of interleukin (IL)-1beta represent
important pathogenic components underlying multiple in-
flammatory disorders. To investigate inflammasome expres-
sion and function in the human brain during HIV-1 infection,
inflammasome-associated genes were examined showing that
IL-1beta, IL-18 and caspase-1 were induced in brains from
HIV-infected persons, largely detected in activated brain my-
eloid cells. Cultured human microglia constitutively
expressed inflammasome-associated genes including IL-
1beta, caspase-1, NLRP3, NLRP1, AIM2 and ASC, unlike
human astrocytes and neurons. HIV-1 induced pro-IL-1beta in
human microglia at 4 hr post-infection with appearance of the
cleaved form and peak IL-1beta release at 24hr, which was
prevented by the caspase inhibitor, YVAD-fmk. Exposure of
microglia to soluble HIV-1 gp120 mediated IL-1beta induc-
tion and subsequent release by microglia. HIV-dependent
release of IL-1beta from a human myeloid cell line, THP-1,
was also inhibited by NLRP3 deficiency and high extracellu-
lar [K+]. In vivo infection by feline immunodeficiency virus
(FIV) caused induction of multiple inflammasome-associated
genes in microglia, which was accompanied by neuronal loss
and neurobehavioral impairments; multivariate analyses of
FIV-infected and uninfected animals disclosed that IL-1beta,
NLRP3 and Caspase-1 represented key molecular determi-
nants in the development of neurovirulence. Thus,
inflammasome activation was an early and integral aspect of
HIV/AIDS neuropathogenesis and might represent a potential
target for therapeutic interventions.
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Murine coronavirus (MHV) accessory protein, ns2 is a phos-
phodiesterase that inhibits activation of the interferon(IFN)-
induced oligoadenylate synthetase(OAS)-RNase L pathway
and facilitates viral replication in macrophage lineage cells
and induces hepatitis. However, efficient MHV replication in
the brain and subsequent encephalitis are independent of
enzymatically active ns2. Compared to the liver and other
peripheral organs, the CNS expresses lower basal levels of
IFN-stimulated genes including several OASs, which are re-
quired for RNase L activation. Thus, we hypothesized that
expression of OAS in the CNS was not sufficient to activate
RNase L after MHV infection. Indeed, an MHV mutant ex-
pressing an inactive ns2 protein (ns2H126R) replicates to a
similar extent as wild type (wt) virus in the CNS. We have
compared replication of wt and ns2H126R in bone marrow
derived macrophages with primary microglia, neurons, astro-
cytes and oligodendrocytes. In contrast to restriction of
ns2H126R replication in macrophages and microglia, wt and
ns2H126R replicatedwith similar kinetics in the other primary
cells. In addition, ns2H126R induced RNase L activity, as
assessed by ribosomal RNA (rRNA) cleavage, in myeloid-
derived cells but failed to do so in other cell types. Parenchy-
mal cells pretreated with IFN restricted wt and ns2H126R to
similar extents indicating that inhibition is not due to RNase L
activity. However, astrocytes and neurons are competent for
RNase L activity as they cleave rRNAwhen transfected with
poly I:C. Thus, RNase L activation depends on the virus,
kinetics of infection and IFN induction. Furthermore, expres-
sion of relatively high levels of OAS genes is necessary but
not sufficient for induction of an effective RNase L antiviral
response. Activation of RNase L is muted in the CNS perhaps
to prevent the potentially destructive effects of unrestricted
activity in nonrenewable cells.
P189
JAM-A and ALCAM are Critical to the Transmigration
Across the BBB of CD14+CD16+ Monocytes Isolated
from HIV Seropositive Individuals: Implications
for NeuroAIDS
Dionna W. Williams1, Kathryn Anastos2, Susan Morgello3,
Joan W. Berman4
(presenting author: dionna.williams@phd.einstein.yu.edu)
1Department of Pathology, Albert Einstein College of
Medicine;
2Departments of Medicine and Epidemiology & Population
Health, Albert Einstein College of Medicine;
3Department of Neurology, Neuroscience, and Pathology,
Mount Sinai School of Medicine;
4Department of Pathology andMicrobiology and Immunology,
Albert Einstein College of Medicine
HIVenters the CNS early after primary infection and results in
HAND, or HIV associated neurocognitive disorders, in 40-
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70% of HIV infected individuals despite successful combined
antiretroviral therapy (cART). Monocytes are critical cells
involved in HAND as they bring virus into the CNS upon
transmigration across the blood brain barrier (BBB). A subset
of circulating mature monocytes that express surface CD14
and CD16 is highly susceptible to HIV infection and accumu-
lates in the brain of those with HAND. The mechanisms by
which these mature monocytes transmigrate across the BBB
are not fully understood. We previously demonstrated using
an in vitro culture system that diapedesis of CD14+CD16+
monocytes across the BBB is facilitated by the junctional
proteins ALCAM, JAM-A, CD99, and PECAM-1. We now
characterize the CD14+CD16+ monocyte subset in HIV
infected individuals from the Manhattan HIV Brain Bank
and the Women’s Interagency HIV Study cohort. We found
that this monocyte population was present in significantly
greater numbers irrespective of cART status, viral load, CD4
count, and gender as compared to individuals without HIV.
We determined that CD14+CD16+ monocytes from these
people preferentially transmigrated across our in vitro model
of the human BBB in response to CCL2, a potent monocyte
chemoattractant elevated in the CNS of HIV infected people
with HAND. CD14+CD16+ monocytes isolated from HIV
seropositive individuals had higher surface expression of
ALCAM, JAM-A, and PECAM-1 relative to HIV seronega-
tive people. Blocking antibodies to ALCAM and JAM-A
inhibited the transmigration of these CD14+CD16+ mono-
cytes to baseline levels, suggesting their importance in facil-
itating monocyte transmigration across the BBB. Targeting
the increased junctional proteins present on CD14+CD16+
monocytes derived from HIV infected people, which prefer-
entially infiltrate the CNS, represents a novel therapeutic
strategy which may reduce the ongoing chronic neuroinflam-
mation which occurs during HIV neuropathogenesis.
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HIV activation of macrophages and microglia cells in the
central nervous system (CNS) triggers the secretion of un-
known neurotoxins, which are thought to be the cause of
neuronal damage. Macrophage phenotype is controlled exten-
sively by extracellular signals but the influence of brain de-
rived signals on macrophage phenotype is poorly understood.
We have recently shown that human macrophages and
monocytes express p75 and TrkA neurotrophin receptors
and respond to the natural ligand, Nerve Growth Factor
(NGF). Flow cytometry showed a decrease in receptors p75
and TrkA on human monocytes after stimulation with HIV
virions and ProNGF +/- HIV while NGF +/- HIV increased
both receptors. Stimulation of macrophages with HIV also
caused prolonged calcium accumulation that was blocked by
pretreatment with NGF. ProNGF pretreatment however
resulted in spikes of calcium activity in macrophages that
was blocked with a neutralizing antibody to the HIV Co-
Receptor, CXCR4 suggesting interactions between
neurotrophin and chemokine receptors . NGF and proNGF
also had opposing effects onmacrophage neurotoxin secretion
as assessed by calcium dysregulation in rat cortical neurons.
HIV virions resulted in increased neurotoxic activity of the
macrophage conditioned medium. Pretreatment with NGF
partially suppressed while ProNGF exacerbated neurotoxicity.
Rearrangement of actin cytoskeleton of macrophages, polarity
and podosome location were also seen with neurotrophin and
HIV stimulation. ProNGF stimulation resulted in an increase
in the polarization of podosomes compared to NGF. As with
neurons where signaling of the pro and mature forms of
neurotrophins results in opposing actions, the pro and mature
forms of NGF may also exert opposing regulation of
monocyte/macrophage phenotypes. Based on these data we
conclude that mature NGF promotes a less destructive mac-
rophage phenotype while proNGF may increase neurotoxici-
ty. Pharmacological control of these interactions may provide
new therapeutic avenues for the treatment of HIV-associated
cognitive disorders.
[NIH Grant R01 MH085606]
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The current clinical studies have focused on the identification
of LTR SNPs derived from peripheral blood (PB) of patients
enrolled in the DrexelMed HIV/AIDS Genetic Analysis Co-
hort in Philadelphia to identify HIV-1-infected individuals
more prone to developing advanced disease and/or neurologic
dysfunction. Patient demographics and clinical parameters
including drug use, CD4/CD8 T-cell count, and viral load
are performed at every visit. Drug abuse is common within
this cohort with cocaine use being favored. The cohort can be
categorized into non-users (PN), preferential cocaine (PC),
and multidrug users (MDU). SNPs have been identified that
associated with CD4 T-cell count and viral load. SNPs were
also identified that are unique to each drug abuse category.
Using an in silico sensitivity analysis, we were able to deter-
mine significant differences in transcription factor footprints
at the Lef-1 site with a variation from an A-to-G at position
321 to be significantly different between the PN and PC and
PN and MDU subcohorts. Additionally, an A-to-G alteration
at position 286 within C/EBP site II was found to be signifi-
cant in both the psychomotor and const ruct ive
neuropsychologically impaired patients. In previous studies,
we have shown this position to have an increased affinity for
C/EBP beta, increased HIV-1 basal LTR activity, a decreased
prevalence in PB-derived LTRs from patients with increased
disease progression, but an increased prevalence in brain-
derived LTRs. These results suggest that cocaine may be
applying selective pressure with respect to the genetic archi-
tecture of the LTR within these critical binding sites. This
work is supported by NIH/NINDS R01 NS32092, NIDA R01
DA19807, NIMH P30 MH092177, and NIMH T32
MH079785.
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La Crosse virus (LACV) is a primary cause of pediatric
arbovirus encephalitis United States resulting in severe neu-
rologic symptoms and even death. LACVencephalitis is char-
acterized by perivascular infiltration of leukocytes into the
central nervous system (CNS) and neuronal death. However,
the mechanisms leading to leukocyte infiltration and the role
of those cells in LACV pathogenesis remains unclear.
Intravenous injection of Evans blue dye demonstrated in-
creased vascular leakage into the CNS at 5 days post infection
(dpi), which is prior to the onset of neurological disease. Brain
endothelial cells at this time point showed decreased expres-
sion of CD31, a primary component of endothelial tight
junctions, as well as increased expression of Ccl2, Ccr2 and
Cxcl11, which are involved in leukocyte recruitment. These
findings suggest CNS blood vessels in LACV infected ani-
mals are permissive to cellular infiltration prior to neurological
signs. Examination of CNS infiltrates determined that activat-
ed monocytes/macrophages, CD4+ and CD8+ T cells were
present at 5dpi, with numbers peaking at neurological disease
onset. Inflammatory monocytes/macrophages were by far the
predominant infiltrating population and were found in close
association with areas of neuronal infection suggesting they
may be relevant to neurological disease. Concordantly, deple-
tion of T cells, which are present in low numbers, did not alter
the kinetics or onset of the disease suggesting their infiltration
is not critical for neurological disease development. Interest-
ingly, Rag1-/- mice were more susceptible to LACV CNS
infection than wildtype controls suggesting B cells antibody
responses have a protective role in disease pathogenesis.
However, B cell infiltration was not observed, suggesting their
role in LACV-induced neurological disease is distant from the
CNS. Collectively, while the role of infiltrating monocytes/
macrophages is still under investigation, we conclude adaptive
immune cell infiltration into the CNS does not appear to
influence the development of LACV-induced neurological
disease.
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Background: HIV-associated neurocognitive disorders
(HAND) persist in spite of antiretroviral therapy. Recent data
demonstrated high HIV-1 DNA in circulating activated mono-
cytes is associated with HAND. These activated monocytes
with HIV-1 DNA migrate to the brain and may represent CSF
viral reservoirs. Studies have shown a correlation between
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oxidative stress and HAND. Therefore we proposed to deter-
mine the relationship between HIV-1 DNA in CSF cells,
oxidative stress, and HAND.
Methods: A retrospective review was performed on prospec-
tively collected clinical data and samples from a cohort of 27
HIV-seropositive Hispanic women, stratified by cognitive
impairment into normal (n=8), asymptomatic (n=6), mild
impairment (n=6), and HAD (n-7). HIV-1 DNAwasmeasured
in CSF cells using real time PCR. The CSF oxidative stress
markers 3-NT were detected by dot-blot analysis while the
protein carbonyls (PC) with oxy- and dot-blot. Cognitive
performance was determined by the established criteria. Para-
metric and non-parametric statistics were used.
Results: A positive association was observed between higher
HIV-1DNA copy/cell in CSF cells and use of cART (p=0.007).
When controlling for cART use there was a negative correla-
tion between higher HIV-1 DNA in CD14+ blood cells with
worse performance in Trail Making B (TMB, p=0.049) and
verbal memory (p=0.036) tests. This negative correlation was
also observed in the CSF cells with higher HIV-1 DNA copy/
cell and lower CSF levels of 3NT (p=0.015) and PC (p=0.014).
Conclusions: Increased HIV-1 DNA in CD14+ correlated
with worse cognitive performance while increased HIV-1
DNA in CSF cells correlated with lower CSF oxidative stress
levels. Findings may suggest persistence of CSF viral reser-
voirs containing latent virus.
Grant support U54MD008149, U54 RR022762; partially by
U54MD007587, S11NS46278, U54NS43011, P20RR11126,
G12RR03051, F31AI081450, R01NS053345, U54MD007584
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The human polyomavirus JC (JCV) is the etiologic agent of the
rare devastating neurologic disease Progressive multifocal
leukoencephalopathy. Globally, the prevalence of infection with
JCV is high and JCV is believed to persist in a latent state after
primary infection. Even though JCVis common in the population,
PML is extremely rare which suggest that the virus is very tightly
regulated by cell-mediated immunity. Previously our laboratory
and others have shown that the JCV promoter and its transcrip-
tional activity are regulated by multiple transcriptional factors.
Here we provide evidence that JC virus promoter activity under
goes another level of regulation by epigenetic events involving
protein acetylation. We have found that histone deacetylase
inhibitors profoundly stimulate the transcription of both the early
and late JC virus promoters in transient transfection experiments
and in stable early and late reporter cell lines. This suggests that
the acetylation status of histones may be an important mechanism
controlling the latency/ reactivation status of JCV.
P195
Statins are a promising candidate adjunctive therapy
for prevention or treatment of HIV-1 associated
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HIV-1 associated neurocognitive disorders (HAND) result
from indirect effects mediated by activated blood monocytes
that traffic to the brain, and activated and/or infected brain
macrophages that release inflammatory chemokines and cyto-
kines (including MCP-1) and neurotoxic mediators (such as
glutamate). HAND remains a major problem even among
patients on antiretroviral therapy (ART) with effective viral
suppression, and has been linked to persistent immune activa-
tion and inflammation. Statins are HMG-CoA reductase inhib-
itors with pleiotropic immunomodulatory properties mediated
by effects on intracellular signal transduction pathways. We
first investigated the immunomodulatory effects of lipophilic
statins (simvastatin & atorvastatin) on human monocyte/
macrophage activation in vitro. Statin treatment reduced the
CD16+ and CD163+ monocyte populations following LPS
and MCP-1 stimulation, and strongly suppressed MCP-1, IL-
8, MIP-1alpha production by activated PBMC. Statin treat-
ment also strongly inhibited monocyte chemotaxis to MCP-1.
Further, we demonstrated that statins inhibited production of
the neurotoxin glutamate by HIV-1 infected macrophages, and
also had a direct neuroprotective effect on rat neurons exposed
to macrophage-HIV supernatants. We then carried out a small
open label in vivo pilot study of five HIV+ / ART+ subjects
treated with Atorvastatin for 12 weeks followed by a 4-week
washout period. In this small number of subjects, atorvastatin
treatment was associated with a trend towards decreased total
CD14+ monocytes, reduced CD16 mean fluorescent intensity
on CD14+ monocytes , and decline in plasma hsCRP during
the treatment period. These observations suggest the potential
of statins as a candidate adjuvant treatment to prevent HAND
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through modulation of monocyte/macrophage function and
through its anti-inflammatory effects, and warrant a larger
randomized clinical trial with a longer treatment period.
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ASTROCYTE: IMPLICATION FOR HAND
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Although ART can effectively suppress viral suppression, ex-
pression of viral proteins such as Tat remains unaffected. This in
turn, could lead chronic activation of glia resulting in neuroin-
flammation. ER stress has recently been implicated to play an
important role in the impairment of CNS homeostasis in HIV+
patients. In response to ER stress, cells activate a set of tightly
controlled regulatory programs, the unfolded protein response
(UPR), to restore normal functioning of the ER. However, if ER
stress is sustained and the adaptive UPR fails to eliminate
unfolded/misfolded proteins, balance shifts to apoptosis as a
mechanism for clearing stressed proteins. We hypothesized that
Tat mediated activation/apoptosis of astrocytes involves the ER
stress response. Our preliminary data demonstrates that HIV Tat
induced ER stress in astrocytes, with activation of the three UPR
pathways-PERK, ATF6 & IRE1. This was accompanied by
disruption of calcium homeostasis, generation of reactive oxi-
dative stress (ROS) & induction of apoptosis. Of particular
interest is the chaperone Sigma-1 Receptor (sigma1-R) that is
critical for ER stress. Intriguingly, overexpression of sigma1-R
in astrocytes significantly decreased Tat-mediated ROS genera-
tion & inhibited the expression of pro-apoptotic CHOP protein.
Reciprocally, knocking down sigma1-R resulted in decreased
expression of the anti-apoptotic Bcl2 & increased cellular apo-
ptosis. Sigma1-R could be envisioned as a critical modulator of
glial cell survival and may be an important target for therapeutic
intervention in HAND.
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NIBP (NIK- and IKK2-Binding Protein) is a novel protein that
enhances cytokine-induced NFkB activation and is required
for neuronal differentiation. TNFalpha and IL-1beta are well
known to stimulate NFkB activation, which contribute to
cytokine-induced HIV-1 reactivation. We hypothesize that
NIBP may regulate HIV-1 infection and reactivation via NFkB
signaling. To test this, we performed HIV-1 long terminal
repeat (LTR) driven firefly-luciferase reporter assay using
mouse brain neural stem/progenitor cells and human fibroblast
with NIBP deletion. To our surprise, NIBP overexpression in
mouse neural stem/progenitor cells significantly inhibited con-
stitutive and TNFalpha-induced LTR promoter activation.
Such inhibition was independent of NFkB signaling be-cause
NFkB site-deletion LTR mutant inhibited TNFalpha-induced
LTR activation but did not prevent NIBP-induced inhibition.
This was validated in other cells and species including human
fibroblast and breast cancer cells as well as rabbit colonic
smooth muscle cells. Interestingly, LTR-luciferase activity
was increased in NIBP deletion fibroblast cells from patient
with mental retardation and overexpression of NIBP in these
fibroblasts rescued such inhibition. NIBP is known to interact
with bovine viral diarrhea virus non-structural protein 5A
(NS5A), which hijacks NIBP-mediated NFkB activation. Co-
immunoprecipitation assay in HEK293T cells cotransfected
with Flag-tagged NIBP and CFP-tagged TAT or YFP-tagged
Vpr vectors showed that both NIBP(1148aa) and NIBP(960aa)
interact with TAT but only NIBP(1148aa) interacts with Vpr.
These data suggests that NIBP may act as a novel restriction
factor to suppress HIV-1 transcription/reactivation through
interacting with HIV-1 viral proteins. Such interaction may
hijack NIBP-mediated NFkB activation. Since NIBP is highly
expressed in HIV-1 non-permissive neurons but not in permis-
sive microglia/macrophage and T cells, NIBP gene therapy
may serve as a novel approach to treat NeuroAids.
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The introduction of HAART has resulted in significantly lower
mortality rates, culminating in anHIVepidemic that increasingly
affects older adults, emphasizing the importance of understand-
ing the risk factors associated with aging and HIV-1 infection.
Additionally, immune failure commonly occurs with both aging
and HIV infection. Current studies focus on the impact of age on
LTR signatures that correlate with HIV-1 clinical parameters
including CD4+ and CD8+ T-cell count and viral load (VL).
A prospective, longitudinal study was conducted on 458 HIV-1-
seropositive patients currently enrolled in the DrexelMed HIV/
AIDS Genetic Analysis Cohort in Philadelphia, PA. History of
illicit drug, alcohol, andmedication use, CD4+ and CD8+ T-cell
count, and viral load, along with patient history including age,
were collected approximately every 6 months. Using a linear
mixed model for longitudinal data, we determined that there
were viral SNPs that significantly correlatedwith increasing age.
Additionally, age modified the SNP effect with respect to CD4+
T-cell counts and VL to different degrees. Both HIV-1 infection
and age are also known to have immunomodulatory effects. The
cytokine profiles of adult and aged individuals were analyzed to
understand the impact of age and HIV-1 infection on cytokine
modulation and HIV-1 disease severity. Interestingly, among the
30 cytokines investigated, the cytokine profiles appeared diffe-
rent between these two populations. In addition, there appeared
to be a number of SNPs that correlated with the age effect on
cytokine levels. In conclusion, age, in the context of HIV-1
infection, appears to impact viral gene expression and immune
activation. This work is supported by NIH/NINDS R01
NS32092, NIDA R01 DA19807, NIMH P30 MH092177, and
NIMH T32 MH079785.
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The central dopamine (DA) neurotransmission plays a
crucial role in the development of neurocognitive dysfunc-
tion in patients with HIV-1 associated neurocognitive dis-
orders (HAND). We have demonstrated that HIV-1 Tat
protein in vitro inhibits DA transporter (DAT) allosterical-
ly and modulates cocaine binding sites on DAT in rat
striatal synaptosomes and cells expressing human DAT.
To understand how in vivo expression of HIV-1 viral
proteins influences DAT function, kinetic analysis of
[3H]DA uptake in prefrontal cortex (PFC) and striatum,
and [3H]WIN35,428 binding in striatum were determined
in HIV-1 transgenic (HIV-1Tg) and Fisher 344 rats. Com-
pared to Fisher 344 rats, the maximal velocity (Vmax) of
DAT-mediated [3H]DA uptake into prefrontal and striatal
synaptosomes in HIV-1Tg rats was increased by 34% and
32%, respectively, whereas the Km values for DA uptake
were reduced in striatum but not in PFC of HIV-1Tg rats.
In addition, HIV-1Tg rats exhibit decreased maximal bind-
ing sites (Bmax) of [3H]WIN35,428 and increased DA
uptake turnover rate (Vmax/Bmax) in striatum, compared
to Fisher 344 rats. To explore the potential mechanism(s)
underlying alteration of DAT function in HIV-1Tg rats,
our ongoing study is to determine whether the increased
DA uptake in both regions is due to redistribution of
membrane DAT or changes in DAT-associated proteins in
membrane microdomains. Collectively, these results sug-
gest that neuroadaptive changes have occurred in the HIV-
1Tg rats that might help to compensate for HIV-1 viral
protein-induced inhibition of the DAT function. Supported
by grant from the NIH to Jun Zhu (R01DA035714)
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We have developed an SIV/pigtailed macaque model that
results in rapid development of CNS disease and AIDS that
provides a robust model for testing of antiretroviral and neu-
roprotective therapeutic strategies.We have also demonstrated
that we can obtain suppression of plasma vRNA to below
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detectable levels using combinations of three different classes
of antiretroviral drugs that are CNS penetrant or nonpenetrant.
In the last few years, a number of HIV-infected patients have
experienced at least functional cures (the Berlin Patient, the
Mississippi Child, the French Cohort), ceasing antiretroviral
therapy without viral reactivation or development of disease.
This has initiated a search for ways to duplicate these natural
experiments. Recently a number of compounds that are able to
activate HIV DNA have been suggested as coadjuvant to
cART therapy. It is proposed that the antiretroviral drugs
would prevent viral spread while host lymphocytes would kill
reactivated infected cells expressing viral proteins. We have
been investigating a hexanoate derivative of Ingenol (Kyo-
IIB), a phorbol ester isolated from Euphorbia tirucalli. Kyo-
IIB treatment of resting CD4+ T cells isolated from virus
suppressed SIV-infected macaques led to a significant in-
crease in reactivated latent cells and viral RNA transcription.
In a pilot trial in SIV-infected macaques, Kyo-IIB was admin-
istered in escalating doses orally BID for one week each,
alternated with off-treatment weeks. Activation markers in
blood leukocytes and plasma viral load increased during treat-
ment and decreased during the washout periods. In contrast to
other phorbol esters, Kyo-IIB is less toxic and can be orally
administered to animals with no apparent side effects.We plan
to treat virus suppressed SIV-infected macaques with Kyo-IIB
to determine the ability of the compound to reactivate SIV
in vivo and reduce the number of SIV latently infected resting
CD4+ T cells, monocytes, and macrophages as proof-of-
concept for a functional HIV cure.
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A major barrier to the eradication of HIV is the persistence of
virus in latent reservoirs. CD4+ T cells have been widely
studied, and resting CD4+ T cells are considered the major
latent reservoir in HIV and SIV infections. HIV and SIV
replicate in activated CD4+ T cells, but a small percentage
of these cells become resting memory cells and, if infected,
harbor latent virus. Monocytes, macrophages, and microglia
in the brain have been shown to support HIV and SIV infec-
tion. In both HIVand SIV infected individuals on combination
antiretroviral therapy, viral DNA is found in the brain, and
ongoing changes in the brain suggest that the virus is persis-
tent and latent. Because of the recent focus on the eradication
of HIV, identification of all latent viral reservoirs has become
crucial. However, little is understood about mechanisms of
HIVor SIV latency inmyeloid cells. In the CNS, the astrocyte,
the most abundant cell in brain, is also infected with HIVand
SIV but infection is not productive. In order to characterize
viral latency in macrophages, microglia, and astrocytes, we
are developing in vitro primary cell latencymodels. In order to
recapitulate the environment in the CNS, cytokines are being
used to determine their role in establishing viral latency in
macrophages, microglia, and astrocytes.
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Myelin pallor is frequently reported in HIV patients, and can
occur in the CNS prior to other evidence of a disease process.
Oligodendrocytes (OLs) are the myelinating cells of the CNS;
they are highly vulnerable to excitotoxicity due to the fact that
1) NMDA receptors (NMDA-Rs) expressed onOLs are weak-
ly blocked byMg2+1, and 2) AMPA receptors (AMPA-Rs) on
OLs lack the Ca2+-impermeable GluR2 subunit2,3. We hy-
pothesized that HIV-1 Tat (transactivator of transcription)
activates NMDA-Rs and AMPA-Rs, which in turn leads to
Ca2+ influx and OL injury. Our repeated measure experi-
ments established that 100 nM Tat1-86 is toxic to immature
OLs, but not mature OLs. On the other hand, mature OLs
exposed to 100 nMTat exhibit reducedmyelin-like membrane
area, indicating potential injury to cell morphology and func-
tion. To investigate if these effects are mediated via Ca2+,
Fura-2 AM was used to quantify [Ca2+]i within individual
cells. Both mature (O4+, MBP+) and immature OLs (O4+,
MBP-) exposed to 1-100 nM Tat showed a dose-dependent,
gradual increase in [Ca2+]i up to ~600 nM vs. ~100 nM in
control, and this high [Ca2+]i level was maintained during a
1 h experimental period. This Tat-induced [Ca2+]i increase is
completely abolished in Ca2+-free medium, suggesting extra-
cellular Ca2+ as the primary source. The NMDA-R antagonist
MK801 reduces Tat-induced [Ca2+]i increase in both imma-
ture and mature OLs. Surprisingly, AMPA/KA-R antagonist
CNQX also attenuates Tat-induced Ca2+ influx in OLs,
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suggesting both NMDA-R and AMPA/KA-R on OLs were
activated by HIV-1 Tat. Importantly, both MK801 and CNQX
block Tat-induced immature OLs death, but only MK801
reverses Tat-induced mature OL membrane area change.
These results add to evidence suggesting that OLs are targets
of HIV, and also suggest that viability and phenotypic changes
in immature and mature OLs, respectively, may involve dif-
ferent Ca2+-mediated glutamatergic mechanisms.
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